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PART I | PRIMARY RECTAL CANCER
Primary rectal cancer
Colorectal cancer is a major problem in the western world and has a rising incidence.
[1,2] Approximately one third of these tumours originate in the rectum. Although colon 
and rectal cancer share similar features there is a distinct difference in clinical behaviour 
and therapeutical approach.[3] The treatment of primary rectal cancer has evolved into a 
multidisciplinary treatment with standardised imaging techniques, surgical procedures, 
pathological assessment, and (chemo)radiation therapeutical options.[1, 4-6] The 
introduction of total mesorectal excision (TME) has lead to a significant decreased local 
recurrence rate[7] in combination with preoperative short-term radiotherapy (5x5Gy).[8, 9] 
Based on the beneficial results reported in the Dutch TME trial[1] the treatment protocol in 
the Netherlands of patients with a tumour in the lower two-third of the rectum was changed 
in 2001.[10] Nowadays all patients are considered to be discussed in a multidisciplinary team 
and a short course of radiotherapy will be given prior to TME surgery. It is unclear if results 
in community hospitals are similar to the results presented in these multicenter trials. In 
chapter 2 we report the results of rectal cancer surgery in a low volume community hospital 
in the region of the Comprehensive Cancer Centre Rotterdam. The aim of the study was to 
identify the compliance to the new standardised treatment protocol i.e. the introduction 
of preoperative radiotherapy. Furthermore, the results of rectal cancer treatment in the 
centre were analysed and compared with reference values based on selected patients from 
randomised trials in the recent literature.
Preoperative radiotherapy
Although long term results of preoperative radiotherapy showed a consistent significant 
difference in local control in the Dutch TME trial, this difference was not present in a 
subgroup analysis for TNM stage I and II.[9] Although short course preoperative radiotherapy 
has become the standard of care for rectal cancers in many centres in the Netherlands and 
other European countries selection criteria are still controversial.[11] Especially in T2 
and T3, N0 rectal cancer patients neo-adjuvant radiotherapy seems to add little to local 
control or survival.[12] In chapter 3 we assessed the outcome of a historical group of T2, 
3 N0 patients treated with a TME alone and compare them with a T2, 3 N0 group who 
was treated with preoperative radiotherapy followed by TME. Time to local recurrence, 
time to distant metastases and overall survival between the different treatment groups were 
compared and predictors of recurrence were identified to analyse the influence of clinical 
variables on outcome.
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PART II | LOCALLY ADVANCED RECTAL CANCER
Primary locally advanced rectal cancer
Primary locally advanced rectal cancer extends into or beyond the enveloping fascia propria 
of the mesorectal compartment and is estimated to account for 6-10% of all primary rectal 
cancers.[13] An adequate circumferential resection margin (CRM>2mm) is related to a 
significantly improved local control after surgery for primary rectal Cancer.[14] Especially 
in locally advanced rectal cancer radical margins and an adequate CRM are often difficult 
to obtain because of infiltration into adjacent structures. Preoperative long course radiation 
therapy have been developed to increase resectability by the effect of downsizing/-staging 
and to ameliorate outcome.[15, 16] In case of a marginal complete or incomplete resection 
intraoperative radiotherapy (IORT) can be applied with the aim to provide better local 
control. In chapter 4 we describe our experience with the multimodality treatment of pre- 
and intraoperative radiotherapy and surgery for a cohort of 123 patients with primary locally 
advanced and initially unresectable rectal tumours.
Preoperative chemoradiation therapy
The addition of 5-FU based chemotherapy to radiation therapy has demonstrated to be 
feasible with an increase in pathological complete response rate and local control for locally 
advanced rectal cancer patients.[17, 18] Capecitabine (oral 5-FU) is a fluoropyrimidine 
carbamate rationally designed to generate 5-FU preferentially in tumour cells as the 
concentration of the key enzyme thymidine phosphorylase is higher in tumour cells 
compared with normal tissue.[19-21] Several phase II studies have been initiated to evaluate 
the tolerance and efficacy of chemoradiation with capecitabine.[22-24] In these studies 
different regimes of capecitabine were used and in some studies leucovorin was added. In 
chapter 5 we describe a phase II study to evaluate the efficacy and toxicity of preoperative 
chemoradiation with capecitabine in large T3/T4 rectal tumours or in patients with local 
lymph node metastases.
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PART III | RECURRENT RECTAL CANCER
Recurrent rectal cancer
Despite improvements in the treatment of primary rectal cancer, local recurrences occur and 
the incidence range between 3-15%.[1] When a recurrence develops in rectal cancer patient, 
prognosis is often poor and without adequate treatment mean survival is approximately 
8 months and 5-year survival rates range between 0-30%.[25-31] Recurrences are often 
associated with severe symptoms, especially neuropathic pain due to ingrowth in the 
pelvic wall.[30] The main goals in the treatment of recurrent rectal cancer are palliation of 
symptoms, good quality of life and, if possible, curative surgery. In recurrent rectal cancer the 
visceral fascia surrounding the rectum has been resected in previous surgery, which makes 
a complete resection of recurrent disease more difficult.[26] Successful complete resection 
of recurrent rectal cancer is often restricted to selected patients, for example with an early-
detected tumour or an anastomosis-limited recurrence after previous sphincter-sparing 
surgery.[32] Preoperative radiotherapy is used in the treatment of recurrent rectal cancer 
based upon the beneficial effects on local control and even overall survival in the treatment 
of primary rectal cancer.[33, 34] In chapter 6 the outcome is described after treatment of 92 
patients with recurrent rectal cancer, with a special interest on the effect of preoperative 
long-term irradiation and intra-operative radiation.
Recurrence after transanal endoscopic microsurgery (TEM)
In an attempt to avoid the morbidity and mortality of TME, local excision has been developed 
as a therapeutic option in the treatment of well-selected patients with early rectal cancer.[2]
Early reports of operations performed through the transanal approach found unacceptably 
high rates of incomplete tumour removal in up to 60 percent of surgical specimens.[35-38] 
The introduction of transanal endoscopic microsurgery (TEM) by Buess et al.[39] proved to 
be an optimised technique for removal of rectal tumours. This technique enables excellent 
access and visualization of the surgical field and allows precise and full-thickness excision 
of the tumour. The rate of tumour resection with clear margins, even with standardised 
pathology, for T1 tumours has increased to more than 90%. [35, 40] Considering the very 
low mortality and morbidity rates, local excision by TEM is now considered a potential 
alternative for the surgical treatment of T1 tumours by many surgeons.[36, 41, 42] However, 
the wide range of local recurrences range from 0 to 24%,[43, 44] and the results of salvage 
surgery in recurrent tumours are matters of concern. In the literature only few series report 
on surgical procedures following recurrent disease after transanal surgery.[45-47] In chapter 
7 we present the results of salvage surgery for local recurrences of a large group of patients 
treated with TEM for T1 rectal cancer.
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PART IV | EXTENDED RESECTIONS AND RECONSTRUCTIONS
Abdominoperineal Sacral resections (APSR)
Despite efforts in the early detection and intense follow-up of rectal cancer patients, primary 
locally advanced and recurrent rectal cancer with involvement into adjacent organs or 
structures is not uncommon. For patients with extraluminal tumour mass involving the 
pelvis or other organs, the treatment used to be strictly palliative. Because of new treatment 
modalities, including preoperative chemoradiation therapy and extensive resections, it 
is possible to obtain complete resections in this group of patients.[48, 49] If the tumour 
has infiltration into or a very close relation with the sacrum, an abdominoperineal sacral 
resection (APSR) might in some patients be the only curative treatment option. In patients 
with primary locally advanced rectal cancer involvement of the posterior bony pelvis almost 
never occurs, but this is sometimes seen in recurrent rectal cancer patients.[50] The symptoms 
often include severe pain in the sacral region. The 5-year overall survival of APSR is reported 
between 15 and 30% and the local control rate between 15 and 40%.[51] In chapter 8 
we evaluate the oncological outcome after APSR for both primary locally advanced and 
recurrent rectal cancer in our tertiary referral centre.
Total pelvic exenteration (TPE)
In case of a locally advanced growth pattern of a primary or recurrent rectal tumour or other 
pelvic tumours, major exenterative surgery might be necessary to provide complete resection 
margins. In case of tumour involvement of the base or trigone of the bladder or the prostate, 
a total pelvic exenteration (TPE) with resection of the rectum together with bladder, lower 
ureters and internal genital organs could salvage the patient. TPE has been performed in 
primary or recurrent cancer of the cervix, rectum, vagina, uterine corpus, vulva, prostate, 
bladder and in pelvic sarcoma.[52, 53] Since the introduction of the technique by Brunswick 
in 1948 the initially poor quality of life and high mortality and morbidity associated with 
the technique have substantially improved.[54-56] However, morbidity after this extensive 
surgical procedure is still high and reports between 13% and 64%.[57-59] Five-year survival 
rates after TPE for patients with primary disease range between 32% and 66% and in patients 
with recurrent disease from 0% to 23%.[49,54,59] The results of TPE in a cohort of 69 patients 
are described in chapter 9.
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Pelvic reconstructions
In chapter 10 we describe our experience with the technique of salvage APR for anal cancer 
patients. The treatment of anal cancer has changed radically during the past few decades, from 
predominantly surgery to (chemo)radiation therapy. Despite the overall excellent results of 
CRT in the primary treatment of anal carcinoma, a proportion of patients fail treatment. 
Initial treatment failure occurs in 10-15% and an additional 10-15% of patients develop 
a local recurrence after an initial complete response to CRT.[60-62] The majority of these 
failures is isolated to the primary tumour site[60, 63, 64] and are therefore curable by a salvage 
abdominoperineal resection (APR). A major problem of surgery in the previously irradiated 
anal area is poor healing of the often large perineal wound.[65] The incidence of perineal 
wound complications is rather high after salvage treatment with APR, and complications 
in more than 30% of patients have been reported.[66, 67] Similar to the report by others the 
VRAM flap reconstructive procedure results in primary healing with acceptable donor-site 
morbidity and low complication rates.[65, 68, 69] Resection margins of the perianal skin can 
easily be compromised when primary closure is performed. The use of a VRAM flap also 
enables the surgeon to remove the recurrent or persistent tumour mass with wide resection 
margins, as the large skin defect can easily be managed.
In chapter 11, the results of the studies performed in this thesis are summarised and discussed.
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AbSTRACT
Objective
The aim of this study was to review the results and long-term outcome after total mesorectal 
excision (TME) for adenocarcinoma of the rectum in a community teaching hospital.
Materials and Methods
Between 1996 and 2003, 210 patients with rectal cancer were identified in our prospective 
database, containing patient characteristics, radiotherapy plans, operation notes, 
histopathological reports and follow-up details. An evaluation of prognostic factors for local 
recurrence, distant metastases and overall survival was performed.
Results
The mean age at diagnosis was 69 (range 40 - 91) years. A total of 145 patients were treated 
by anterior rectal resection; 65 patients had to undergo an abdominoperineal resection 
(APR). Anastomotic leakage rate was 5%. Postoperative mortality was 3%. After a median 
follow up of 3.6 years, the local recurrence free rate in patients with microscopically 
complete resections was 91%. The 5-year overall survival rate was 58%. An increased serum 
CEA, an APR, positive lymph nodes and an incomplete resection all significantly decreased 
5-year overall survival and local recurrence rate. In a multivariate analysis age was the most 
important prognostic factor for overall survival.
Conclusions
Patients with rectal cancer can safely be treated with TME in a community teaching hospital 
and leads to a good overall survival and an excellent local control. In patients aged above 
80, treatment related mortality is an important competitive risk factor, which obscures the 
positive effect of modern rectal cancer treatment.
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INTRODUCTION
The ultimate goal in the treatment of rectal cancer is to maximise local control and to improve 
overall long-term survival. Local recurrence is a serious problem in the treatment of rectal 
cancer, since it causes disabling symptoms and is difficult to treat; besides, it is thought to be 
an important factor in overall long-term survival. After conventional surgery, a high incidence 
of local recurrence up to 40% was reported.[1, 2] Heald described a new concept in operative 
anatomy, the total mesorectal excision (TME) technique in which the entire mesorectum is 
enveloped and resected.[3-5] The introduction of this surgical technique resulted in a local 
recurrence rate of less than 10% in specialised centres. It was recognised that involvement 
of the circumferential margin by tumour cells is predictive for local recurrences.[6] With 
this new standardised technique, a unique chance was given to study the effect of (neo-) 
adjuvant therapy. Based on the good results of preoperative radiotherapy in Sweden,[7] the 
Dutch Colorectal Cancer Group started a randomised multicentre trial. They investigated 
whether the addition of preoperative radiotherapy increases the benefit of total mesorectal 
excision.[8-10] The outcome of this study showed a significant reduction in local recurrences 
with preoperative radiation compared to operation alone in patients with rectal cancer (5.6% 
vs.10.2% at 6.1 years).[11] Differences were not significant for tumours in the upper third 
of the rectum. Therefore, from the year 2001 onwards, the Comprehensive Cancer Centre 
Rotterdam (CCCR), decided to standardise preoperative radiotherapy for each patient with 
a tumour up to 10 cm from the anal verge. A course of 5 x 5 Gy was given to all these patients. 
However the TME study was performed in selected patients under optimal conditions and 
low volume centres still report higher recurrence rates.[12, 13]
This study was designed to assess the outcome after treatment of primary rectal cancer in a 
community teaching hospital with special emphasis on local recurrence and overall survival.
PATIENTS AND METHODS
Patients and Preoperative Assessment
Between 1996 and 2003, the hospital charts of 210 patients with primary rectal cancer 
were recorded in our prospective database. Medical records were examined to obtain all 
necessary data. All patients had histologically proven adenocarcinoma of the rectum, 
without evidence of distant metastases at that stage. The inferior margin of the tumour was 
located not further than 15 cm from the anal verge to be defined as a rectal tumour. Prior to 
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surgery, medical history, physical examination, and routine blood tests were assessed. Work-
up consisted of colonoscopy with biopsy, followed by an x-ray of the chest in combination 
with abdominal ultrasound to exclude distant metastases. In most cases also a CT-scan of 
the abdomen was made. In selected cases, especially to rule out the suspicion of growth of 
the tumour into adjacent organs, a MRI of the pelvis was made. Our database consists of 
hospital notes, radiotherapy plans, operation notes and histopathological reports to obtain 
the following information: demographics, preoperative diagnostic intervention, tumour 
staging, radiotherapy technique, surgical details, histopathological details and complications. 
Follow up was registered using hospital notes, medical letters and in some cases by general 
practitioner information. 
External beam Radiation Therapy (EbRT)
Starting in 2001, short term EBRT was given to all patients with a tumour up to 10 cm.[8] A 
radiation dose of 25 Gy in 5 daily fractions was delivered. In patients with a locally advanced 
tumour 50Gy radiotherapy was given in 25 daily fractions of 2 Gy. Locally advanced tumour 
growth was defined as infiltration of the tumour in the environment and/or pathologically 
enlarged lymph nodes near the circumferential margins of the mesorectum on a CT-scan. 
Afterwards an evaluation of the effect of radiation therapy was done again by CT-scan. When 
thought feasible an explorative laparotomy was done with the intention to do a resection. 
EBRT was administered by a three-field technique, using one posterior and two lateral ports.
Surgery
All patients underwent surgery according to the TME principle, as advocated by Heald.
[3] In patients with a high rectal cancer, the mesorectum was divided 5cm below the 
tumour and a partial mesorectal excision was performed. Surgery was planned 3–5 days 
after short-term radiotherapy. For locally advanced or T4 tumours re-evaluation was done 
after irradiation. When feasible, the patient was operated on 5-6 weeks later. Prophylactic 
intravenous antibiotics were given at the induction of anaesthesia in all patients. Three well-
trained TME surgeons performed all operations. In case of an anterior resection, a side to 
end anastomosis was made using the double stapling technique. A diversion stoma was made 
in case of complicated procedures, a positive leakage test or incomplete doughnuts. Loop 
ileostomy was the preferred method in these cases. With a positive leakage test, the leakage 
was localised and sutured when discovered.
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Pathology
The pathologists were trained to identify CRM, positive nodes and lateral spread of tumour 
according to the protocol of Quirke et al.[14]
Adjuvant Therapy
Generally patients were not treated with adjuvant chemotherapy, irrespective of nodal status. 
After 2005 there was a tendency to give adjuvant chemotherapy in well-conditioned patients 
with positive lymph nodes.
Statistics
Local control and overall survival curves were calculated from the time of TME and were 
based on the method of Kaplan and Meier. All statistical analyses were executed in SPSS. 
Univariate comparisons of survival end points were calculated using the log-rank test. 
Significance was defined as P<0.05. For multivariate analysis, Cox-regression was used to 
evaluate prognostic factors.
RESULTS
Patients
A total of 210 patients were operated with curative intent. One hundred and thirteen 
(54%) of the patients were male and 97 (46%) were female with a median age of 70 (range 
40 to 90 years) The median level of preoperative CEA was 2,8 (range 0,2–142). Patient 
characteristics and presenting symptoms are shown in Table 1. Fifty-three patients (25%) 
received preoperative radiotherapy. The majority of these patients (n=42) received short-
term radiotherapy. Eleven patients were treated with 50 Gy external beam radiation therapy 
because of preoperatively defined locally advanced tumours. Since 2001, due to changing 
policy in preoperative radiotherapy, a growing amount of patients received EBRT. Of the 40 
patients (with a tumour below 10 cm) included in this study from 2001, 36 received short-
term radiotherapy.
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Table 1. Preoperative characteristics
Total %
 − Symptoms
 − Bloodloss
153 73
 − Mucus 38 18
 − Tenesmus 47 22
 − Diarrhea 44 21
 − Constipation 35 17
Distance of tumour from anal verge
 − ≤ 5 cm
 − 5-10 cm
 − 10-15 cm
59
87
64
28
41
31
Surgical results
A LAR was done in 145 patients (69%) and an APR in 65 patients (31%). Of the 145 
patients with a LAR, a diverting stoma was made in 26 patients (18%), which was closed in 
18 patients. Five patients underwent a local excision of the tumour (Transanal Endoscopic 
Microsurgery) as initial treatment before TME was performed. Thirteen patients (6%) 
proved to have hepatic metastases during surgery. In 10 of these patients hepatic metastases 
were not diagnosed by ultra-sonography or computer-tomography during the preoperative 
workup, but discovered during surgery. The median duration of surgery was 110 min 
(range 45–210 min) and the median operative blood loss was 600 ml (range 50–4000ml). 
The median bloodloss was significantly lower in LAR compared to APR, 400 vs. 1000ml 
respectively (P<0.001). 
Complications are depicted in Table 2. Postoperative mortality was 3%. Twelve patients 
underwent a relaparotomy because of abdominal symptoms. During operation an anastomotic 
leakage was found in 8 patients; 3 patients were treated with a loop ileostomy and in 5 
patients a colostomy was performed after removal of the anastomosis. A re-anastomosis was 
performed, after 6 and 9 months, in 2 of these patients. Perineal infections were present in 
12 patients (18%) after an APR and treated conservatively. All these 12 patients had been 
treated with preoperative radiotherapy. 
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Table 2. Postoperative complications and reinterventions
Total %
Minor complications
 − Urinary infection
 − Bladder retention
 − Wound infection abdominal
16
3
17
8
1
8
Major complications
 − Wound infection perineal
 − Anastomotic leakage
 − Intra abdominal fluid collection without leak
12
8
3
18*
5
1
Reintervention
 − Abscess drainage
 − Relaparotomy
 − Permanent colostomy
 − Permanent ileostomy
 − Temporary ileostomy
3
12
7
2
3
1
6
3
1
1
* 18% of 65 abdomino-perineal resections
Pathology
In 199 patients (95%) a microscopic radical resection was performed (R0). In 11 (5%) 
patients the resection was microscopically irradical (R1) including 4 patients with a pT4 
tumour. The postoperative tumour stage is given in Table 3. Two patients had no residual 
disease after TME. However, these patients had undergone a TEM before TME. TME was 
performed because the local excision was irradical on pathology. One of these patients had a 
T1 and one a T2 tumour at the initial pathology. Three patients had a carcinoma in situ. A 
T1 tumour was seen in 23 patients, a T2 in 63, a T3 in 106 and a T4 tumour in 15 patients. 
One-hundred-twenty-and-eight patients were node negative, 45 had metastasis in 1 to 3 
regional lymph nodes (N1), and 37 had metastasis in 4 or more regional lymph nodes (N2).
Follow-up
The median follow up was 3.6 years (range 0.4–8.4 years). In total, 21 patients developed 
a local recurrence, most of them (83%) discovered during the first two years of follow-up. 
Fourteen of 199 patients with a complete resection developed a local recurrence (7%). Seven 
of 11 patients with an incomplete resection developed a local recurrence (64%). A complete 
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resection versus an incomplete resection was of significant importance on local control 
(P<0.001, Figure 1). The actuarial overall 3- and 5-year local control rates were 92% and 
88%, respectively. Nineteen of the local recurrences were found in tumours primary located 
in the lowest 2/3 of the rectum. A high level of CEA (>5), an APR, positive lymph nodes and 
an incomplete resection negatively influenced the local recurrence rate significantly. There 
was no significant difference in age, gender and preoperative radiotherapy regarding local 
recurrence (See Table 4). The significant prognostic factors were entered in a multivariate 
analysis (See Table 5). The most important factor was completeness of the resection. CEA in 
this multivariate analysis was not of significant importance anymore. 
Table 3. Pathology
Total %
Residual tumour
 − R0
 − R1
199
11
95
58
AJCC pTNM stage
 − CIS
 − I
 − II
 − III
 − IV
3
67
53
74
13
1
33
25
35
6
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Figure 1. Local recurrence according to a complete versus an incomplete resection (P<0.01)
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Distant metastases
Forty-five patients developed distant metastases, of which 40% was discovered during the 
first year of follow-up. Thirty-four patients developed hepatic metastases, 18 lung metastases 
and 5 bone metastases. Lung and/or bone metastases were in 38% synchronic with hepatic 
metastases. 
Table 4. Univariate analysis on 5-year Local Free Recurrence (LR) and Overall Survival (OS)
N LFR OS
Radiotherapy yes
Radiotherapy no
53
157
82%
93% P=0.32
67%
55% P=0.17
LAR
APR
145
65
93%
63% P<0.01
61%
50% P=0.02
CEA <5
CEA >5
151
59
90%
65% P=0.05
65%
48% P=0.04
Male
Female
114
96
90%
85% P=0.55
57%
55% P=0.60
Age < 80
Age > 80
173
37
85%
75% P=0.36
64%
30% P<0.01
Node negative
Node positive
82
128
93%
79% P<0.01
65%
34% P=0.01
Complete
Incomplete
199
11
92%
20% P<0.01
62%
17% P=0.05
Tumour height
 − 0-5 cm
 − 5-10 cm
 − 10-15 cm
59
87
64
82%
85%
95% P=0.11
52%
56%
65% P=0.23
Overall survival
The actuarial overall 3- and 5-year survival rates were 72% and 58%, respectively. Five-year 
overall survival demonstrated a statistically significant difference between the pTNM stages, 
type of resection, lymph nodes, CEA levels, age and completeness of the resection (See table 
4). Patient’s gender and preoperative radiotherapy were not of statistic significance. Increased 
age, advanced T-stage, positive lymph node status, increased CEA and completeness of the 
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resection were independent risk factors for overall survival in the multivariate analysis (See 
Table 5). In a Cox regression model age was the most important factor. 
Table 5. Results of the Multivariate Cox regression analysis for Local Recurrence and Overall 
Survival
Local recurrence Overall Survival
HR 95% CI P HR 95% CI P
Type of resection
 − APR 0.20 0.1–0.5 0.000 0.74 0.4–1.2 0.284
Lymph Nodes
 − positive 3.63 1.5–8.9 0.005 1.99 1.2–3.3 0.007
Completeness
 − incomplete 0.00 0.00–100+ 0.000 1.01 0.4–2.5 0.981
Level of CEA
 − >5 2.05 0.8–4.9 0.105 1.83 1.1–3.0 0.019
Age
 − > 80 - - - 2.76 1.5–5.0 0.000
HR = Hazard Ratio, CI = Confidence Interval
0%
25%
50%
75%
100%
0 1 2 3 4 5
Lo
ca
l r
ec
ur
re
nc
e f
re
e S
ur
vi
va
l
APRLow Anterior
N=145 
N=65 
P<0.01 
Years aer surgery
Figure 2. Local recurrence according to type of resection (P<0.01)
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Figure 3. Overall survival according to CEA (P=0.04)
DISCUSSION
Since the introduction of TME as the standard operative technique, the rate of local 
recurrence after resection of rectal carcinomas spectacularly decreased from 37% in the 
early 1980s after conventional surgery to <10% at present.5 TME provides sharp meticulous 
dissection to keep the visceral layer of the pelvic fascia intact and this is important to avoid 
breach in the mesorectum, which is now an important cause for local recurrence.[15-18] 
Neoadjuvant radiotherapy demonstrated to improve the TME results with a decreased local 
recurrence rate, but without an impact on survival.[11] In the present study, this impact of 
radiotherapy on local recurrence was not demonstrated, but the number of patients is small.
To define the value of TME in a general hospital population, we decided to include all 
patients of all ages with a potentially resectable rectal carcinoma. Evaluation of the results, 
therefore, includes patients previously treated by local transanal resection and patients with 
postoperatively proven T4 tumours and elderly patients or patients who are not fit enough 
to enter clinical trials. Bearing this in mind, our results are encouraging. The local recurrence 
rate was 13% in the whole group at 5 years, including patients with and without preoperative 
radiotherapy. When considering the microscopically complete resected tumours, the 
recurrence rate was 9%. R1 resections showed a 21% local recurrence rate, which is similar 
to what has been described in the literature.[17, 19] Adequate surgery plays a key role in 
preventing local recurrences.[20, 21] Quirke showed a linear correlation between the 
development of a local recurrence and an inadequate resection with positive circumferential 
margins.[14, 22] It is, therefore, of crucial importance to optimise preoperative work-up 
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to identify those patients who will need preoperative treatment in order to downsise and 
downstage the tumour. In our study, four patients with a local recurrence proved to have T4 
tumours, which were not preoperatively correctly diagnosed and, therefore, did not undergo 
preoperative chemoradiotherapy. New imaging techniques using MRI to stage these tumours 
accurately will improve this in the future.[23–2]
The use of sharp perimesorectal dissection and the practice of “close shave” anterior resection 
has not only led to fewer recurrences but also increased the sphincter saving rate. Heald 
et al.[28] reported that APR was required in 23% of patients with tumours in the lower 
rectum. In the present study, an APR was performed in 30% of the patients. Since there is a 
significantly worse outcome on both local control and overall survival and the high rate of 
perineal complications in patients with an APR pretreated with preoperative radiotherapy, it 
is favourable to have fewer APR .[8]
Anastomotic leakage is a major complication associated with TME. As the risk of leakage 
depends on the level of the anastomosis, the incidence of leakage is high following TME 
in low rectal tumours (7–9%).[29] A total of eight patients (5%) in our study developed an 
anastomotic leakage. Six of them (75%) were located in patients with very low anastomoses 
(below 5 cm), which increases the risk for leakage. All these patients had been treated with 
preoperative radiotherapy, which is known to increase the risk for leakage.[30-32]
The prognosis in our patient series is similar to other reported data, showing an overall 
survival of more than 60% after 5 years.[33, 34] To identify prognostic factors, a univariate 
analysis was included. As expected, TNM classification was of significant importance for 
prognosis.[17] As reported by many others,[8, 11, 13, 35-39] completeness of the resection was 
also a significant prognostic factor. New treatment protocols (neoadjuvant chemoradiation) 
and meticulous preoperative work-up will possibly lead to more complete resections in the 
future. Furthermore, in contrast with previous reports,[40] high levels of CEA levels were of 
significant importance on both overall survival and local recurrence in the present study.[41-
44] Age >80 was also an important factor for a decreased overall survival in the present study. 
After 5 years, the overall survival of patients above 80 was 30% compared to 64% in patients 
under the age of 80. The incidence of comorbidity, which renders the patient vulnerable 
to postoperative complications, is also highest after this age.[45, 46] After major resectional 
treatment, elderly patients with rectal cancer have an increased 30-day and 6-month mortality 
compared with younger patients. Treatment-related mortality is an important competitive 
risk factor, which obscures the positive effect of modern rectal cancer treatment in those 
aged 75 years and above.[37, 46-48]
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CONCLUSION
TME is a feasible technique with an acceptable rate of postoperative morbidity and low 
mortality also in a community hospital. Patients with positive lymph nodes, an incomplete 
resection, aged above 80, and/or a high level of CEA have a poor prognosis. Meticulous 
preoperative work-up is of great importance to decrease incomplete resections and improve 
results in future patients.
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AbSTRACT
background
Treatment of rectal cancer with preoperative radiotherapy followed by TME is nowadays 
the standard treatment. It reduces local recurrences and improves overall survival. However, 
in patients with T2, 3 N0 rectal cancer, the role of preoperative radiotherapy remains 
controversial. The aim of this study was to review the benefit of radiotherapy in T2 and T3, 
N0 rectal cancer patients.
Methods
Between 1996 and 2003, 103 patients with T2, 3 N0 rectal cancer, were identified in our 
prospective database. This study evaluated time to local recurrence, distant metastases and 
overall survival.
Results
The median age at the time of diagnosis was 70 (range 40–91) years. Median follow up was 
4.3 years. The 5-year local control rate was 94%. The five-year overall survival was 65%. The 
5-year disease free survival rate was 82%. Preoperative radiotherapy did not show any statistic 
differences. Abdominal perineal resection and T3 tumours negatively influenced overall 
survival (P=0.02). Advanced age was of significant importance on overall survival.
Conclusions
Preoperative radiotherapy does not seem to be of significant importance in patients with T2, 
3 N0 rectal cancer regarding local recurrence and survival. Since preoperative radiotherapy 
is associated with short- and long term morbidity, patients with T2, 3 N0 tumours should be 
identified and treated with surgery alone. 
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INTRODUCTION
The ultimate goal in the treatment of rectal cancer is to maximise local control and to 
improve overall long-term survival. Local recurrence is a serious complication in the 
treatment of rectal cancer, since it causes disabling symptoms and is difficult to cure.[1, 2] 
After conventional surgery a high incidence of local recurrence up to 40% was previously 
reported.[3, 4] Heald described a new concept in operative anatomy, the Total Mesorectal 
Excision (TME) technique in which the entire mesorectum is enveloped and resected.[5, 6] 
The Dutch Colorectal Cancer Group started a randomised multicentre trial and showed a 
superior local control in patients treated with preoperative radiotherapy followed by TME 
surgery.[7] Long term results showed a consistent significant difference in local control, 
however this difference was not present in a subgroup analysis for TNM stage I and II.[8] 
Since several years, preoperative radiotherapy has become the standard of care for all rectal 
cancers in many medical centres, but selection criteria are still controversial.[9] Although 30% 
of T2 and T3, N0 patients die as a result of disseminated disease, neo-adjuvant radiotherapy 
seems to add little to local control or survival.[10] This study was intended to assess the 
outcome of a historical group of T2, 3 N0 patients treated with a TME alone and compare 
them with a T2, 3 N0 group who was treated with preoperative radiotherapy followed by 
TME. Time to local recurrence, time to distant metastases and overall survival between the 
different treatment groups was compared and predictors of recurrence were identified to 
assess the influence of clinical variables on outcome.
PATIENTS AND METHODS
Patients and Preoperative Assessment
Between 1996 and 2003, the hospital charts of 210 patients with primary rectal cancer were 
recorded in our prospective database. Of these, 103 patients had a pT2 or a pT3 tumour with 
negative lymph nodes. In case of preoperative radiotherapy, a radiation dose of 25 Gy in 5 daily 
fractions was delivered. Radiotherapy was administered by a three-field technique, using one 
posterior and two lateral ports. All patients underwent complete curative resection and were 
observed prospectively. Follow-up, primarily obtained from the institution database, was 
updated by clinical chart review, physician records, patient’s correspondence and telephone 
interviews. Clinical factors including age, gender, node status, CEA levels, radiotherapy, 
type of resection and completeness were correlated with time to local recurrence, distant 
metastases, disease free survival and overall survival. 
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Surgery
All patients underwent surgery according to the Total Mesorectal Excision principle, as 
described by Heald.[5] Surgery was planned 5–7 days after short-term radiotherapy and 
prophylactic intravenous antibiotics were given at the induction of anaesthesia in all patients. 
Three well-trained TME surgeons performed all operations. In case of an anterior resection, 
a side to end anastomosis was made using the double stapling technique. A diversion stoma 
was made in case of complicated procedures, a positive leakage test or incomplete doughnuts. 
Loop ileostomy was the preferred method in these cases. In case of a positive leakage test, the 
leakage was localised and sutured when discovered.
Pathology
The pathologists were trained to identify Cirumferential Resection Margin (CRM), positive 
nodes and lateral spread of tumour according to the protocol of Quirke et al.[11] Complete 
resection was defined as absence of residual disease (<1mm) after surgical resection.
Follow-up
Clinical evaluation every 3 months during the first year after surgery and yearly thereafter 
for at least two more years was mandatory and included yearly liver imaging and endoscopy. 
Physical examination was carried out and CEA levels were measured. If the patients had 
complaints and/or the CEA level was risen a CT-scan or MRI was made, followed by 
pathology if there was suspicion of recurrence. A local recurrence was defined as evidence of 
a tumour within the lesser pelvis or the perineal wound. Distant recurrence was defined as 
evidence of a tumour in any other area.
Statistics
Local control and overall survival curves were calculated from the time of TME and were 
based on the method of Kaplan and Meier. All statistical analyses were executed in SPSS. 
Univariate comparisons of survival end points were calculated using the log-rank test. 
Significance was defined as P<0.05. Multivariate analysis was done by Cox regression with 
significant independent univariate parameters
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RESULTS
Patient and tumour characteristics
One hundred and three patients were included with a mean age of 70 (range: 40–91 years). 
Patient and tumour characteristics are depicted in table 1. Preoperative serum CEA levels 
were recorded in 91 of 103 patients (90%) with median serum preoperative CEA of 2, 6 
(range: 0,2–133 ng/ml). All patients were node negative (N0) on pathologic review. Median 
number of lymph nodes removed at surgery was 6 (range: 0–24). All but three resections 
were complete, with microscopically negative circumferential and distal margins. Median 
distance from the circumferential- and distal margin was measured on original pathologic 
examination and recorded for 79 and 70 of 103 patients, respectively. Median distance from 
the circumferential margin was 10 mm (range 1–45 mm) and from the distal margin 25 
mm (range 4–120 mm). Patients with pT2, 3 N0 lesions did not receive additional adjuvant 
therapy.
Table 1. Patient and Tumour Characteristics
Rtx no* Rtx yes Total
Sex
 − male
 − female
42 (58%)
30 (42%)
20 (65%)
11 (35%)
62 (60%)
41(40%)
AJCC T Stage
 − pT2
 − pT3
34 (47%)
38 (53%)
13 (42%)
18 (58%)
47 (46%)
56 (54%)
Type of resection
 − Low Anterior Resection
 − Abdomino perineal resection
48 (66%)
24 (34%)
22 (71%)
9 (29%)
70 (69%)
33 (31%)
Grade
 − well differentiated
 − moderately differentiated
 − poor differentiated
5 (7%)
51 (71%)
16 (22%)
2 (6%)
18 (58%)
11 (36%)
7 (7%)
69 (67%)
27 (26%)
* Rtx = radiotherapy 
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Follow-up
Median follow-up of all patients was 4.3 years (range 0.4–8.4 years). During follow-up 10 
patients died because of ongoing or recurrent disease. Five patients died postoperatively 
(4.9%).
Local Recurrence
Local recurrences were demonstrated during follow-up in 4 patients. Three recurrences 
occurred in the patients who had an incomplete resection of the tumour. The actuarial overall 
3- and 5-year local control rates were 97% and 94%, respectively. An incomplete resection 
significantly influenced outcome. There was a trend to a higher risk on local recurrences in 
patients with an elevated preoperative CEA (p=0.07). In the univariate analysis preoperative 
radiotherapy, age, gender, ASA classification, bloodloss during operation preoperative pain 
were no significant prognostic factors for the risk of local recurrence (Table 2 and Figure 1).
Distant metastases
Thirteen patients developed distant metastases during follow-up. The actuarial overall 3- and 
5-year distant metastases free rates were 93% and 87%, respectively. The actuarial disease free 
survival rates were 86% and 80%, respectively. For T2 tumours, the 5-year disease free survival 
was 87% compared with 75% for patients with a T3 tumour (P=0.34). The mean time to 
develop distant metastases in pT2 tumours was 3,5 years. In pT3 tumours this was 1,2 years. 
Twelve patients developed hepatic metastases, 5 patients’ lung metastases and 1 patient bone 
metastases. Lung and/or bone metastases were in 38% synchronous with hepatic metastases. 
There were no statistical significant differences for the development of distant metastases.
Overall survival
The actuarial overall 3- and 5-year survival rates were 75% and 65%, respectively. Five-year 
overall survival demonstrated a statistically significant difference between the pTNM stages 
(Figure 2), type of resection (Figure 3), completeness of the resection and age (Table 2.). 
Advanced age (>80 years) was also an independent negative factor in a multivariate analysis 
(Figure 4).
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Table 2. Survival and Local Recurrence
Outcome Number of patients % P value 95% CI
5-year local free recurrence
All patients 103 94 0.88–0.99
 − pT2
 − pT3
47
56
96
91 P=0.34
0.87–1.00
0.83–1.00
 − LAR
 − APR
70
33
94
88 P=0.53
0.89–1.00
0.75–1.00
 − CEA <5
 − CEA >5
76
27
95
84 P=0.07
0.92–1.00
0.66–0.93
 − Age <80
 − Age >80
81
22
95
85 P=0.76
0.87–0.99
0.71–0.99
 − Rtx yes
 − Rtx no
31
72
95
93 P=0.69
0.87–1.00
0.85–1.00
 − Complete resection
 − Incomplete resection
100
3
96
0 P=0.02
0.89–1.00
0.00–1.00
5-year overall survival
All patients 103 65 0.55–0.74
 − pT2
 − pT3
47
56
77
55 P=0.03
0.62–0.89
0.42–0.69
 − LAR
 − APR
70
33
75
52 P=0.02
0.58–0.82
0.35–0.70
 − CEA < 5
 − CEA > 5
75
28
70
54 P=0.14
0.60–0.81
0.16–0.51
 − Age < 80
 − Age > 80
81
22
72
34 P=0.00
0.62–0.81
0.16–0.51
 − Rtx yes
 − Rtx no
31
72
73
63 P=0.65
0.54–0.87
0.51–0.74
 − Complete resection
 − Incomplete resection
100
3
77
0 P=0.04
0.66–0.82
0.13–1.00
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Figure 1. Local control according to pre-operative radiotherapy
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Figure 2. Overall survival according to pTNM stages
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Figure 3. Overall survival according to type of resection
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Figure 4. Overall survival according to age
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DISCUSSION
Since the introduction of TME as the standard operative technique, the rate of local recurrence 
after resection of rectal carcinomas decreased spectacular from 30–40% in the early 80’s after 
conventional surgery to less than 10% at present.[12, 13] In the present study 5-year local 
recurrence rate for T2, 3 N0 patients was 6%, without a difference between patients who did 
and did not underwent preoperative radiotherapy. Final results of the Dutch TME trial has 
demonstrated that five-year local recurrence rate of patients undergoing a macroscopically 
complete local resection was 5.6% in case of preoperative radiotherapy compared with 10.9% 
in patients undergoing TME alone (P<0.001).[8, 14] This has resulted in the administration 
of a short course of radiotherapy in nearly all patients with rectal cancer in the Netherlands.
[15] However, preoperative radiotherapy has short- and long-term negative side effects such 
as increased leakage,[16] wound infections[7] and faecal incontinence.[8] Surgical nerve 
damage may play a major role in the development of faecal and urinary incontinence, but 
there is a significant additional effect of radiotherapy and faecal incontinence can worsen 
over time in case of radiotherapy.[17] Sexual dysfunction; erectile dysfunction, ejaculatory 
problems, dyspareunia and vaginal dryness, occurs frequently after rectal cancer treatment 
and is caused by surgical (nerve) damage with again an additional effect of preoperative 
radiotherapy.[18] Moreover, a recent update of the Dutch TME trial demonstrated that 
there is no benefit of radiotherapy on local recurrences in T2, 3 NO patients, similar as 
has been demonstrated in the present study.[8] Kapiteijn et al.[7] reported that preoperative 
radiotherapy only seems to be beneficial in patients with positive lymph nodes (i.e., TNM 
stage III).[8] Thus, preoperative radiotherapy might not be indicated in early tumours of the 
rectum and needs to be reconsidered as standard treatment for all rectal cancer patients.
In the present study, preoperative increased serum CEA levels showed a trend for an increased 
local recurrence rate (p=0.07). Nissan et al.[10] found that serum CEA levels are a significant 
prognostic factor for both local control and overall survival. A significant prognostic 
factor for increased local recurrences and reduced survival in this study was an incomplete 
resection, which has already been recognised as an important factor in the literature.[8, 19-21] 
Furthermore, as previously reported by others[8, 10, 22-24] a significant reduced survival was 
identified in patients who underwent an APR.
Advanced age (>80 years) was the most important factor for a decreased overall survival in the 
present study. In a multivariate analysis age was the only significant independent factor. After 
5 years the overall survival of patients above 80 years was 34% compared to 72% in patients 
under the age of 80. More importantly, 45% (10 patients) of the elderly patients died during 
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the first 6 months after surgery. The incidence of co morbidity, which renders the patient 
vulnerable to postoperative complications, is also highest after this age.[25, 26] Treatment-
related mortality is an important competitive risk factor, which obscures the positive effect 
of modern rectal-cancer treatment in those aged 75 years and above.[26-29] Thus, surgery 
might not be the best option for all elderly patients with rectal cancer and alternative 
treatment option should be considered in the elderly frail patients such as radiotherapy only, 
or radiotherapy in combination with local excision, to minimise morbidity.
As we obtained the good results for T2, 3 N0 patients, it is of great importance to identify 
this specific group of patients before treatment is started. Meticulous preoperative work-up 
is therefore important to identify patients with lymph node involvement preoperatively, but 
neither clinical assessment nor imaging tools, including MRI, CT, PET an ERUS have the 
ability to accurately identify lymph node involvement. Recent studies demonstrated that the 
accuracy of preoperative imaging (including ERUS/MRI) for staging T3N0 rectal cancer was 
limited because 22% of patients will have undetected mesorectal lymph node involvement.
[30, 31] Further studies are needed to improve the accuracy of imaging modalities to establish 
treatment options that will provide the best outcome for this group of patients. 
CONCLUSION
Patients with limited (T2-3) rectal tumours without lymph node metastases have an excellent 
local control and overall survival. Preoperative radiotherapy had no demonstrable effect on 
local recurrence or survival, therefore patients with early, limited rectal cancers, should be 
treated with surgery alone. Improvements in imaging modalities are necessary to identify 
patients without lymph node involvement who should be refrained from preoperative 
radiotherapy treatment.
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AbSTRACT
Purpose
The study was designed to analyse the results of a multimodality treatment, using preoperative 
radiotherapy, followed by surgery and intraoperative radiotherapy in patients with primary 
locally advanced rectal cancer.
Methods
Between 1987 and 2002, 123 patients with initial unresectable and locally advanced rectal 
cancer were identified in our prospective database, containing patient characteristics, 
radiotherapy plans, operation notes, histopathological reports and follow-up details. An 
evaluation of prognostic factors for local recurrence, distant metastases and overall survival 
was performed.
Results
All patients were treated preoperatively with a median dose of 50 Gy radiotherapy. Surgery 
was performed 6-10 weeks after radiotherapy. Twenty-seven patients were treated with 
IORT because margins were incomplete or equal or less than 2 mm. Postoperative mortality 
was 2 percent. The median follow up of all patients was 25.1 months. The overall 5-year 
local control was 65 percent and the overall 5- year survival was 50 percent. Positive lymph 
nodes and incomplete resections negatively influenced local control and overall survival. 
Intraoperative radiotherapy improved 5-year local control (58 percent vs. 0 percent, p=0.016) 
and overall survival (38 percent vs. 0 percent, p=0.026) for patients with R1/2 resections. 
Conclusions
The presented multimodality treatment is feasible with an acceptable mortality and a 5-year 
overall survival of 50 percent. Addition of intraoperative radiotherapy for patients with a 
narrow or microscopic incomplete resection seems to overrule the unfavourable prognostic 
histologic finding.
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INTRODUCTION
Colorectal cancer is a major problem in the western world, has a rising incidence and a 
mortality rate of approximately 50 percent.[1, 2] Rectal cancer is different from colon 
cancer because of its close relationship to surrounding structures, which leads to high local 
recurrence rates of 3–25 percent after resection.[3-5]
Primary locally advanced rectal cancer (i.e. tumour tissue extending into or beyond the 
enveloping fascia propria of the mesorectal compartment) represents approximately 10 
percent of all rectal cancer patients. Often these tumours infiltrate adjacent structures and 
therefore have a higher risk to develop a local recurrence which might lead to disabling 
symptoms including unrelenting pain.[6]
Locally advanced rectal cancer, when left untreated, results in a median survival of 7–8 
months.[7] Primary radiation therapy for locally advanced rectal carcinomas provides good 
palliation but a limited chance of cure. Because surgery alone has been reported to result in 
5-year survival rates of only 19 to 33 percent, preoperative radiotherapy has been used to 
downstage advanced tumours and make it possible to perform a complete resection.[8, 9]
Primary locally advanced rectal cancer can be cured using aggressive treatment modalities 
including preoperative (chemo)radiotherapy, extensive surgery and intraoperative radio-
therapy (IORT).[10] IORT refers to the delivery of radiation at the time of surgery and is 
used when resection margins are narrow or involved with tumour cells. IORT can be applied 
very specifically to an area at risk, under direct visual control and with the possibility to 
shield the surrounding structures from radiation. The biologic effectiveness of single-dose 
IORT is considered to be as effective as two to three times the equivalent dose of fractionated 
radiotherapy. Eble et al.[11] demonstrated that IORT was feasible, safe and resulted in very 
low local recurrence rates, even in patients with microscopic residual disease or close resection 
margins. Previous reports of treatment programs using external beam radiation therapy, 
surgical resection and IORT for patients with locally advanced primary rectal carcinoma 
described excellent local control and high survival rates.[1]
At our tertiary referral hospital we have initiated a treatment protocol for patients 
with primary locally advanced or recurrent rectal cancer, which combines preoperative 
radiotherapy followed by surgery and IORT. In this report the experience with this combined 
modality therapy for 123 patients with primary locally advanced and initially unresectable 
rectal cancer is described. Prognostic factors were evaluated for local recurrence, metastases-
free and overall survival.
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MATERIALS AND METHODS
Data collection
Between January 1987 and March 2003, 123 patients with locally advanced or initially 
unresectable rectal cancer were referred to our tertiary referral centre. All tumours were 
biopsy-proven invasive adenocarcinomas. Each tumour was clinically classified as large 
T3 with narrow circumferential margins to the mesorectal fascia on CT or MRI imaging 
or fixed, initially unresectable T4 tumours. Our prospective database consists of hospital 
notes, radiotherapy plans, operation notes and histopathologic reports to obtain the 
following information: demographics, preoperative diagnostic intervention, tumour 
staging, radiotherapy technique, surgical details, histopathologic details, and complications. 
Follow-up was registered using hospital notes, medical letters, and in some cases by general 
practitioner information.
Preoperative and intraoperative radiotherapy
In a minority (n=15) of cases a four-field technique was used to cover the treatment volume 
defined by the supervising radiotherapist. In the majority (n=108) of cases three fields (one 
posterior and two lateral fields) were used. A radiation dose of 50 Gy in 25 daily fractions 
of 2Gy was planned for all patients. IORT with HDR brachytherapy was given from 1997 
to those patients (n=27) who had a minimal circumferential free resection margin equal 
to or less than two millimeters. The resection margin was judged on frozen sections taken 
during surgery. A boost of 10 Gy was directly given in the operation field with the Flexible 
Intraoperative Template (FIT) developed at our department.[12] The FIT is a 5 mm thick 
flexible silicon template containing parallel catheters spaced 1 cm apart. The shape of the FIT 
was determined by the surgeon and radiation oncologist and was adjusted to the target area. 
Before positioning the FIT, 3 to 4 surgical clips were placed widely around the target surface. 
Active dwell positions were chosen according to the size and shape of the actual FIT. The 
dose was specified at the reference depth (usually 10 mm from the surface of the FIT). The 
position of the clips was reconstructed from the reconstruction films made using a dedicated 
brachytherapy localiser. The individual treatment plan was calculated by importing the dwell 
times from the standard treatment plan in the reconstructed FIT geometry. The actually 
delivered dose, i.e. the treatment dose, was defined as the average dose in dose points, placed 
on a line perpendicular to the reconstructed FIT at the prescribed depth. This dose was 
expected to be 10 Gy because of the anatomy of the pelvis.
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Surgery
Surgery was planned 6-10 weeks after the final radiation treatment. The majority of patients 
(n=76) were operated on in the Erasmus MC-Daniel den Hoed Cancer Centre, Rotterdam. 
When patients did not need extensive surgery or IORT was not considered necessary, surgery 
was in some cases performed in other hospitals (n=47).
Statistical analysis 
Patient characteristics are presented by tabulation. Overall survival, local failure-free and 
metastasis-free survival were calculated using the actuarial method of Kaplan and Meier.13 
The IORT and non-IORT groups were compared using the log rank test. Overall survival, 
local control and distant metastasis were analysed as a function of completeness of the 
resection, lymph node stage (negative vs. positive), IORT (yes vs. no), preoperative pain (yes 
vs. no) and type of hospital (tertiary centre or community hospital). Cox regression was 
used to evaluate the prognostic factors for overall survival.[14] P-values less than 0.05 were 
regarded as significant.
RESULTS
Patients
Preoperative radiotherapy followed by surgery was performed in 123 patients; 87 male 
and 36 female. Mean age at the time of surgery was 66 year (range 20–90 year). Presenting 
symptoms were pain in twelve patients (10 percent), defecation abnormality in 56 patients 
(46 percent), perineal pressure in 9 (7 percent) and a combination of these in 36 patients 
(29 percent). Only 10 patients (8 percent) presented without symptoms. The tumour was 
clinically fixed to adjacent organs or the pelvic wall in 99 patients (80 percent). 
Treatment
In 66 patients (54 percent) a diversion colostomy was performed, prior to radiotherapy. 
The omentum or the distal sigmoid was used to fill the pelvis to prevent the small bowel 
from radiation damage in 53 patients, an artificial spacer (breast prosthesis) was used in 
two patients. The majority of patients (n=104) received 50 Gy radiotherapy. The remaining 
patients received various doses between 25 and 52 Gy. 
Surgery was performed 6–10 weeks after radiotherapy and included low anterior resection in 
23 patients (19 percent), abdominalperineal resection in 60 (49 percent) or abdominal sacral 
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resection in 3 patients (2 percent). When there was tumour growth into the vagina or cervix 
or into the bladder or prostate, respectively a posterior- (n=19) or total exenteration (n=18) 
was performed. A complete resection (R0) could be performed in 104 patients (85 percent), 
a microscopic incomplete (R1) in 17 patients (14 percent) and macroscopic incomplete (R2) 
in 2 patients (1 percent). Other tumour characteristics are depicted in Table 1. There was 
a statistically significant difference in tumour stage between the referral hospital and the 
community hospitals (P=0.001). More advanced tumour stages were treated in the tertiary 
center, e.g. 29/76 patients operated on had a T4 tumour vs. 2/47 patients in the community 
hospitals. Twenty-seven patients (22 percent) were treated with IORT because the resection 
was incomplete or the margin equal or less than 2 mm.
The median operation time was 345 minutes (range 135–670 minutes) and the median 
bloodloss 3.6 liters (range 0,5–20 litres). Perioperative liver metastases were found in 3 
patients. These metastases were resected during a second intervention in all patients.
Follow-up
Median follow up was 25.1 months (range 1–136 months). Postoperative complications 
are depicted in Table 2. Postoperative in hospital (within 30 days after surgery) mortality 
occurred in 3 patients (2 percent). Three (3 percent) patients complained of possible 
radiotherapy related late toxicity: 2 patients reported chronic perineal pain and 1 patient 
experienced chronic diarrhea.
Local control
The overall 3-year and 5-year local control rates were 75 and 65 percent, respectively. There 
was a significant difference in the 5-year local control rate between a complete resection 
or incomplete resection (P=0.002) (Figure 1), negative lymph nodes and positive lymph 
nodes (P<0.001), surgery in center or community hospital (p=0.02) and preoperative pain 
(P=0.002). Fixation of the tumour and type of resection were not of significant importance 
(Table 3).
Distant metastases 
The overall 3-year and 5-year actuarial distant metastases free survival rates were 59 percent 
and 53 percent, respectively. The 5-year metastases free survival rate was statistically 
significantly different for complete versus incomplete resection (P<0.001), positive vs. 
negative lymph nodes (P<0.001) and preoperative pain (P=0.002). Type of hospital, fixation 
of the tumour and type of resection were not of significant importance (Table 3).
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Table 1. Treatment characteristics of 123 patients after multimodality treatment
N (%)
Tumour localization (distance to anal verge)
 − <5 cm
 − 6-10 cm
 − >10 cm
 − Unknown
83
28
8
4
67
23
7
3
Resection of adjacent organs
 − Prostate 
 − Prostate partial
 − Seminal Vesiculae
 − Bladder
 − Vaginal wall
 − Uterus
 − Part of sacrum
 − Os coccygis
17
14
20
18
22
15
4
10
14
11
16
15
18
12
3
8
TNM-classification (pathology)
Tumour
 − T0
 − T2
 − T3
 − T4
 − Tx
Node
 − N0
 − N1
 − N2
 − Nx
Metastases
 − M0
 − M1
2
17
70
31
3
68
24
9
22
120
3
1
14
57
25
2
56
20
7
18
97
3
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Table 2. Postoperative complications
N (%)
Postoperative complications
 − Local complications
 − Abdominal / perineal wound infection
 − Intra-abdominal / perineal abscesses
 − Anastomotic leakage*
General complications
 − Urinary tract infection
 − Bladder retention
 − Pneumonia
18
12
4
9
21
10
15
10
18
7
17
8
Reinterventions
 − Revision stoma
 − Revision Bricker
 − Abscess drainage 
7
2
7
6
1
6
* Counted only in those patients who underwent a low anterior resection (n=22)
  
 
 
C
um
ul
at
iv
e p
er
ce
nt
ag
e 
 
 
0 12 24 36 48 60
0
25
50
75
100
 complete
 incomplete
 months
 At risk:
 complete 104  71  54  29  20  13
 incomplete  19  10  4  3  3  1
 Logrank P=.002
Figure 1. Local control by completeness of resection
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Table 3. Univariate analysis of prognostic factors
N Local control (5yr) Metastases free (5yr) Overall survival (5yr)
Resection
 − Complete (R0)
 − Incomplete (R1,2)
104
19
72%
31% (P=0.002)
60%
17% (P<0.001)
57%
20% (P<0.001)
Lymph node stage
 − N -
 − N +
 − N x
68
34
21
83%
0%
65% (P<0.001)
77%
12%
33% (P<0.001)
67%
30%
34% (P=0.001)
Preoperative pain
 − No
 − Yes
Type of Hospital
 − Referral Centre
 − Community Hosp.
Fixation of tumour
 − No
 − Anterior
 − Posterior
 − Lateral
 − Multiple sites
Type of resection
 − LAR
 − APR
 − APSR
 − Total exenteration
 − Post exenteration
105
11
76
46
23
35
12
11
33
22
60
3
18
19
73%
17% (P=0.002)
75%
44% (P=0.020)
59%
59%
89%
79%
65% ns
75%
54%
100%
85%
70% ns
59%
14% (P=0.002)
52%
53% ns
38%
56%
88%
79%
36% ns
78%
48%
67%
47%
50% ns
53%
38% ns
56%
41% ns
48%
53%
64%
81%
35% ns
54%
46%
67%
44%
66% ns
N - = no positive lymp nodes; N+ = positive lymph nodes; LAR = low anterior resection; APR = 
abdominoperineal resection; APSR = abdominopreineal sacral resection; ns = not significant
Overall Survival
The overall 3-year and 5-year survival rates were 58 percent and 50 percent, respectively. Five-
year overall survival was significantly different between complete and incomplete resection 
(P<0.001) and lymph node status (P=0.001) (Figure 2). Preoperative pain had no effect on 
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overall survival. Type of hospital, fixation of the tumour and type of resection were also not 
of significant importance (Table 3). 
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Figure 2. Overall survival by lymph node status
Table 4. Five-year actuarial local control and overall survival by IORT administration
Resection N IORT* Local control Overall survival
Complete 
Complete 
Incomplete 
Incomplete
85
19
8
11
No
Yes
No
Yes
71%
72% ns
 0%
58% (P=0.016)
56%
66% ns
 0%
38% (P=0.026)
IORT = intra operative radiotherapy; ns = not significant
* IORT added for patients with margins ≤ 2mm after 1997
IORT
Of the 19 patients who underwent an incomplete (R1, 2) resection 8 did not receive IORT, 
because of high radiation therapy in the past (e.g. cervix carcinoma), poor physical situation, 
or because IORT was not available. All these 8 patients developed a local recurrence and all 
died within 5 years (Table 4). When IORT was delivered to patients with an incomplete 
resection, local control and survival were substantially improved relative to patients who did 
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not receive IORT (5-year local control 58 percent vs. 0 percent, P=0.016; 5-year overall 
survival 38 percent vs. 0 percent, P=0.026). Patients who underwent IORT for a marginal 
complete resection (margin <2 mm) had a similar local control and overall survival compared 
to the total group of patients who underwent a complete resection. In a multivariate Cox 
analysis including the factor IORT combined with completeness of resection, age, sex, and 
lymph node status, significant independent prognostic information was obtained from 
IORT and lymph node status. An incomplete resection without IORT was significantly 
inferior (P<0.001) to a complete resection or an incomplete resection with IORT.
DISCUSSION
Patients with locally advanced tumours should preferably receive some form of neoadjuvant 
treatment to downstage the tumour and enable a potentially curative resection. In the present 
study, a multimodality treatment consisting of preoperative radiation therapy followed 
by aggressive surgery with or without intraoperative radiotherapy was demonstrated to 
be feasible with an acceptable mortality and a five-year local control of 65 percent and an 
overall survival of 50 percent. In the literature, several studies do not discriminate between 
primary locally advanced and recurrent rectal cancer and results are described as one group.
[1,15] It seems important to differentiate between these two, because five-year overall 
survival of patients treated for recurrent rectal cancer is generally reported between 15 to 55 
percent16–20 compared with a much higher 40 to 70 percent in primary locally advanced 
rectal cancer.[7,20–23] A similar difference in local control in favour of locally advanced 
rectal cancer has been described.
In the present study, patients who underwent a complete resection had a significantly 
improved five-year local control rate compared with incompletely resected patients (72 
vs. 31 percent). This is in concordance with results demonstrated in the Dutch TME trial 
representing mainly T2 and 3 rectal cancer patients. A margin of 2 mm was associated 
with a local recurrence risk of 16 percent compared with 5.8 percent in patients with more 
mesorectal tissue surrounding the tumour (P<0.0001).[24] Willett et al.[7] reported similarly 
high local control rates in patients with locally advanced rectal cancer who underwent 
complete tumour resection. Even if the tumour invades adjacent organs and a total pelvic 
exenteration is considered necessary, local control rates can be high as long as complete 
tumour resections are achieved.[25]
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Lymph node status and the presentation of preoperative pain also proved to be significantly 
important factors for local control in the present study. Pain often is not described as a 
predictive factor in primary locally advanced rectal cancer but is known to be a negative 
prognostic factor in local recurrences and leads to a significant decrease in overall survival.
[18,26]
Local control is significantly related to the dose of irradiation; however, because of toxicity 
to radiosensitive organs, such as small bowels, the external radiation dose should not exceed 
60 Gy.[27] A combination of external irradiation and IORT allows the safe delivery of higher 
effective doses of irradiation than can be delivered with external beam-only techniques. IORT 
is a boosting technique that has been proven to be feasible to integrate in the multimodality 
treatment of locally advanced rectal cancer without increased normal tissue toxicity.[28] 
Previous studies have demonstrated that IORT achieves good local control and high survival 
rates in primary locally advanced rectal cancer.[7,10,11,21,29-32] Most of the results reported 
regarding IORT in rectal cancer originate from a few centres, and randomised trials are 
lacking. In the present study, IORT improves the five-year local control rate in patients 
with an incomplete resection to 58 percent compared with 0 percent in patients who did 
not receive IORT. Nakfoor et al.[22] and Gunderson et al.[33] similarly reported high local 
control rates with IORT even for patients who had macroscopic residual disease. The Mayo 
series demonstrated five-year overall survival of 55 percent in R1 resected patients and 21 
percent in R2 patients.[34] Despite the fact that patients treated in the referral hospital 
had more advanced tumours, local control was 75 percent compared with 44 percent in 
community hospitals after five years (P=0.02). Similar results were reported by Wibe et 
al.[35] who demonstrated that local recurrence rate was higher in patients treated in hospitals 
with a low annual caseload of fewer than 10 procedures compared with hospitals with a high 
treatment volume of 30 procedures or more.36 Patients treated in smaller hospitals also had 
a lower long-term survival rate than those treated in larger hospitals. Begg et al.[37] reported 
that mortality rates are lower when complex surgical oncologic procedures are performed by 
surgical teams in hospitals with special expertise. Based on these results, we emphasise that 
not only volume but also the necessity of a multidisciplinary team, including a radiation 
oncologist, urologist, surgical oncologist, plastic surgeon, and gynaecologist, is important for 
these surgical procedures, which preferably are performed in specialised centers. The overall 
survival rate in the present study is comparable to what has been reported in the literature 
for these advanced tumours.[21,31,38] Significantly important prognostic factors for overall 
survival are completeness of resection and negative lymph node status. In the literature, these 
are known prognostic factors, but other factors, such as extent of resection and fixation of 
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tumour, also are reported.[7,11,30,31] However, these latter factors did not seem important 
in the present study. IORT was applied in 19 patients who were treated with a narrow but 
complete resection (margin, 0–2 mm). The survival of these patients was similar to the total 
group of patients with a complete margin who did not receive IORT. Nagtegaal et al.[24] 
have demonstrated that circumferential margins are extremely important for developing 
a local recurrence. For rectal cancer patients with circumferential margin of <1 mm, a 
recurrence rate of 16 percent after two years was described. In the present study, addition 
of IORT seems to overrule the unfavourable prognostic histologic finding in patients with 
narrow resection margins. In patients with incomplete resection margins (R1/2 resection), 
addition of IORT resulted in acceptable local control (58 percent) and overall survival rates 
(38 percent). This was in contrast to patients who underwent an incomplete resection and 
were not treated with IORT who all died within five years. In the present study, radiotherapy 
only was used as neoadjuvant treatment to reduce tumour mass. Addition of chemotherapy 
to preoperative radiotherapy recently demonstrated an improvement of local control in two, 
large, randomised trials.[7,39-41] The European Organisation for Research and Treatment 
of Cancer (EORTC) 22921 four-arm randomised trial[42] demonstrated the benefit of 
preoperative chemoradiation vs. preoperative radiation alone in T3–T4 resectable rectal 
cancer patients. The addition of 5-fluorouracil and leucovorin to preoperative radiation 
slightly increased the amount of acute toxicity and, more importantly, increased the number 
of complete responses and decreased the local recurrence rate after five years.[43] In future 
multimodality treatment protocols for locally advanced rectal cancer, the addition of 
chemotherapy to radiotherapy should be considered.[44]
CONCLUSION
IORT for patients with a narrow complete or incomplete resection seems to overrule the 
unfavourable prognostic histologic finding for local control and overall survival. The future 
of treatment for primary locally advanced rectal cancer will be the successful integration of 
IORT into multimodality treatment programs as described in this study.
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AbSTRACT
background
Preoperative radiation therapy in combination with 5-fluoracil (5-FU) improves local tumour 
control in locally advanced rectal cancer. The aim of our study was to evaluate the toxicity 
and efficacy of preoperative chemoradiation using the oral 5-FU prodrug capecitabine in 
locally advanced rectal cancer.
Methods
Sixty patients with locally advanced rectal cancer were treated with preoperative 
chemoradiation. Radiotherapy consisted of a total dose of 50 Gy delivered in 25 fractions to 
the pelvis. Chemotherapy was concurrently administered and consisted of oral capecitabine 
only on radiotherapy days. Surgery was performed six to ten weeks after completion of 
chemoradiation.
Results
The patient population consisted of 19 females and 41 males, with a median age of 61 years. 
All but two patients received the full dose of chemoradiation. No grade 3 or 4 haematological 
toxicities developed. Two patients (3%) developed grade 3 radiation dermatitis and one a 
grade 3diarrhoea. All patients underwent definitive surgery; 19 patients underwent an 
abdominal perineal resection (APR), 25 a low anterior resection (LAR) and 16 patients a 
Hartmann’s procedure. One patient with a low anterior resection developed an anastomotic 
leakage (4%). Final pathology demonstrated eight patients (13%) with a complete 
pathological response. Primary tumour and nodal downstaging occurred in 67 and 84% of 
the patients, respectively. Two patients (3%) had an R1 resection, one after an APR and one 
after an LAR.
Conclusion
Preoperative chemoradiation with oral capecitabine is safe and well tolerated in locally 
advanced rectal cancer patients. This preoperative treatment has a considerable downstaging 
effect on the tumour and lymph nodes.
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INTRODUCTION
Preoperative radiotherapy with concurrent 5-fluorouracil (5-FU) based chemotherapy has 
received increased interest over the last decade in the treatment of locally advanced colorectal 
cancer. The addition of chemotherapy to radiation therapy has been demonstrated to be 
feasible, with an increase in pathological complete response rate and possibility of sphincter 
preservation. Preoperative chemoradiation therapy with 5-FU confers a significant benefit 
with respect to local control.[1,2] Continuous 5-FU infusion has been proven superior to 
bolus administration in terms of tumour response and is associated with a lower incidence of 
haematological and nonhaematological toxicity.[3,4] Disadvantages of continuous infusion 
are requirement of hospitalisation and potential complications resulting from central venous 
access.[5] Capecitabine is a fluoropyrimidine carbamate rationally designed to generate 
5-FU preferentially in tumour cells as the concentration of the key enzyme thymidine 
phosphorylase is higher in tumour cells compared with normal tissue. After irradiation 
thymidine phosphorylase is upregulated in tumour tissue resulting in a supra-additive affect 
of capecitabine on radiotherapy.[6-8] Capecitabine is administered daily to mimic continuous 
infusion of 5-FU. A phase I study of preoperative radiotherapy with 50.4 Gy given in 28 
fractions in five weeks combined with escalating doses of capecitabine was reported by Ngan 
et al.[9] For phase II studies, they recommended a capecitabine dose of 1800 mg/m2/day. 
This overall dose is similar to that used when capecitabine is given as a single agent for 
metastatic disease either in the 42-day continuous regimen (825 mg/m2 twice daily) or in the 
intermittent schedule (1250 mg/m2 twice daily for two weeks, one every three weeks).[10,11] 
Dunst et al. also conducted a phase I study and recommended 825 mg/ m2 capecitabine twice 
a day for phase II evaluation.[12] Three phase II studies have been initiated to evaluate the 
tolerance and efficacy of chemoradiation with capecitabine. In these studies different regimes 
of capecitabine were used and in some studies leucovorin was added.[13-16] We initiated 
a phase II study to evaluate the efficacy and toxicity of preoperative chemoradiation with 
capecitabine in large T3/T4 rectal tumours or in tumours with local lymph node metastasis. 
In this study capecitabine was only administered on radiotherapy days.
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MATERIALS AND METHODS
All patients treated in this study were evaluated including a complete history and physical 
examination, colonoscopy, tumour biopsy, abdominal ultrasound, computed tomography 
(CT) scan of the abdomen and pelvis and magnetic resonance imaging (MRI) of the pelvis, a 
chest X-ray and/or chest CT scan. All CT and MRI images of the patients were discussed in 
our multidisciplinary meeting which includes a colorectal surgeon, gynaecologist, urologist, 
radiotherapist, radiologist and medical oncologist. Complete laboratory tests included a full 
blood count with differential, serum chemistries including electrolytes, liver function tests, 
creatinine, and carcinoembryonic antigen.
Inclusion criteria
All patients had a histologically proven adenocarcinoma of the rectum. This was defined as 
any tumour within 15 cm of the anal verge or a tumour located distal from the line between 
the promontory and symphysis on sagittal MRI. The location of the tumour was measured 
from the anal verge using colonoscopy. Patients with large T3 or T4, Nx or any T3, N1-2 
rectal adenocarcinoma were eligible for the study. Large T3 tumours were defined on 
pelvic MRI as tumours with narrow margins (<2 mm) to the circumferential rectal fascia. 
Mesorectal and obturator lymph nodes were considered positive on pelvic MRI if a node was 
larger than 8 mm or multiple nodes larger than 3 mm. All patients needed to have an Eastern 
Cooperative Oncology Group (ECOG) performance status ≤2 and be aged between 18 and 
80 years. Patients also had to have adequate liver, renal and bone marrow function as follows: 
bilirubin <30 mmol/l, aspartate aminotransferase and alanine aminotransferase less than five 
times the upper level of normal (ULN), creatinine <1.5 x ULN, leucocytes >3.5 x 109/l, 
and platelets 100 x 109/l. Patients of child-bearing age were required to practice approved 
methods of birth control.
Exclusion criteria
Patients with severe comorbidity such as cardiomyopathy or other cardiovascular disease were 
excluded. Patients with known risk of adverse reaction to fluoropyrimidines were excluded, as 
well as patients who were participating in other trials or receiving any investigational drugs.
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TRIAL DESIGN AND ENDPOINTS
This was a single-armed, multicentre phase II study of preoperative radiotherapy with 
concurrent capecitabine for locally advanced rectal cancer. Primary endpoints were toxicity, 
grade of tumour downstaging and pathological complete response. Secondary endpoints 
were rate of sphincter preservation and postoperative complications. Primary endpoints 
were haematological and nonhaematological toxicity. Toxicity was scored with Radiation 
Therapy Oncology Group criteria and the National Cancer Institute Common Toxicity 
Criteria version 3.0. Secondary endpoints were complete pathological response, pathological 
downstaging and sphincter preservation. Our definition of downstaging and complete 
response was based on the comparison of the clinical tumour node metastasis (TNM) and 
the pathological TNM stage. Pathological complete response was defined as no tumour cells 
in the pathological specimen, but only a fibrotic mass.
Chemotherapy
Capecitabine was administered orally at a dose of 825 mg/m2 twice a day only on radiotherapy 
days. The first daily dose was given two hours before radiotherapy and the second dose 
twelve hours later. Dose modifications were applied if the patient experienced any grade 3 
or 4 haematological toxicity or any grade 3 nonhaematological toxicity, such as hand-foot 
syndrome, except for alopecia. Chemotherapy was restarted at a 75% dose if toxicity levels 
resolved to grade 1 or less. If toxicity was clearly related to radiotherapy, for example radiation 
dermatitis, local therapy was administered and capecitabine was not stopped.
Radiotherapy
All patients were treated with preoperative radiotherapy and received a dose of 50 Gy 
delivered in 25 fractions of 2.0 Gy.Radiotherapy was administered by a three-field technique, 
using one posterior and two lateral portals, a four-field box or with five fields using intensity 
modulated radiotherapy. The lateral pelvic borders were defined as 1.5 cm lateral of the bony 
pelvis, the cranial border was the promontory, and the caudal border was below the foramina 
obturatoria to 2 cm under the anus, depending on tumour position. Patients were evaluated 
four times during the course of chemoradiation to assess acute toxicity and compliance with 
the oral capecitabine. Blood tests were taken each time and consisted of full blood count, 
platelets, leucocytes and neutrophils.
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Surgery
Surgery was performed six to ten weeks after completing chemoradiation. Patients were 
reassessed for respectability by pelvis CT scanning or MRI of the pelvis. Total mesorectal 
excision technique was performed in all patients, and extended multivisceral resections were 
performed in clinically T4 patients. Intraoperative radiotherapy was administered in those 
patients in whom the circumferential margins were considered at risk.
RESULTS
A total of 60 patients were included between July 2005 and November 2006. The median 
age was 61 years (range 32 to 82 years) and the majority of patients had T3N1-N2 (48%) 
stage of disease. Other patient characteristics are shown in table 1. Median distance to the 
anal verge was 5 cm (range 0 to 20 cm). Most of the tumours were located in the lower 
parts of the rectum, with only a minority (13%) above 10 cm (table 2). In one patient the 
tumour was measured at 20 cm from the anal verge, but after discussing this case in our 
multidisciplinary team, we considered the bulk of the tumour to be in the upper part of the 
rectum, in close relation to the bladder. In this case downsizing of the tumour was aimed for 
and chemoradiation was proposed. All patients underwent surgery and were evaluated for 
pathological response and downstaging.
Toxicity
Toxicity was moderate and is summarised in table 3. Hand-foot syndrome did not occur 
in any of the patients. No haematological grade 3 or 4 toxicities occurred. Haematological 
toxicity was mild with grade 2 anaemia, leucocytopenia and neutropenia in 7, 12 and 3% 
of the patients, respectively. The only grade 3 nonhaematological toxicity was radiation 
dermatitis (3%) and diarrhoea (2%). Chemoradiation was not stopped in two patients who 
developed grade 3 radiation dermatitis. This occurred at the end of therapy and was managed 
by applying local therapy. All but two patients received the full dose of chemoradiation. A 
56-year-old male reported severe chest pain while taking capecitabine, which was absent 
in the weekend. There was no history of cardiac disease. Capecitabine was stopped and 
radiation continued. A second patient was a 49-year-old female who experienced grade 3 
diarrhoea which required intravenous fluid replacement. Capecitabine was stopped and not 
restarted at patient’s request; radiotherapy was continued.
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Table 1. Baseline patient characteristics
Category Number (%)
Gender
 − Male
 − Female
41 (68)
19 (32)
Performance status (ECOG)  
 − 0 40(67)
 − 1 20(33)
Histological differentiation  
 − Moderately 44(73)
 − Poorly 3(5)
 − Unknown 13(22)
Clinical Tumour stage  
 − cT3NO 3(5)
 − cT3N+ 29(48)
 − cT4NO 12(20)
 − cT4N+ 16(27)
ECOG= Eastern Cooperative Oncology group
Table 2. Tumour location and surgical treatment
Tumour location Number APR (%) LAR (%) Hartmann (%)
10 cm
5–10 cm
<5 cm
All tumours
8
20
32
60
1 (12)
2 (10)
16 (50)
19 (32)
4 (50)
13 (65)
8 (25)
25 (42)
3 (38)
5 (25)
8 (25)
16 (27)
APR = abdominoperineal resection; LAR = low anterior resection
Response
Surgery was performed in ten different hospitals and all patients underwent definitive 
surgery. In 19 patients an abdominal perineal resection (APR) was performed, in 16 a 
Hartmann’s resection and in 25 a low anterior resection (LAR). Of the patients with T4 
tumours, 18 underwent a multivisceral resection: five posterior exenterations, three total 
exenterations, three vagina resections, two partial bladder resections, three seminal vesicle 
resections and two partial prostate resections. A complete pathological response was 
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achieved in eight patients (13%) (table 4). Overall tumour and nodal downstaging occurred 
in 51 patients (85%). Tumour downstaging was seen in 40 patients (67%) and overall 
nodal downstaging in 38 patients (84%). Tumour progression during chemoradiation was 
not observed. Final pathology demonstrated T0 in eight patients (13%), T1 in six patients 
(10%), T2 in 14 patients (23%), T3 in 27 patients (45%) and T4 in five patients (8%). Of 
the 32 patients with initial tumour location less then 5 cm from the anal verge, 16 underwent 
an abdominal perineal resection and eight (25%) sphincter preservation by performing a 
low anterior resection. The majority of patients with the initial tumour location more than 
5 cm from the anal verge underwent an LAR; only three patients underwent an APR, and 
eight a Hartmann’s resection. In two patients (3%) an R1 resection was performed; one male 
patient with a tumour located at 3 cm from the anal verge underwent an APR and another 
male patient with a tumour located at 8 cm from the anal verge underwent a low anterior 
resection. No R2 resections were performed. Anastomotic leakage in the low anterior group 
occurred in one patient (4%).
DISCUSSION
Patients with locally advanced rectum carcinoma should preferably receive some form of 
neoadjuvant treatment to downstage the tumour and enable a potentially curative resection. 
5-FU-based chemoradiation is currently a well-accepted approach in the management of 
locally advanced rectum carcinoma. We conducted the present study to evaluate toxicity and 
efficacy of preoperative chemoradiation using oral 5-FU (capecitabine) in locally advanced 
rectal cancer. This should potentially lead to improved local tumour control and improved 
chance of sphincter preservation. We demonstrated that preoperative chemoradiation 
therapy with capecitabine is feasible with acceptable overall grade 3 toxicity of 5% and a 
13% complete response rate. All patients treated in this study completed radiotherapy and 
all but two completed chemotherapy. The incidence of acute toxicity in the present study was 
slightly lower than other phase II trials using capecitabine.[13-15] Table 5 demonstrates the 
results from the present study and three previously published studies. These differences can 
possibly be explained by the regime of capecitabine that was administered. Considering the 
radiation sensitising dose and effect of capecitabine in this set-up,[17] we designed the study 
to give capecitabine only on radiotherapy days. Because of the two-day resting period every 
five days, toxicity might therefore be lower than in the other series where capecitabine was 
administered twice daily, seven days a week. Kim et al.[16] used a regime consisting of two 
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cycles of 14 days followed by a resting period of seven days and also added leucovorin to their 
regime. It is noteworthy that one of the patients in the present study had severe chest pain 
with no history of any myocardial disease. Cardiotoxicity is a well-known but rare adverse 
effect of capecitabine and has been reported in several case reports.[18-20] In a previous study 
of locally advanced rectal carcinoma in our centre, radiotherapy was used at a similar dose 
(25 x 2Gy), but without capecitabine demonstrating a complete pathological response rate 
of only 2%.[21] In the present study a large group of patients (47%) who had a clinical T4 
tumour were treated and despite this a complete pathological response of 13% and a total 
tumour downstaging of 67% were observed. Complete pathological response rates were 
slightly higher in the other reported phase II trials, but these differences can be explained by 
the fact that other phase II studies had considerably less patients with clinical T4 tumours. In 
the subgroup of patients with T4 staged tumours, one patient (4%) had a complete response 
and 24 of 28 patients (84%) had a total tumour downstaging. Of the 45 patients with clinical 
positive nodal status only eight (18%) had pathological nodal involvement. Unfortunately, 
there is a potential bias in all studies that report on rectal cancer downstaging. The real 
downstaging effect of the chemoradiation treatment can not be accurately measured, since 
clinical nodal staging is based on diagnostic imaging and is not pathologically proven. 
However, we used strict criteria for node positivity on pelvic MRI and all patients were 
discussed in a multidisciplinary team. All patients in our study had definitive surgery after 
preoperative therapy. Multivisceral resection, which was previously proven to enable good 
local control and acceptable survival, was performed in 18 patients.[22] The considerable 
downstaging effect of the addition of capecitabine to a long series of radiation may increase 
the chance of sphincter preservation and decrease the need for multivisceral resection. 
Bujko et al. demonstrated no significant increase in sphincter preservation after 5-FU 
based chemoradiation therapy, despite an increased clinical response rate.[23] Other studies 
demonstrated a significant correlation between chemoradiation and sphincter preservation.
[24] In the present study only eight patients (25%) with a low-lying tumour (≤5 cm from anal 
verge) underwent sphincter preserving surgery. Therefore, conclusions regarding the benefit 
of chemoradiation on sphincter saving surgery can not be made based on the experience 
in this study. The incidence of circumferential margin involvement in patients with locally 
advanced rectal cancer is higher compared with rectal cancers were the tumour is confined 
to the mesorectum. Especially in APR patients circumferential resection margins are more 
often involved compared with patients who undergo an LAR.[25] In the present study, two 
patients (3%) had an R1 resection; one after an APR and one after an LAR. The downstaging 
effect of chemoradiation might decrease the risk of circumferential involvement, but surgical 
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technique is also important. For instance, in patients who underwent an APR resection, wide 
perineal resection seems to decrease the risk of involved margins and improve outcome.[26] 
Further improvement of outcome can be expected using new neoadjuvant chemoradiation 
protocols including chemotherapeutic drugs such as oxaliplatin or irinotecan.[27,28] Willet 
et al. have reported promising results using a vascular endothelial growth factor (VEGF) 
specific antibody (Bevacizumab) in combination with 5-FU-based radiotherapy.[29] This has 
lead to the conduction of a multicentre feasibility trial (RAX) in the Netherlands for which 
patients are currently being included.
CONCLUSION
Preoperative chemoradiation with oral capecitabine is safe and well tolerated in locally 
advanced rectal cancer patients. In addition, this preoperative treatment has a considerable 
downstaging effect on the tumour and lymph nodes resulting in few R1/R2 resections in 
large T3 and T4 rectal carcinoma. Capecitabine is used as a radiation sensitiser and there 
seems to be no need to administer it on nonradiotherapy days. By doing so it might minimize 
toxicity without influencing response.
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AbSTRACT
background
When local recurrent rectal cancer is diagnosed without signs of metastases, a potentially 
curative resection can be performed. The aim of this study was designed to compare the 
results of preoperative radiotherapy followed by surgery with surgery only.
Methods
Between 1985 and 2003, 117 patients with recurrent rectal cancer were prospectively 
entered in our database. Ninety-two patients were suitable for resection with curative intent. 
Preoperative radiation with a median dosage of 50 Gy was performed in 59 patients and 
33 patients did not receive preoperative radiotherapy. The median age of the patients was 
respectively 66 and 62 years.
Results
The median follow-up of patients alive for the total group was 16 (range 4–156) months. 
Tumour characteristics were comparable between the two groups. Complete resections (R0) 
were performed in 64 percent of the patients who received preoperative radiation and 45 
percent of the nonirradiated patients. A complete response after radiotherapy was found 
in 10 percent of the preoperative irradiated patients (n=6). There were no differences in 
morbidity and reintervention rate between the two groups. Local control after preoperative 
radiotherapy was statistically significantly higher after three and five years (P=0,036). Overall 
survival and metastases free survival were not different in both groups. Complete response to 
preoperative radiotherapy was predictive for an improved survival.
Conclusions
Preoperative radiotherapy for recurrent rectal cancer results in a higher number of complete 
resections and an improved local control compared to patients treated without radiotherapy. 
Preoperative radiotherapy should be standard treatment for patients with recurrent rectal 
cancer.
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INTRODUCTION
In the quest to obtain improved disease control and sphincter preservation the treatment 
of primary rectal cancer has developed in recent years to mesorectal excision, with adequate 
circumferential margins and excision of the lymph nodebearing area. With the introduction 
of this surgical technique local recurrence rates dropped from 25–40 percent in the 
literature[1-5] to <10 percent in recent series.[2,6 5] Preoperative short period radiotherapy 
(5x5 Gy) followed by total mesorectal excision (TME) further decreased local recurrence 
rates.[5] The ultimate goal is to increase local control, and thereby improve overall long 
term survival. When a recurrence occurs in rectal cancer patients, prognosis is often poor. 
Even with adequate treatment overall five-year survival rates reported in the literature 
ranges from 0–30 percent.[7,8-13] Recurrences are often associated with severe symptomatic 
disease, especially pain.7 For most patients, especially patients with extraluminal tumour 
mass involving other organs, the treatment used to be strictly palliative. Radiotherapy as a 
palliative treatment option has an effect on the tumour mass for a period of 6 to 11 months, 
without the possibility of prolonging overall survival.[4,14] Due to new treatment modalities 
including preoperative and intraoperative radiotherapy, it is possible to obtain a radical 
resection even in this group of patients.[15]
The main goals in the treatment of recurrent rectal cancer are palliation of symptoms, good 
quality of life and, if possible, curative surgery. In case of incomplete or marginal resection 
intraoperative radiotherapy can deliver an extra boost of 10 Gy, which can achieve the 
biologic equivalence of two or three times that of the equivalent dose of fractionated external 
beam therapy.[13,16,17] In several studies this has been suggested to improve both local 
control and overall survival, but patient numbers are often small in these series. The current 
treatment of the recurrent rectal carcinoma in our tertiary referral cancer centre consists of 
a “multimodality” approach, consisting of preoperative high dose radiotherapy, followed by 
resection and intraoperative radiotherapy when surgical margins are narrow or incomplete.
This study was designed to assess the outcome after treatment of recurrent rectal cancer in 
our cancer centre. We especially focused on the effect of preoperative long-term irradiation 
and intraoperative radiation in the multimodality treatment of recurrent rectal cancer.
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PATIENTS AND METHODS
All patients treated between 1985 and 2003 in the Erasmus MC – Daniel den Hoed Cancer 
Centre for a recurrent rectal carcinoma were analysed. Medical records were examined to 
obtain all necessary data. A total of 117 patients with recurrent rectal cancer were examined 
for surgical treatment; 25 were excluded for resection. Most of the excluded patients were 
considered not fit enough to undergo major surgery (n=16). Two patients deteriorated after 
their preoperative radiotherapy treatment and were not scheduled for surgery, and another 
seven patients were not operated because preoperative staging after radiotherapy revealed 
distant metastases in lung or liver.
The remaining 92 patients were considered suitable for curative surgery of their recurrent 
tumour. Curative intent was defined as a surgical resection with intent of complete resection 
of the tumour. All patients had previously undergone resection of a primary rectal tumour 
located within 15 centimetre of the dentate line.
Patients were divided in two subgroups; one group with 59 patients who were treated with 
preoperative radiotherapy followed by surgery six to eight weeks later, and another group 
with 33 patients who were operated on without preoperative radiotherapy. The preoperatively 
irradiated group consisted of 64 percent males and 36 percent female, with a median age of 
66 years, and the preoperatively nonirradiated group of 58% men and 42% women, with a 
median age of 62 years at reoperation. The median follow-up of all 92 patients was 16 (range 
4–156) months at the moment of statistical analysis.
All patients were histologically proven recurrent rectal adenocarcinoma. Staging consisted 
of magnetic resonance imaging and CT scanning of the pelvis to define the localization and 
growth of the recurrence. Exclusion of distant disease was performed by a thoracoabdominal 
CT scan and by perioperative palpation of the liver and the peritoneal contents. The 
recurrences were classified with two different systems: the Wanebo classification and 
the Suzuki classification.[15,18] In general, patients were seen every three months at our 
outpatients department for the first postoperative year and every six months thereafter. 
Physical examination, carcinoembryonic antigen in serum, and an annual abdominal CT 
scan were performed to demonstrate local or systemic recurrences.
External beam Radiotherapy (EbRT)
Patients who were treated with preoperative EBRT received a median dose of 50Gy (range 
25–60) delivered in 25 fractions of 2.0 Gy. EBRT was administered by either a three-
field technique, using one posterior and two lateral portals, or a four-fieldbox. The lateral 
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pelvic borders were defined as 1.5-cm lateral of the bony pelvis, the cranial border was the 
promontory, and the caudal border was below the foramina obturatoria to 2 cm under the 
anus, depending on tumour position. Preoperative EBRT was performed in all patients 
treated after 1997; concurrent chemotherapy was not administered in the described group 
of patients.
The four most recent irradiated patients in the multimodality group were irradiated with a 
new radiation technique: intensity modulated radiotherapy (IMRT). This technique is used 
to diminish the toxicity of radiation dosed to the abdominal organs.
Surgery
The objective of the surgical approach was to obtain free circumferential margins. The 
circumferential plane consists of four quadrants. In all quadrants recurrent tumour growth 
can occur and require extended surgery. In case of ventral growth, for example growth 
into the base of the bladder, the prostate or the seminal vesicles, a total pelvic exenterative 
procedure was performed. In case of growth into the posterior plane, for example into the 
sacrum below S2, an abdominoperineal-sacral resection (APSR) was performed. A low 
anterior resection or an abdominoperineal resection treated centrally located recurrences. 
Complications were classified as major complications, if they did extend the hospitalization 
or did require reintervention.
Intraoperative Radiotherapy
In 1997 the high-dose-rate intraoperative radiotherapy (HDR-IORT) program was started 
at the Erasmus MC – Daniel den Hoed Cancer Centre.[19-21] All patients treated with HDR-
IORT were treated preoperatively with EBRT. The HDR-IORT was performed if resection 
margins to the tumour were ≤2 mm. This was judged perioperatively on frozen sections. 
A silicon template with 1-cm-spaced parallel source tubes running through the centre of 
the template was placed over the marginal radical or irradical spot. This irradical spot was 
marked by three to four surgical clips, and size and shape of the template were adjusted to 
the target surface. The template was positioned and pressed against the target surface using 
gauze pads. The radioactive source was lead through the tubes, hereby delivering a boost with 
a median dose of 10 Gy at 1-cm depth from the applicator surface. IORT was not available 
in patients treated without preoperative radiotherapy, because they were all treated before 
1997.
90 | Chapter VI
Statistical analysis
Local failure-free survival and overall survival estimates were calculated by the method of 
Kaplan and Meier.[22] All statistical analyses were executed in Stata. (Statacorp, Texas, USA) 
Univariate comparisons of survival endpoints were executed using the log-rank test. The Cox 
proportional hazards analysis was used for multivariate analysis of prognostic factors for 
local control and overall survival.[23] Significance was defined as P<0.05.
RESULTS
The median interval between treatment of the primary tumour and the diagnosis of the 
recurrence was 15 (range 2–72) months in the preoperatively nonirradiated group and 16 
(range 5–186) months in the preoperatively irradiated group. The characteristics of the 
primary tumours of both groups are depicted in Table 1. Tumour histology grade, stage and 
type of resection were statistically not significantly different. Pain as a preoperative symptom 
was found in 31 percent of the patients treated for a local recurrence. Tumour characteristics 
and classifications for the recurrent tumours were similar for both groups treated with or 
without preoperative radiotherapy (Table 2). A complete (R0) resection was possible in 
45 percent of the preoperatively nonirradiated group and 64 percent of the preoperatively 
irradiated group (P=0,08; Table 3). In 46 percent of the resections in the preoperatively 
irradiated group IORT was performed because of a marginal complete or incomplete 
resection. Operation characteristics and hospitalization are summarised in Table 3.
The duration of operation was significantly longer in patients who received intraoperative 
radiotherapy (IORT, 445 minutes vs. non-IORT, 343 min; p=0,018). Loss of blood was not 
statistically significantly different in patients treated with IORT (median 6500 ml; range 
1500–17000) in comparison with patients who did not receive IORT (median 5000 ml; 
range1100- 21000; P=0,402). The results of the local control and overall survival of patients 
who received IORT compared with patients who did not are depicted in Table 4. Both 
groups are divided by the completeness of the resection (R0 vs. R1/2).
In the preoperatively irradiated group, the perioperative mortality was 3 percent (n=2) 
and no postoperative mortality occurred. One patient died during operation because of 
massive bleeding caused by disseminated intravascular coagulation, and the other because 
of a myocardial infarction during operation. In the group of patients that did not receive 
neoadjuvant radiotherapy, no perioperative and postoperative death occurred. All other 
complications were classified as minor. Complications and reinterventions are depicted in 
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Table 5. In the preoperatively nonirradiated group 88 percent of the 33 patients received 
postoperative radiotherapy, with a median dose of 50 (range 30–60) Gy. Eight patients were 
administered chemotherapy postoperatively because of positive lymph nodes or distant 
disease.
Table 1. Characteristics of the primary tumour
No pre-op RTX (n=33) Pre-op RTX (n=59)
Grade
 − Well differentiated
 − Moderately differentiated
 − Poorly differentiated
 − Unknown
15
73
3
9
7
86
2
5
UICC
 − Stage 1
 − Stage 2
 − Stage 3
 − Stage 4
 − Unknown
15
42
36
0
6
20
39
32
2
7
Type of resection
 − LAR
 − APR
 − Hartman / Transanal resection
79
12
9
56
32
12
Pre-op RTX = pre-operative radiotherapy; No pre-op RTX = no pre-operative radiotherapy; LAR = low 
anterior resection; APR = abdomino-perineal resection. Data are presented in percentages
Local control
After three and five years, respectively, 28 and 18 percent of the patients of the preoperative 
radiation group were without local recurrence. Local control is significantly higher when 
compared to the 13 and 13 percent of the preoperatively nonirradiated group (P=0,037; 
Figure 1). Prognostic factors important for local control are shown in Table 6. Preoperative 
radiotherapy was the only prognostic important factor studied to have a significant impact 
on local control. Patients of the preoperatively irradiated group who had a complete response 
after radiotherapy had higher local control rate (40 percent) compared to the patients who 
had no complete response (14 percent), but because of small numbers this failed to become 
statistically significant. There is a trend towards better local control after three and five 
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Table 2. Tumour characteristics of rectal cancer recurrence
No pre-op RTX  
(n = 33)
Pre-op RTX
(n = 59)
Tumour status
 − T0
 − T1
 − T2
 − T3
 − T4
 − Tx
0
0
3
42
45
9
7
2
3
41
41
6
Nodal status
 − N0
 − N+
 − Nx
15
15
70
17
7
76
Grade
 − Well differentiated
 − Moderately differentiated
 − Poorly differentiated
 − Unknown
9
73
6
12
2
61
20
16
Wanebo classification
 − Tr 1(limited recurrence in submucosa)
 − Tr 2 (growth in full thickness rectal wall)
 − Tr 3 (growth into surrounding soft tissue)
 − Tr 4 (penetration anterior structures)
 − Tr 5 (penetration posterior structures)
 − Unknown
0
3
33
30
21
12
2
3
41
25
19
10
Suzuki classification
 − F 0 (no contact to pelvic wall)
 − F 1 (contact < ¼ of pelvic wall)
 − F 2 (contact ¼ to ½ of pelvic wall)
 − F 3 (contact > ½ of pelvic wall)
 − F 4 (infiltration in bony structures / small bowell)
 − Unknown
18
30
21
0
15
15
20
31
19
5
20
5
Pre-op RTX = pre-operative radiotherapy; No pre-op RTX = no pre-operative radiotherapy. Data are percentages
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years between R0 vs. R1/2 surgery (P=0,079) and toward negative lymph node status of 
the primary rectal cancer vs. involved lymph nodes (P=0.067). Preoperative symptomatic 
pain at the time of diagnosis, Wanebo-stage and Suzuki-stage, and application of IORT had 
no prognostic value on local control. After multivariate analysis the effect of preoperative 
radiotherapy on local control was also significant (P=0,020; Table 7). An interval between 
the operation of the primary tumour and the diagnosis of the recurrence longer than one year 
and positive lymph node status were not predictive for local control.
Table 3. Operation characteristics
No Preop RTX  
(n = 33)
Preop RTX 
(n = 59)
P Value
Resection
 − R0
 − R1
 − R2
45
36
18
64
22
14
Type of resection
 − LAR
 − APR
 − APSR
 − TPE
 − PE
0
73
3
6
18
5
43
19
14
19
Median bloodloss (ml)
Median operating time (min)
Median hospitalization (days)
3.000
255
17
6.000
415
24
<0.001
0.016
0.189
Preop RTX = pre-operative radiotherapy; R0 = microscopically complete resection; R1 = microscopically 
incomplete resection; R2 = macroscopically complete resection; LAR = low anterior resection; APR = 
abdominoperineal resection APSR = abdominoperineal sacral resection; TPE = total pelvic exenteration; PE = 
Posterior exenteration. Data are percentages unless otherwise indicated
Overall survival
The three- and five-year survival rates of patients who were treated with preoperative 
radiotherapy were respectively 34 percent and 11 percent. These results did not differ 
significantly when compared to the 30 percent and 15 percent of patients who did not 
receive preoperative radiotherapy (P=0,426; Figure 2). Positive lymph nodes of the primary 
treated rectal cancer were an important prognostic factor for a worse survival when compared 
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with a negative nodal stage (P=0,009; Table 6). A complete response after radiotherapy is 
a statistically significant prognostic for an improved survival (P=0.024). After a complete 
“curative” resection (R0), the overall survival was statistically significantly improved when 
compared with the incomplete (R1/2) resections (P=0,036). Patients with preoperative 
symptomatic pain, IORT, and Suzuki- and Wanebo-stage had no significant different overall 
survival. Multivariate analysis also failed to shown an impact of preoperative radiotherapy 
and an interval between the operation of the primary tumour and the diagnosis of the 
recurrence longer than one year on overall survival (Table 7). After multivariate analysis 
positive lymph node status seemed prognostic for a worse overall survival (P=0,015).
Table 4. Three-year actuarial local control and overall survival by IORT administration and 
completeness of resection 
No. of patients Local control (3yr) Overall survival (3yr)
IORT
 − Complete (R0)
 − Incomplete (R1/2)
17
10
45
21 (P=0.25)
35
21 (P=0.75)
Non-IORT
 − Complete (R0)
 − Incomplete (R1/2)
21
11
24
19 (P=0.58)
41
27 (P=0.45)
IORT = intraoperative radiotherapy
Data are numbers or percentages with P values in parentheses
Table 5. Post-operative results
Complications and reinterventions No Preop RTX (n = 33) Preop RTX (n = 59)
Minor
Major
Reinterventions
Postoperative radiotherapy
Postoperative chemotherapy
52
21
9
88
24
59
26
15
15
2
Preop RTX = preoperative radiotherapy. Data are percentages
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Table 6. Local control and overall survival
Local control Overall survival
No. of  
patients
3-year 5-year P Value 3-year 5-year P Value
Negative lymph nodes primary
Positive lymph nodes primary
No symptomatic pain
Symptomatic pain
Preop RTX
No Preop RTX
Suzuki stage 0,1,2
Suzuki stage 3,4
Wanebo Tr 1 – 3
Wanebo Tr 4 – 5
Complete response
Incomplete response
Complete (R0) resection
Incomplete (R1/2) resection
IORT
Non-IORT
57
33
61
30
59
33
64
20
39
43
6
53
53
39
27
32
24
14
20
27
28
13
23
17
18
16
80
20
31
11
34
17
20
7
17
14
18
13
23
-
18
5
40
14
26
5
23
14
0.067
0.445
0.037
0.525
0.889
0.186
0.079
0.084
35
28
35
30
34
30
33
31
37
22
100
39
24
31
33
20
-
16
9
11
15
12
8
6
11
67
0
21
3
24
11
0.009
0.681
0.426
0.857
0.427
0.011
0.036
0.375
Preop RTX = pre-operative radiotherapy; IORT = intra-operative radiotherapy; - = not assessable
Data are percentages unless otherwise indicated. All bold data are significantly different (P<0.05) 
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Table 7. Multivariate Cox-analysis for local control and overall survival
Local control Overall survival
No. of  
patients
Hazard  
ratio
P Value Confidence 
Interval
Hazard  
ratio
P Value Confidence 
Interval
Radiotherapy
 − No Preop RTX
 − Preop RTX
33
59
1
0.529 0.02 0.31-0.90
1
0.791 0.334 0.49-1.24
Interval prim-rec
 − <12 months
 − >12 months
34
58
1
0.667 0.144 0.38-1.15
1
0.88 0.606 0.54-1.43
Lymph Node status
 − negative
 − positive
59
33
1
1.735 0.054 0.98-3.04
1
1.852 0.015 1.13-3.04
Preop RTX = pre-operative radiotherapy; Interval prim-rec = interval between operation primary tumour and 
diagnosis recurrence
total RTX dose
0 12 24 36 48 60
0.00
0.20
0.40
0.60
0.80
1.00
 No Pre-operative RTX
 
Pre-operative RTX
 months
 At risk:
No Pre-op RTX  33  11  6  3  3  3
Pre-op RTX  59  31  13  6  4  2
 Logrank P=0.037
Figure 1: Local control pre-operative RTX vs no pre-operative RTX
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 33  24  14  10  5  5
 59  44  26  14  8  2
total RTX dose
0 12 24 36 48 60
0.00
0.20
0.40
0.60
0.80
1.00
 No Pre-operative RTX
Pre-operative RTX
 months
 At risk:
No Pre-op RTX
Pre-op RTX
 Logrank P=0.43
Figure 2: Overall survival pre-operative RTX vx. no pre-operative RTX
DISCUSSION
Local recurrent rectal cancer has a poor prognosis. Local radiotherapy can offer good 
palliation for some months, but has not been associated with long-term survival benefits.[24] 
A selective group of patients with recurrent disease can be operated on with curative intent.
[7] The choice of therapy depends upon prior therapy and the local extent of the recurrence. 
Curative treatment seems best possible in selected patients with true anastomotic recurrence 
or those without pelvic sidewall involvement and early detection of the tumour.[18] Factors 
contributing to improvement of surgery for recurrent rectal cancer in the recent decade are 
the improved preoperative workup with advanced radiodiagnostic techniques, ameliorated 
preoperative treatment modalities, and the possibility of the performance of more extensive 
operations.[7,25-28]
The use of preoperative radiotherapy in the treatment of recurrent rectal cancer with 
curative intent is based upon studies in primary rectal cancer that identify a beneficial effect 
of radiation therapy on the resectability, the local control, and even overall survival.[29,30] 
However, there are no good comparative data from prospective trials in recurrent rectal 
cancer. In this article, we have focussed on the effects of preoperative radiotherapy, without 
adjuvant chemotherapy. For an identification of the effect of the neoadjuvant radiotherapy, 
we have compared our series of patients who were all treated by a multimodality approach 
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(preoperative radiotherapy, surgery, and IORT on indication) with a historical group of 
patient treated with surgery only, followed by postoperative radiotherapy in most patients 
(88 percent). Although overall follow-up for the total group of patients is relatively short 
for determining differences in local failure (16 months), we were able to show a significant 
difference in local control in favour of patients who received preoperative radiotherapy 
(P=0,037). Because of the nonrandomised character of our study the difference in local 
control cannot be entirely attributed to the preoperative radiotherapy. Both groups, however, 
are highly comparable concerning the tumour stages of the primary and recurrent tumours. 
The multivariate analysis also indicated the beneficial prognostic value of preoperative 
radiotherapy on local control (P=0,02). We were not able to identify a beneficial effect 
of the neoadjuvant radiotherapy on overall survival. Overall survival is dependent on the 
development of metastases, which is not influenced by local treatment modalities, but might 
be improved with new systemic adjuvant chemotherapy protocols. Pathological analysis of 
the resection specimens showed that preoperative radiotherapy was associated with multiple 
histological changes such as necrosis and fibrosis, resulting in a 10 percent complete response 
percentage. This percentage compares favourable to response rates of 5 to 9 percent reported 
in the literature after neoadjuvant (chemo)radiation treatment protocols.[4,7,31] Wanebo 
et al. described that patients with a complete response to neoadjuvant therapy showed an 
identical behaviour to the rest of the group.[15] In contrast to these results. Our small group 
(n=6) of patients with CR did not only show a trend towards improved local control but also 
a statistically significantly improved overall survival when compared with patients who did 
not have a complete response after preoperative radiotherapy.
Preoperative radiation causes destruction of malignant cells, but also postradiation fibrosis. 
Both in preoperative and perioperative staging, it is hard to differentiate between post-
radiation fibrosis and tumour cells.[31] In the preoperative setting the diagnostic modalities 
cannot always differentiate the tumour from fibrosis.[26,32] Differentiation between tumour 
and fibrosis, but also growth and invasion of tumour have major consequences for the 
treatment and prognosis of the patient. Recent studies have shown that with the modern 
magnetic resonance imaging techniques a higher accuracy can be guaranteed when compared 
with the CT scan staging.[25,27] Perioperative staging problems consist of a limited possibility 
of identification of microscopically positive margins. To avoid this problem of intraoperative 
assessment our pathology department examines the resected material with frozen section 
examination during the operation when there is doubt of the surgical margins.
In the past, resections of recurrent rectal cancer that resulted in complete removal of all 
tumours were scarce; reported R0 resections were approximately 20 percent.[33] Studies 
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showed that the current multimodality treatment provides possibility for curative resection 
in 40 to 80 percent.[4,7,31,34-38] Our R0 resection rate of 64 percent is comparable with 
these published results and was nearly 20 percent higher when compared with patients who 
did not receive preoperative radiotherapy. We assume that this difference is caused by the 
effect of downstaging and downsizing after neoadjuvant radiotherapy. Both preoperative 
and postoperative radiation have the capability to sterilise tumour cells to a certain 
extend, but the effect of preoperative radiotherapy facilitates more complete resections. 
The higher rate of complete resections in our group can also be explained by the more 
extensive surgery performed in the preoperatively irradiated group. Our repertoire of 
surgical techniques performed to obtain negative surgical margins has developed in recent 
years. This development is visible in the higher rate of performed sacral resections and total 
pelvic exenterations. Wanebo and Marcove[28] reported in 1981 that palliative resection of 
tumours with invasion or tight adherence to the sacrum can be safely performed; however 
sacral resections are associated with a high morbidity rate that differs between 42 and 82 
percent.[39,40] The value of performing a complete resection was shown by the significant 
better overall survival after complete (R0) resections when compared with incomplete 
(R1/2) resections (p=0,036). A beneficial effect on the local control was noticed in our 
group, however without statistical significance.
Two techniques for intraoperative radiotherapy have been developed; intraoperative 
electron beam radiotherapy (IOERT), and the other is the high-doserate brachytherapy 
(HDR-IORT). In our centre patients are treated with HDR-IORT in case of a positive 
or narrow surgical margin IORT, thereby delivering a radiation boost to a specific area 
without exceeding the radiation limits of adjacent normal tissue and with the possibility of 
sterilizing the pelvis from any residual tumour. Although there are no data from prospective 
randomised study, there are previous studies that suggest a safe performance and beneficial 
effect on local control. In some studies a beneficial effect on survival has been demonstrated 
after an intraoperative radiation boost.[4,18,41-44] In our series we applied IORT in the 
group of patients with marginal radical resections or irradical resections, a group with an 
unfavourable prognosis on local control and survival when compared with the patients with 
a widely resected tumour. Table 4 shows that despite this worse prognosis, local control and 
overall survival of the intraoperatively irradiated group were not significantly different from 
patients with a widely resected tumour. This pleads for the use of IORT, because IORT 
ameliorates and equalises the unfavourable prognosis of the patients with positive surgical 
margins up to the level of the group of patients with complete resections. Gross residual 
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remains one of the most significant predicting factors for local and systemic failure, because 
HDR-IORT cannot compensate for these macroscopically incomplete resections.[7,45]
In contrast to previously published data that indicate significantly higher postoperative 
morbidity rates after preoperative radiotherapy, we cannot demonstrate a significant 
difference when compared with our nonirradiated historical group.[31,46] A higher rate of 
complications could be expected in the preoperatively irradiated group because of the higher 
rate of extensive resections. Most common morbidities were minor wound infections and poor 
wound healing, as described in other studies.[31] The major complications rate of 26 percent 
in the preoperative radiation group was identical to a previous report by the Mayo Clinics.[7] 
Intraoperative loss of blood and operating time were high in patients who were operated on 
by the modern standards. These differences can be explained by the more extensive surgery 
that was performed. The higher operating time after the modern multimodality treatment 
can be attributed to the application of IORT, which is a time consuming procedure. Saito 
et al. reported results for blood loss that were comparable to our results, but their operating 
time was near twice as high.[35] Resection of the recurrent tumour was feasible with 3 
percent perioperative mortality and no 30-day postoperative mortality. Both patients who 
died during operation were treated with preoperative radiotherapy, due to small numbers 
this is not significantly different from the rate in the historic nonirradiated group and is 
comparable to mortality rates described in the literature.[7,18,31,35,47-49]
Because of the altered anatomy after prior surgery the conventional staging systems are 
inadequate for recurrent rectal cancer. The UICC TNM classification, used to classify the 
primary tumour, cannot be used because the visceral fascia surrounding the rectum has been 
resected and the recurrence is not confined to the original rectal boundaries.[13]Therefore, 
other classification systems have been developed. Suzuki and co-workers from the Mayo 
Clinics use a system that is based on the degree of fixation of the tumour to the surrounding 
organs or structures according to pathological and/or surgical examination.[18]Wanebo et 
al. uses a modified version of the UICC TNM-classification, which resembles the original 
system, with an exception of the addition of an extra stage. This stage, Tr5, indicates extensive 
invasion of the pelvis.[15] In our study we have used both classification systems and did not 
find any predictive value of the two staging systems on local control and overall survival. 
This is in contrast with results of the Mayo-Clinics, which showed an increased number of 
sites were significantly associated with a decreased local control and an inferior survival.[7,18] 
An increasing number of sites involved, indicated by the Suzuki-classification, can point 
out a more advanced stage of recurrence. Until now, only two studies reported a significant 
influence of fixation site on the local control and survival.[7,48] When we compared the 
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Suzuki stages F0-F2 with the Suzuki stages F3-F4, no significant differences were found. 
Comparison of the Wanebo stage Tr1-3 tumours with the Wanebo Tr4-5 also showed no 
significant differences in local control, survival, and metastases free survival.
Symptoms accompanying the recurrence, especially pain can be related with an inferior 
outcome in both local control and survival. Alike, the degree of fixation, symptomatic disease 
indicates a more advanced recurrence, which will require more extended surgery to obtain 
radical margins.[7,42] Preoperative symptomatic pain had no significant prognostic value for 
local control and overall survival in our series.
In the choice of treatment and prognosis for patients with recurrent rectal cancer not only 
the current tumour stage of the recurrence is of importance. Our study shows a significant 
negative influence of the positive nodal stage of the primary tumour on overall survival 
(P=0,009).
CONCLUSION
Overall survival of the patients with recurrent rectal cancer is poor. The application of 
preoperative radiotherapy has lead to a significant better local control in our group. New 
modalities, such as neoadjuvant chemoradiation, seem promising to improve resectability 
and the rate of sphincter-saving procedures.[4,31] Prospective randomised studies containing 
these new modalities have to be conducted. A new radiotherapy technique, intensity 
modulated radiotherapy, which has been introduced recently in our cancer centre will offer 
the possibility to reduce radiation toxicity to surrounding vital structures and to deliver 
higher dosages to the tumour. The treatment of recurrent rectal cancer is complicated and 
requires the latest in modern diagnostic and operational techniques. It has to be performed 
in a specialised hospital with a multidisciplinary team that can provide a high quality 
preoperative workup and perform the complicated and often extended resections.
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AbSTRACT
Purpose
Recurrent disease after local excision of T1 rectal cancers is not uncommon, but its impact 
on survival is not clear. Aim of this study is to evaluate the management and outcome of local 
recurrences after transanal endoscopic microsurgery (TEM) for T1 rectal cancer.
Methods 
A total of 88 consecutive patients who underwent TEM for pT1 rectal cancer were registered 
in a prospective database. Of these eighteen patients developed a local recurrence during 
follow-up. In this study these 18 patients were analysed with special emphasis on salvage 
surgery and survival.
Results
Median time to local recurrence was 10 months (range, 4–50 months). Median age at 
diagnosis of the recurrence was 73 years (range, 56–83 years). Two patients were not 
operated because of concomitant metastatic disease. All of the remaining sixteen patients 
underwent salvage surgery, without the need for extensive surgical procedures. In 44% of 
patients a permanent colostomy was created. There was no postoperative mortality. Fifteen 
patients had a microscopic radical resection and one patient a microscopic irradical resection. 
Median follow-up following salvage surgery was 20 months (range, 2–112 months). One 
patient developed a re-recurrence and seven patients developed distant metastases. The 
3-year overall survival was 29% and the 3-year disease-free survival was 57%. 
Conclusions
Recurrent disease after TEM for T1 rectal cancer is a major problem. Although salvage 
surgery is feasible in most of the patients, survival is impaired. A microscopic radical 
resection can almost always be obtained, without the need for extensive surgical procedures. 
In the near future we need to focus on improving selection in T1 rectal cancers suitable for 
TEM. Also possible adjuvant treatment strategies following salvage procedures need to be 
explored, in order to safe as many patients the adverse effects of TME.
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INTRODUCTION
Total mesorectal excision (TME) is the gold standard for rectal cancer, because this treatment 
modality offers the highest chance of cure. This standardised and optimised surgical 
technique has lowered the recurrence rates and improved survival.[1, 2] In an attempt to 
avoid the substantial morbidity and mortality of TME, local excision has been suggested a 
therapeutic option in the treatment of well-selected patients with early rectal cancer. But, 
after transanal excision unacceptable high rates of incomplete tumour removal in up to 39 
percent have been observed, proven to be a key predictor for recurrence.[3-7]
Transanal endoscopic microsurgery (TEM), introduced by Buess et al.[8], is an optimised 
technique for the removal of rectal tumours. This technique enables excellent access and 
visualization of the surgical field and allows precise and full-thickness excision of the tumour. 
Using TEM, the rate of microscopic radical excision margins, even with standardised 
pathology, for T1 tumours has increased to more than 90%.[9, 10] Because of this latter, in 
combination with the very low mortality and morbidity rates, TEM is nowadays considered 
a potential curative alternative for T1 tumours by many surgeons.[3, 11, 12] 
However, even after TEM, local recurrence rates range from 0 to 24%, and the results of 
salvage surgery in recurrent tumours are matters of concern.[13-15] In the literature only 
few series report on surgical procedures and outcome of recurrent disease after transanal 
surgery.[16-18] To our knowledge no data exist on patients treated for a recurrence after TEM 
surgery. In this study we present the outcome of patients with a local recurrence after TEM 
for T1 rectal cancer.
PATIENTS AND METHODS
From 1996, in the IJsselland hospital, a referral centre for TEM, 88 consecutive patients 
underwent TEM for pT1 rectal cancer and were followed as part of a prospective, comparative 
study. As described previously all patients were screened according to a standard protocol.
[15] The initial TEM procedure was performed by two surgeons. Full-thickness excision was 
performed in all lesions. All specimens were pinned on cork and were studied according to 
standardised pathology. None of the patients received any form of (neo-) adjuvant treatment. 
Only patients with microscopic complete excision margins were considered eligible for 
intensive follow-up. Follow-up was according to the Dutch guidelines on rectal cancer 
with additional rigid rectoscopy and endorectal ultrasound (ERUS) every 3 months the 
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first 2 years, and every 6 months thereafter for the detection of local recurrences. Magnetic 
resonance imaging (MRI) of the lesser pelvis was introduced as a part of the follow-up 
protocol during the study period., and nowadays is routinely performed at 12, 24 and 36 
months following TEM. A local recurrence was defined as recurrent tumourous tissue within 
the lesser pelvis and endoluminally, if present, within the proximity of the scar tissue of the 
initial operation. Histological confirmation was mandatory. When appropriate, salvage 
surgery was performed. Initially patients were treated without neo-adjuvant treatment (five 
patients), later on with preoperative short-course radiotherapy (six patients) and nowadays 
with preoperative long-course chemoradiotherapy (five patients).
Following salvage surgery, patients were followed according to the Dutch guidelines for rectal 
cancer. Patient data were collected in a central, digital database. Percentages and continuous 
data were compared using the Chi-square test or the Mann-Whitney test, respectively. Patient 
survival was assessed using the Kaplan-Meier life-table method. P values given are two-tailed; 
P=0.05 was considered the limit of significance.
RESULTS
Out of 88 patients followed, in 18 patients a local recurrence occurred. Patient and salvage 
characteristics are depicted in table 1 and 2. Median age of patients at the time of recurrence 
was 74 years (range, 56 to 84), 50% of the patients were male. Median time to a local 
recurrence after the initial TEM procedure was 10 months (range, 4 to 50). Ten recurrences 
were found intra-luminal in the proximity of the scar during rectoscopy and in six patients 
an extra-luminal recurrence was found with ERUS during intensive follow-up visits. In two 
patients a late recurrence was detected only with MRI. The first patient (patient number 13) 
withdrew from the intensive follow-up protocol, and one year after the last visit a MRI was 
performed because of complaints, and a locally advanced (cT4) recurrence was diagnosed. 
The second patients (patients number 15) had complaints in between two (intensive) follow-
up visits, and also additional MRI was performed. A locally advanced local recurrence (cT4) 
was diagnosed, which probably was missed at rectoscopy and ERUS. Following neo-adjuvant 
chemoradiotherapy a microscopic radical resection was possible in both.
Two patients were not operated. One patient (patient number 9) was initially diagnosed 
as having a tubulovillous adenoma. After a T1 carcinoma was diagnosed, additional 
investigations, focusing on metastatic disease, were not performed. Six months after the 
TEM procedure already a local recurrence was suspected, which could only be confirmed 
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half a year later, after several biopsies. At the time of diagnosis, massive hepatic metastases 
were found and based on these findings and patients’ condition, no treatment was started. 
She died three months later. The other patient (patient number 6) withdrew from intensive 
follow-up and presented elsewhere with low back pain 20 months after the TEM procedure. 
A clinical T4 local recurrence was found with synchronous metastatic disease in the liver. 
Palliative chemotherapy was started, and the patient died ten months later.
All remaining 14 patients adhered to the intensive follow-up protocol. In two patients 
(patient number 3 and 6) synchronous liver metastases, initially deemed resectable, were 
found. Despite obtaining a microscopic radical resection in both, rapidly progressive 
metastatic disease developed and patients were treated with palliative chemotherapy. They 
died eight and respectively 22 months following the salvage procedure.
In 15 out of 16 salvage procedures, a microscopic radical resection was possible without the 
need for extensive surgical procedures. In one patient a microscopic irradical resection (R1) 
was performed, and patient received adjuvant chemotherapy. There was no post-operative 
mortality. Median follow up after salvage treatment of all patients with a recurrence was 20 
months (range, 2-112). One of the operated patients developed a local re-recurrence and 7 
patients developed distant metastases and died because of progressive disease. 
The actuarial 3-year overall survival was 29% (figure 1). Patients in which a microscopic 
radical resection could be obtained without the presence of metastatic disease, 3-year 
survival was better compared to non-operated patients, stage IV disease at presentation or 
microscopic irradical resections (40 versus 0%; p=0.001).
The 3-year disease-free survival was 57% (figure 2).
DISCUSSION
Transanal endoscopic microsurgery (TEM) is method of choice in the treatment of rectal 
adenomas. Morbidity and mortality are reduced in comparison to total mesorectal excision 
(TME).[15] But in rectal cancer the choice for type of surgical treatment has to be based 
on more than differences in morbidity and mortality of the surgical procedure. When 
considering local excision for fit patients with rectal cancers, surgeons face a dilemma. 
Although, a large majority (70-85%) of patients are cured by TEM, the risk of cancer 
recurrence is substantially higher, varying between 10% and 28% for pT1 rectal cancer.[19-
22] After TME this is reported to be only 0.4 to 1.7%.[2, 19, 23] 
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Figure 1. Overall survival following salvage operation
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Figure 2. Disease free survival following salvage operation
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Table 1. Patient- and initial tumour characteristics
Patient number Age Sex Asa-classification Low- vs high-risk Disease free interval 
(months)
1 74 female 2 LR 10
2 83 female 3 LR 6
3 79 male 3 HR 19
4 82 male 3 LR 5
5 77 female 3 LR 7
6 72 female 1 LR 20
7 68 male 3 HR 5
8 61 male 3 HR 12
9 84 female 2 LR 11
10 56 male 1 LR 6
11 80 male 2 LR 11
12 71 female 1 LR 12
13 75 male 3 LR 41
14 72 female 1 LR 10
15 64 male 1 LR 50
16 80 female 1 LR 24
17 73 female 2 LR 4
18 59 male 1 LR 7
ASA= American Society of Anaesthesiology; LR= low-risk; HR= high-risk
Low-risk= good or moderately differentiated without lymf-/angioinvasion
High-risk= poor differentiated and/or lymf-/angioinvasion
In most studies reporting on local recurrences following local excision for T1 rectal cancers, 
there is a bias in patient and tumour selection. This is a major confounding factor when 
interpreting outcome. In the present series, all T1 rectal cancers excised with TEM were 
included, out of a consecutive group of patients and regardless of other histopathological 
criteria. Pathology was standardised and a microscopic radical excision (R0) had to be 
confirmed.[15] In contrast to primary TME, in our series obtaining a R0 excision did 
not prevent from a local recurrence. Therefore, improving tumour selection is of major 
importance. Whether basic histopathological criteria, differentiating high- and low-risk T1 
rectal cancers, is able to perform this, is subject of debate. [24-27] Further studies focusing on 
adequate tumour selection are urgently needed.
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Besides improving patient selection, early diagnosis of a local recurrence is considered of 
utmost importance. Local recurrences may be intra-luminal or extra-luminal. Therefore, 
next to rectoscopy, endorectal ultrasound is mandatory in the follow-up regimen in patients 
treated with TEM for T1 rectal cancer. In our series, six out of 18 local recurrences were 
solely found with ERUS, which otherwise may have been missed. This was also found in 
other series focusing on the role of ERUS in the follow-up regimen of locally excised rectal 
cancers. (ref Hernandez et al, DCR 2004) ERUS however, still has its limitations and 
therefore MRI of the lesser pelvis is added as well in our hospital. This was mainly based on 
the two patients with a late recurrence, of which one was actually missed with rectoscopy 
and ERUS. By applying this intensive follow-up regimen in our patients, out of 16 patients 
who adhered to this protocol, only one was diagnosed at an advanced, incurable stage. In the 
remaining patients, almost always a microscopic radical resection was possible (93% R0).
The three-year overall survival in the total group of patients with a local recurrence is 
low (29%), and improving outcome for this initial early staged cancers is imperative. 
Obtaining a microscopic radical resection is a prerequisite, however does not seem to be 
the only parameter influencing outcome. In the present series the large number of patients 
diagnosed with metastatic disease is striking. Never metastatic disease occurred without a 
local recurrence. Maybe this actually is a biological different group, and salvage treatment 
should be intensified. Adding adjuvant treatment in patients with a local recurrent tumour 
might improve outcome, although based on this series this will be impossible to prove as 
only patient was given adjuvant treatment. Curative options in the presence of metastatic 
disease are limited and does influence the survival-rates in our series. One has to realize in our 
series seven patients were ASA 3 and therapeutic options were limited anyhow. This is also 
reflected by the higher 3-years disease-free survival of 57%, meaning patients actually died 
from other causes and were saved the adverse effects of a TME.
In  conclusion, recurrent disease after TEM for T1 rectal cancer is a major problem. Although 
salvage surgery is feasible in most of the patients, survival is impaired. A microscopic radical 
resection can almost always be obtained, without the need for extensive surgical procedures. 
In the near future we need to focus on improving selection in T1 rectal cancers suitable for 
TEM. Also possible adjuvant treatment strategies following salvage procedures need to be 
explored, in order to safe as many patients the adverse effects of TME. 
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AbSTRACT
Introduction
Complete resection is the most important prognostic factor in surgery for pelvic tumours. 
In locally advanced and recurrent pelvic malignancies radical margins are sometimes difficult 
to obtain, because of close relation to or growth in adjacent organs/structures. Total pelvic 
exenteration (TPE) is an exenterative operation for these advanced tumours and involves en 
bloc resection of the rectum, bladder and internal genital organs (prostate/seminal vesicles 
or uterus).
Methods
Between 1994 and 2008 a TPE was performed in 69 patients with pelvic cancer; 48 rectal 
cancer (32 primary and 16 recurrent), 14 cervical cancer (1 primary and 13 recurrent), 
5 sarcoma (3 primary and 2 recurrent), 1 primary vaginal – and 1 recurrent endometrial 
carcinoma. Ten patients were treated with neo-adjuvant chemotherapy and 66 patients with 
preoperative radiotherapy to induce down staging. Eighteen patients received IORT because 
of an incomplete or marginal complete resection. 
Results
The median follow up was 43 months (range 1–196). Median duration of surgery was 448 
min (range 300-670), median blood loss was 6300 ml (range 750-21000) and hospitalization 
was, 17 days (range 4–65). Overall major and minor complication rates were 34% and 57%, 
respectively. The in hospital mortality rate was 1%. A complete resection was possible in 75% 
of all patients, a microscopically incomplete resection (R1) in 16% and a macroscopically 
incomplete resection (R2) in 9%. Five-year local control for primary locally advanced rectal 
cancer, recurrent rectal cancer and cervical cancer was respectively 89%, 38% and 64%. 
Overall survival after 5 year for primary locally advanced rectal cancer, recurrent rectal 
cancer and cervical cancer was 66%, 8% and 45%.
Conclusion
Total pelvic exenteration is accompanied with considerable morbidity, but good local control 
and acceptable overall survival justifies the use of this extensive surgical technique in most 
patients, especially patients with primary locally advanced and recurrent cervical cancer. 
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INTRODUCTION
Locally advanced pelvic tumours without distant metastases can cause severe local problems, 
such as pain, defecation problems and can result in a decreased quality of life.[1, 2] Extensive 
surgery is often the only possibility for complete resection, thereby attempting to provide 
local control and palliation. In case of involvement of the base or trigone of the bladder 
or the prostate, a total pelvic exenteration (TPE) with resection of the rectum together 
with bladder, lower ureters and internal genital organs could potentially salvage the patient.
[3] After resection of the bladder an ileal conduit is usually constructed according to the 
technique described by Bricker.4 TPE has been performed in primary or recurrent cancer 
of the cervix, rectum, vagina, uterine corpus, vulva, prostate, bladder and in pelvic sarcoma.
[5, 6] 
Since the introduction of the technique by Brunswick in 1948 the initially poor quality 
of life and high mortality and morbidity associated with the technique have substantially 
improved.[7-9] However, morbidity after this extensive surgical procedure is still high and 
reports between 13% and 64%.[10-12] Five-year survival rates after TPE for patients with 
primary disease range between 32% and 66% and in patients with recurrent disease from 
0% to 23%.[3, 7, 12] Hence, a careful selection in a multidisciplinary setting of patients is of 
paramount importance.
In the present study, all patients who underwent a pelvic exenteration were reviewed. 
Preoperative morbidity and mortality, local recurrence, disease free and overall survival rates 
were studied and prognostic factors for local control or survival were analysed.
PATIENTS AND METHODS
In the Erasmus University Medical Centre - Daniel den Hoed Cancer Centre, 69 TPE’s were 
performed in the period between 1994 and 2008 for locally advanced primary or locally 
recurrent pelvic malignancies. Forty-eight patients with rectal cancer (32 primary locally 
advanced and 16 recurrent), 14 with cervix cancer (1 primary and 13 recurrent), 5 with 
pelvic sarcoma (3 primary and 2 recurrent), one primary vagina carcinoma and one recurrent 
endometrial carcinoma. Fifty patients were male, with a median age of 61 years (range 30–76 
years).
Patients were preoperatively analysed and selected using CT- and/or MRI-scanning of the 
small pelvis (90% and 59%, respectively). On indication a cystoscopy was used to identify 
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growth into the bladder. Screening for distant metastases was performed using thoracic and 
abdominal CT-scan in all patients.
All 32 patients with primary rectal cancer received 50 Gy preoperative (chemo)radiation. 
Thirteen of twenty-six patients (10 cervical, 2 sarcoma and 1 rectal cancer patient) with 
recurrent cancer previously received radiotherapy during treatment of the primary tumour 
(median dosage 50 Gy, range 46-60 Gy). One patient was re-irradiated (27Gy) after 50Gy 
adjuvant radiation after primary treatment for rectal cancer. One patient with recurrent 
rectal cancer received chemotherapy as primary treatment. Primary surgery for patients with 
recurrent cancer is described in Table 1.
Table 1. Previous procedures in patients with recurrent pelvic cancer
Rectal n=16 Abdominal perineal resection
Low anterior resection
Rectosigmoid resection and end colostomy
8
5
3
Cervical n=13 Radical hysterectomy
Extrafascial abdominal hysterectomy
Vaginal hysterectomy
Chemoradiation
7
3
1
2
Sarcoma n=2 Local excision
Hysterectomy
1
1
Endometrial n=1 Abdominal uterus extirpation 1
In 1997 an intraoperative radiation therapy (IORT) program was started in our hospital and 
the technique is described previously.[13] Briefly, IORT with HDR brachytherapy was given 
to patients who had a minimal circumferential free resection margin equal to or less than 
two millimeters. The resection margin was judged on frozen sections taken during surgery. 
IORT was performed using the Flexible Intraoperative Template (FIT) developed at our 
department, delivering a dose of 10 Gy, usually at 1 cm depth from the applicator surface.
Pathology
All staging, except from the staging of sarcoma, was performed according to the AJCC TNM 
criteria, and completeness of resection was divided in R0 (complete resection of tumour), 
R1 (microscopic tumour remnant in circumferential margin) and R2 (macroscopically 
not complete resection). Recurrent rectal tumours were staged according to the Wanebo 
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classification for recurrent tumours.[14] Since 2002 all pathology examination for rectal 
cancer was performed by the guidelines of Quirke.15
Evaluation of morbidity and mortality
Hospital charts were studies to collect patient characteristics, operation techniques and 
follow-up. Surgery related morbidity is divided in major and minor complications. Major 
morbidity is defined as a complication that requires (surgical) reintervention. All other 
complications were classified as minor.
Statistical analysis of survival and local control
Survival time was calculated from the date of resection of the tumour until the last follow-up 
attendance or until death. Local control was calculated from the date of resection until the 
histological or evident radiological presence of a local recurrence. The cumulative survival 
and local control rate after surgery were calculated using the Kaplan-Meier method.[16] 
Univariate survival comparisons were executed using the log-rank test. The Cox proportional 
hazards analysis was used for multivariate analysis of prognostic factors for local control and 
overall survival.[17] The level of significance was defined as P<0.05.
 
RESULTS
At the time of diagnosis patients presented with complaints of pain (19%), changes in 
defecation (25%), changes in urinary miction (7%), perineal pressure (6%) and with a 
combination of these complaints (33%). Only 7 patients (10%) did not have complaints and 
were diagnosed during routine follow-up.
At preoperative physical examination 47% of the gynaecological tumours were clinically 
fixed to the rectum and 74% percent of the rectal tumours were clinically fixed to the prostate 
and bladder. 
An exploratory staging laparotomy to create a colostomy or ileostomy was performed 
in fifteen patients (one sarcoma, one recurrent cervical, 12 primary locally advanced and 
one recurrent rectal cancer). No distant metastases were found during prior surgery and 
preoperative screening.
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Preoperative treatment
Ten patients (14%) received neo-adjuvant chemotherapy (5 rectal cancer, 1 primary and 3 
recurrent cervical and 1 vagina carcinoma). Forty-six patients (67%) received preoperative 
radiotherapy (median dosage 50Gy, range 27–67 Gy).
Surgery
The median duration of surgery was 448 minutes (range 300–670). The median bloodloss 
was 6300ml (range 750–21000ml). Fifty-eight patients received a small bowel as urostoma 
and 11 patients a colon conduit. In all but 6 patients an omentoplasty and in 5 patients an 
unilateral gracilis muscle transposition was used for primary pelvic reconstruction. Indirect 
reconstruction with gracilis transposition (one bilateral and three unilateral) was performed 
in 3 patients because of persistent perineal wounds. No flap-necrosis occurred and eventually 
after secondary reconstruction all perineal wounds closed in a median of 86 days (range 43–
304 days).
Intra-and post-operative treatment
IORT was applied in 18 patients (6 primary rectal, 10 recurrent rectal, 2 recurrent cervical 
cancer): 8 with a marginal radical (R0) resection, 9 with a microscopically irradical resection 
(R1) and 1 with macroscopic tumour mass (R2).
One primary sarcoma and two recurrent cervical tumours were post-operatively irradiated. 
None of the patients received adjuvant chemotherapy.
Postoperative
TNM- and Wanebo stages and completeness of resection are depicted in table 2. The median 
postoperative hospital stay was 17 days (range 4–65) with an increase for the recurrent 
tumours compared to the primary treated tumours (20 vs. 14 days).
Complications are depicted in table 3. The most common minor complications were a 
superficial wound infection (34%) and pulmonary infections (8%). Forty-eight percent of 
all reinterventions were performed because of complications related to the construction 
of the urostomy. All these patients had received radiotherapy (1 in primary treatment, 9 in 
neo-adjuvant setting and one as well in previous treatment, intraoperatively as in adjuvant 
treatment).
The major and minor complication rates were not significantly different for patients treated 
with or without radiotherapy. 
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Table 2. Pathology characteristics
Rectal Cervical
Prim Rec Prim Rec
Total no. 32 16 1 13
T stage T0
T2
T3
T4
-
-
35%
65%
 8%*
-
25%**
67%***
-
-
-
100%
9
9
36
45
N stage N0
N1
N2
Nx
57%
9%
9%
26%
42%
16%
-
42%
100%
-
-
-
45
-
-
54
Completeness R0
R1
R2
82%
9%
9%
58%
25%
17%
100%
-
-
64
36
-
* no TNM-classification available
**Wanebo classification for recurrent rectal cancer stage Tr 0 (No recurrence)
***Wanebo classification for recurrent rectal cancer stage Tr 3 (Growth into surrounding soft tissue)
****Wanebo classification for recurrent rectal cancer stage Tr 4 (Penetration anterior structures)
Local Control
The 5-year local control of primary rectal, recurrent rectal and other cancer is 89%, 38% and 
64% (Figure 1). All four patients with a soft tissue sarcoma and the patients with a primary 
cervical tumour and with a primary vaginal tumour remained without a local recurrence after 
5 years. A recurrence at the urethra was observed 10 months after resection in the patient who 
was operated for a third recurrence of an endometrial tumour. The recurrence was treated 
with local palliative resection and the patient was systemically treated with chemotherapy.
At univariate analysis significant prognostic factors for an improved local control were the 
interval from primary resection to local recurrence more than 12 months (P=0.012), type 
of tumour (primary rectal)(P=0.009), completeness of resection (P<0.001) and absence of 
preoperative pain (P<0.001). Sex, age, preoperative radiotherapy and positive lymph nodes 
did not have prognostic value on local control.
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Table 3. Complications and reinterventions
Prim rectum
(n = 32)
Rec rectum
(n = 16)
Cervix
(n = 14)
Others Total
(n = 69)
Complications
 − Minor only
 − Major only
 − Major and minor
 − No complication
12 (38%)
-
9 (28%)
11 (34%)
5 (31%)
4 (25%)
4 (25%)
3 (18%)
2 (14%)
-
6 (43%)
6 (43%)
3 (43%)
-
1 (14%)
3 (43%)
22 (32%)
4 (6%)
20 (29%)
23 (33%)
Minor complications
 − Wound infection perineal
 − Wound infection midline
 − Pneumonia
 − Central venous catheter sepsis
 − Fever without known cause
 − Urinary tract infection
 − Neuropathy
 − TIA
 − Decubitus
4 (12%)
6 (19%)
4 (12%)
1 (3%)
1 (3%)
3 (9%)
1 (3%)
-
1 (3%)
1 (6%)
3 (19%)
1 (6%)
1 (6%)
-
-
1 (6%)
1 (6%)
1 (6%)
3 (21%)
3 (21%)
1 (7%)
-
-
2 (14%)
-
-
-
2 (28%)
1 (14%)
1 (14%)
-
-
1 (14%)
-
-
-
10 (14%)
13 (19%)
7 (10%)
2 (3%)
1 (1%)
6 (9%)
2 (3%)
1 (1%)
2 (3%)
Major complications/ required 
interventions
 − Urostomy-related
 − Nefrodrain placement
 − Small bowel leakage repair
Reimplantation ureter
2 (6%)
2 (6%)
1 (3%)
2 (13%)
1 (6%)
-
2 (14%)
1 (7%)
1 (7%)
-
-
-
6 (9%)
4 (6%)
2 (3%)
Other
 − Gracilis flap wound repair
 − Sartorius flap fistula repair
 − Abdominal dehiscence repair
 − Ileus relaparotomy
 − Bleeding relaparotomy
 − Abscess drainage
 − Suture leakage repair
 − Enterocutaneous fistula repair
2 (6%)
-
1 (3%)
-
-
-
-
-
-
1 (6%)
-
1 (6%)
-
2 (12%)
-
-
-
-
-
-
-
3 (21%)
1 (7%)
1 (7%)
-
-
-
-
1 (14%)
1 (14%)
-
-
1 (1%)
1 (1%)
1 (1%)
1 (1%)
1 (1%)
6 (9%)
1 (1%)
1 (1%)
Major complication: a complication that causes the need for reintervention or is the cause of prolonged 
hospitalization.
Minor complication: a complication that does not cause the need for reintervention or is the cause of prolonged 
hospitalization.
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Figure 1. Kaplan-Meier curve for local control
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Figure 2. Kaplan-Meier curve for overall survival
Overall survival
The 5 year overall survival of patients with primary, recurrent rectal and other cancer was 
66%, 8% and 45%, as depicted in figure 2. All patients with soft tissue sarcoma were alive 
after 5 years. At last follow-up, 46 months after resection, the patient with primary cervical 
cancer was alive without evidence of disease. The patient with a primary vaginal tumour 
remained under local control but developed bone-metastases 16 months after TPE and died 
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6 months later. The patient with the 3rd recurrence of endometrial cancer was lost to follow-
up 9 months after developing a local recurrence.
An interval from primary resection to local recurrence more than 12 months, type of tumour 
(primary rectum) and completeness of resection were prognostic factors for an improved 
survival (P=0,010, P=0.010 and P<0.001 resp.). Sex, age, preoperative radiotherapy and 
positive lymph nodes did not have prognostic value on overall survival.
DISCUSSION
The technique of total pelvic exenteration was introduced as a palliative procedure for patients 
with advanced gynaecological cancer. Nowadays it is performed with curative intent in the 
treatment of locally advanced and recurrent pelvic disease (rectal, cervical, endometrial, 
vaginal, vulvar tumours and soft tissue sarcoma).[8] In locally advanced tumours (without 
distant metastasis) complete resection is the only possibility for cure and in rectal cancer 
patients the overall survival rate of 66% and local control rate of 89% after 5 years shows that 
survival with excellent local control is possible after TPE.[10, 12, 13] These results combined 
with the high R0-rate and acceptable complication rate justify the performance of TPE in 
this subgroup.[3] The results of TPE for recurrent rectal cancer, with local control of 38% 
and 8% overall survival after 5 years, indicate the poor prognosis and questionable benefit 
of major surgery in this group. The results however are comparable with rates after non-
exenterative surgery for recurrent rectal cancer and the high occurrence of distant metastasis 
emphasises the importance of thorough patient selection.[5, 10, 12 13]
The majority of TPE in gynaecological cancer is performed in recurrent cervical cancer.[18-
20] One-third of patients with primary carcinoma of the cervix will have residual disease 
or recurrent disease, and in up to 25% of these patients there is only local disease without 
systemic metastases.[21] The treatment for recurrent cervical cancer can be radiotherapy, and 
in a selected population, without distant metastases, exenterative surgery (posterior, anterior 
or total exenteration). The 5-year overall survival after treatment of recurrent cervical cancer 
of 45% in the present study compares to rates reported in the last decade varying from 24%–
54%.[18, 19, 22] This is the same for local recurrence free rate of 64% after 5 years, which is 
comparable with rates varying from 40–78% in the literature.[18, 22] For more uncommon 
tumours, case reports or small series describe different results. Barakat et al. described that 
surgery for recurrent endometrial cancer is associated with only 20% long-term survival and 
high morbidity.[23] Preoperatively irradiated patients with locally advanced vaginal cancer 
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are appropriate candidates for TPE with >50% survival after 5 year according to Berek et 
al.[19]
Pelvic sarcoma are also rare tumours and originate from the stroma of pelvic viscera or from 
the retroperitoneum. Complete resection and tumour grade are the main prognostic factors 
for survival.[25] The four patients with sarcomas (2 primary and 2 recurrent) in the present 
study were all completely resected and did not recur in the pelvis. The 100% overall survival 
without local relapse in this small cohort compares favorably to the 66% survival after 2 years 
recently described by Lopes et al.[6] 
Overall complete resection rate in the present study was 75% for all tumours. The curative 
potential of resection differs between primary and recurrent tumours. A complete resection 
in patients with recurrent disease was possible in 65% of the patients in the present study, 
which was substantially lower than for patients with a primary tumour (85%). Complete 
resection is more difficult in recurrent cancer because of primary resection of visceral fascia. 
Successful complete resection of recurrent disease is often restricted to selected patients, 
for example with early-detected or limited tumour mass. As described in previous reports, 
complete resection of tumour is a significant prognostic factors for local control and survival.
[5, 10, 12, 26] All 4 patients with a macroscopically incomplete resection (2 primary and 2 
recurrent rectal cancer) died during follow-up with a mean survival of 13 months. 
Morbidity rates reported after TPE for primary and locally recurrent rectal cancer vary from 
13-78%.[10, 11, 27] We have previously reported overall morbidity rates of 61% in primary 
rectal cancer (26% major and 35% minor) and 83% in recurrent rectal cancer (50% major 
and 58% minor.[3] Infectious complications as midline (14%) and perineal (19%) wound 
infection, fistula (4%) and abscesses (12%) are the most common complications after TPE. 
Preoperative radiotherapy did not lead to an increase in complications, which is in contrast 
to what has been described by Lopez et al. who identified significant higher complication 
rates in the irradiated group of patients.[28]
Thirty-eight percent of all major complications were related to the construction of the 
urinary conduit. Houvenaegel et al. showed similar complications (42%) related to the 
construction of a noncontinent urostomy. High complication rates after construction of a 
Bricker urostomy in irradiated patients have often been reported because of postradiation 
fibrosis. The Bricker procedure remains the most performed technique for urinary diversion. 
Other procedures using intestinal segment outside of the radiation field as jejunum or colon 
have been proposed, but each with their own related complications; use of jejunum can lead 
to metabolic complications and colon conduits are reserved for patients without previous 
colon resection, to prevent absorption problems.[29, 30] The use of continent pouches is 
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increasingly reported, with related functional advantages leading to improved quality of life; 
however also related with 46 % pouch-related complications.[30] 
For many years age was considered a contraindication for the performance of TPE. In the 
present study patients over 70 years had similar outcome after TPE compared to younger 
patients, which is confirmed by other recent studies.[20, 22] Not age, but physical condition 
and co-morbidities are considered as the important criteria in selecting patients for TPE.
As a specialised cancer centre a weakly multidisciplinary meeting where all patients with 
pelvic tumours are presented and where the treatment program of each individual patient is 
discussed and planned.
CONCLUSION
Total pelvic exenteration is accompanied with considerable morbidity, but good local control 
and acceptable overall survival justifies the use of this extensive surgical technique in selected 
patients with primary locally advanced and recurrent pelvic tumours. 
Total pelvic exenteration for primary and recurrent malignancies | 131
REFERENCES
1. Ferenschild FT, Vermaas M, Nuyttens JJ, et al. Value of intraoperative radiotherapy in locally advanced 
rectal cancer. Dis Colon Rectum 2006;49:1257-65.
2. Vermaas M, Ferenschild FT, Nuyttens JJ, et al. Preoperative radiotherapy improves outcome in recurrent 
rectal cancer. Dis Colon Rectum 2005;48:918-28.
3. Vermaas M, Ferenschild FT, Verhoef C, et al. Total pelvic exenteration for primary locally advanced and 
locally recurrent rectal cancer. Eur J Surg Oncol 2007;33:452-8.
4. Bricker EM. Bladder substitution after pelvic evisceration. Surg Clin N Amer 1950;30:1511.
5. Kecmanovic DM, Pavlov MJ, Kovacevic PA, Sepetkovski AV, Ceranic MS, Stamenkovic AB. Management 
of advanced pelvic cancer by exenteration. Eur J Surg Oncol 2003;29:743-6.
6. Lopes A, Poletto AH, Carvalho AL, Ribeiro EA, Granja NM, Rossi BM. Pelvic exenteration and 
sphincter preservation in the treatment of soft tissue sarcomas. Eur J Surg Oncol 2004;30:972-5.
7. de Wilt JH, van Leeuwen DH, Logmans A, et al. Pelvic exenteration for primary and recurrent 
gynaecological malignancies. Eur J Obstet Gynecol Reprod Biol 2007;134:243-8.
8. Brunschwig A. Complete excision of pelvic viscera for advanced carcinoma. Cancer 1948;1:177.
9. Chen HS, Sheen-Chen SM. Total pelvic exenteration for primary local advanced colorectal cancer. World 
J Surg 2001;25:1546-9.
10. Law WL, Chu KW, Choi HK. Total pelvic exenteration for locally advanced rectal cancer. J Am Coll 
Surg 2000;190:78-83.
11. Saito N, Koda K, Takiguchi N, et al. Curative surgery for local pelvic recurrence of rectal cancer. Dig Surg 
2003;20:192-200.
12. Yamada K, Ishizawa T, Niwa K, Chuman Y, Aikou T. Pelvic exenteration and sacral resection for locally 
advanced primary and recurrent rectal cancer. Dis Colon Rectum 2002;45:1078-84.
13. Nuyttens JJ, Kolkman-Deurloo IK, Vermaas M, et al. High-dose-rate intraoperative radiotherapy for close 
or positive margins in patients with locally advanced or recurrent rectal cancer. Int J Radiat Oncol Biol 
Phys 2004;58:106-12.
14. Wanebo HJ, Antoniuk P, Koness RJ, et al. Pelvic resection of recurrent rectal cancer: technical 
considerations and outcomes. Dis Colon Rectum 1999;42:1438-48.
15. Quirke P, Durdey P, Dixon MF, Williams NS. Local recurrence of rectal adenocarcinoma due to 
inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. 
Lancet 1986;2:996-9.
16. Kaplan ES MP. Nonparametric estimation from incomplete obeservations. Journal of American Statistical 
Association 1958;53:457-81.
17. Cox DR. Regression models and life tables. Journal of the Royal Statistical Society 1972;B 34:187-220.
18. Sharma S, Odunsi K, Driscoll D, Lele S. Pelvic exenterations for gynecological malignancies: twenty-year 
experience at Roswell Park Cancer Institute. Int J Gynecol Cancer 2005;15:475-82.
19. Berek JS, Howe C, Lagasse LD, Hacker NF. Pelvic exenteration for recurrent gynecologic malignancy: 
survival and morbidity analysis of the 45-year experience at UCLA. Gynecol Oncol 2005;99:153-9.
20. Goldberg JM, Piver MS, Hempling RE, Aiduk C, Blumenson L, Recio FO. Improvements in pelvic 
exenteration: factors responsible for reducing morbidity and mortality. Ann Surg Oncol 1998;5:399-406.
132 | Chapter VIII
21. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999;49:33-64, 1.
22. Roos EJ, Van Eijkeren MA, Boon TA, Heintz AP. Pelvic exenteration as treatment of recurrent or 
advanced gynecologic and urologic cancer. Int J Gynecol Cancer 2005;15:624-9.
23. Barakat RR, Goldman NA, Patel DA, Venkatraman ES, Curtin JP. Pelvic exenteration for recurrent 
endometrial cancer. Gynecol Oncol 1999;75:99-102.
24. Lewis JJ, Leung D, Woodruff JM, Brennan MF. Retroperitoneal soft-tissue sarcoma: analysis of 500 
patients treated and followed at a single institution. Ann Surg 1998;228:355-65.
25. Moriya Y, Akasu T, Fujita S, Yamamoto S. Total pelvic exenteration with distal sacrectomy for fixed 
recurrent rectal cancer in the pelvis. Dis Colon Rectum 2004;47:2047-53; discussion 53-4.
26. Jimenez RE, Shoup M, Cohen AM, Paty PB, Guillem J, Wong WD. Contemporary outcomes of total 
pelvic exenteration in the treatment of colorectal cancer. Dis Colon Rectum 2003;46:1619-25.
27. Lopez MJ, Standiford SB, Skibba JL. Total pelvic exenteration. A 50-year experience at the Ellis Fischel 
Cancer Center. Arch Surg 1994;129:390-5; discussion 5-6.
28. Mills RD, Studer UE. Metabolic consequences of continent urinary diversion. J Urol 1999;161:1057-66.
29. Karsenty G, Moutardier V, Lelong B, et al. Long-term follow-up of continent urinary diversion after 
pelvic exenteration for gynecologic malignancies. Gynecol Oncol 2005;97:524-8.
Chapter IX
Abdominosacral resection in locally 
advanced and recurrent rectal cancer
Floris T.J. Ferenschild
Maarten Vermaas
Cees Verhoef
Roy S. Dwarkasing
Alexander M.M. Eggermont
Johannes H.W. de Wilt
British Journal of Surgery 2009; accepted for publication.
134 | Chapter IX
AbSTRACT
background
The results of resection of locally advanced and recurrent rectal cancers, including sacral 
resection, were analysed critically.
Methods
Between 1987 and 2007, 353 patients with locally advanced or recurrent rectal cancer, all 
treated in a tertiary referral centre, were identified from a prospective database. Twenty-five 
patients (eight primary and 17 recurrent tumours) underwent en bloc sacral resection.
Results
A mid sacral resection was carried out in 12 patients (level S3) and a low sacral resection in 
13 (level S4/S5). Nineteen patients had an R0, four an R1 and two an R2 resection. There 
was no postoperative mortality. Median follow-up was 32 months. Incomplete resection had 
an independent negative influence on local control (5-year local recurrence rate 42 vs. 0 per 
cent in those with and without incomplete resection; P<0·001). The 5-year overall survival 
rate was 30 per cent. Five patients with recurrent tumour had pathological invasion into the 
sacral bone and none survived beyond 1 year.
Conclusion
Abdominosacral resection can be performed in patients with locally advanced and recurrent 
rectal cancer. Patients who cannot undergo a complete resection or have clear evidence of 
cortical invasion have a poor prognosis.
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INTRODUCTION
Despite efforts in early detection and intense follow-up of rectal cancer, primary locally 
advanced and recurrent rectal cancer with involvement into adjacent organs or structures 
is not uncommon. Primary locally advanced rectal cancer is estimated to account for 6–10 
per cent of all primary rectal cancers. Local recurrence is the most common cause of failure 
following surgical resection of rectal cancer and occurs in 3–38 per cent.[1-3] Patients 
with primary cancers that do not extend beyond the muscularis propria have good clinical 
outcome with resection alone, but those with primary and recurrent locally advanced 
cancers have better outcomes if they undergo preoperative chemoradiation therapy, even 
those with a complete resection.[4-8] For patients with extraluminal tumour involving the 
pelvis or other organs, treatment used to be strictly palliative. Because of new treatment 
modalities, including preoperative (chemo)radiation therapy and extensive resection, it is 
possible to obtain complete resections in such patients.[3,9,10] Furthermore, the addition 
of intraoperative radiation therapy (IORT) might further improve the local control rate in 
patients whose rectal cancer resection was marginal.[1,4,5] The posterior bony pelvis is almost 
never involved in patients with primary locally advanced rectal cancer and is occasionally 
involved in recurrent rectal cancer.[11] The symptoms often include severe pain in the 
sacral region. If the tumour has infiltrated, or lays very close to, the sacrum, abdominosacral 
resection might be the only curative treatment option in some patients. The 5-year overall 
survival rate after abdominosacral resection is between 15 and 30 per cent, and the local 
control rate between 15 and 40 per cent.[12,13] Performing sacral resections as high as the S1–
S2 interspace may lead to serious bladder and anorectal dysfunction but seems manageable 
without incurring musculoskeletal disability. For resections levels limited to S3–S4 there 
are usually no major problems with bladder or anorectal function. The aim of this study 
was to evaluate the oncological outcome after abdominoperineal sacral resection (APSR) for 
primary locally advanced and recurrent rectal cancer in a tertiary referral centre.
METHODS
Three hundred and fifty-three patients with locally advanced primary (195) or recurrent 
(158) rectal cancer, operated in the authors’ tertiary referral centre between January 1987 
and December 2007, were identified. The tumours were classified as primary locally advanced 
when the tumour was clinically or radiographically a large T3 lesion (larger than 5 cm) with 
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narrow circumferential margins, or a T4 tumour. Recurrent rectal tumours were all biopsy-
proven invasive adenocarcinomas. Of these 353 patients, 25 underwent an APSR. The 
following information was extracted from the hospital notes, radiotherapy plans, operation 
notes and histopathological reports: demographics, preoperative diagnostic intervention, 
tumour stage, radiotherapy technique, surgical details, anaesthetic details, histopathological 
details and complications. Follow-up data were obtained from hospital notes, medical letters 
and, for some patients, from the general practitioner.
Preoperative and intraoperative (chemo)radiation therapy
One but one patient received preoperative radiotherapy. This patient was treated before 
preoperative radiotherapy was standard treatment at this centre. One received concomitant 
chemotherapy with capecitabine. A radiation dose of 50 Gy in 25 daily fractions was 
prescribed. From 1997, IORT was given to patients who had a minimal circumferential free 
resection margin of 2 mm or less. The resection margin was judged on frozen sections taken 
during surgery. A boost of 10 Gy was given directly in the operative field with the flexible 
intraoperative template (FIT) developed at this department.[14,15] This template is a 5-mm 
thick pad made of flexible silicone with 1- cm spaced parallel source guide tubes running 
through the centre of the template. Before positioning the FIT, three to four surgical clips 
were placed around the target surface. The size and shape of the FIT was then adjusted to the 
target surface. Treatment was planned using standard geometries present in the treatment 
planning system. Two orthogonal pelvic radiographs were taken to see whether the target 
surface (clips) was encompassed by the applicator. If the applicator was positioned well, a 
dose of 10 Gy was delivered at a depth of 1 cm from the applicator surface.[5,16]
Surgery
Determination of the surgical approach for complete resection was based predominantly 
on computed tomography (CT) or magnetic resonance imaging (MRI) findings. Criteria 
for an abdominosacral resection for either primary or recurrent cancer were invasion into 
the sacrum or growth into the lateral pelvic walls or pelvic floor muscles, and the need 
for wider dorsal access to improve visualization to enable complete tumour resection. The 
abdominosacral resection required a two-phase approach. The abdominal phase consisted of 
exploration with careful examination to exclude liver metastases or signs of extrapelvic spread. 
The rectum was dissected until the area of fixation was reached dorsally. From 2001 onwards, 
the internal iliac veins were tied or dissected routinely with an endostapler to prevent blood 
loss. The abdominal part of the operation has been described in detail previously. [1] After 
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the abdominal phase, the patient was turned around and the posterior approach started with 
a separate intergluteal incision through which the sacrum was exposed. The ligamentous 
attachments of the sacrum to the rest of the pelvis were incised. Using an osteotome the 
sacrum was transected at the desired level. The level of transection was based on imaging 
findings before neoadjuvant treatment and the intraoperative judgement of the surgeon. 
The entire specimen was removed en bloc through the sacral incision. The defect was closed 
primarily and, if omentum was available, an omentoplasty was carried out. In some patients 
a muscle flap reconstruction was used to close the perineal wound.[17]
Surgery-related morbidity was divided in major and minor. Minor morbidity was defined 
as a complication for which no reintervention was needed. Major morbidity required a 
prolonged hospital stay owing to the complication or reintervention.
Statistical analysis
Univariable analysis of predictive variables was performed using the log rank test. P<0·050 
was considered statistically significant. Overall survival and local control were analysed as 
functions of extent of resection, completeness of resection, lymph node stage (negative versus 
positive), level of sacral resection, preoperative pain and IORT (yes vs. no). Results were 
calculated from the time of operation by the method of Kaplan and Meier.[18]
RESULTS
Of 353 patients in the prospective database, 25 had an APSR for primary locally advanced (8) 
or recurrent (17) rectal cancer. Previous treatment in those with recurrent rectal cancer was 
low anterior resection in seven patients, abdominoperineal resection in nine and a Hartmann 
procedure in one patient. Preoperative imaging comprised CT of the thorax, abdomen and 
pelvis in all patients, and additional MRI of the pelvis in 16. All 25 patients were operated 
with curative intent. There were 19 men and six women, with a mean age of 62 (range 43–78) 
years. Presenting symptoms and tumour characteristics are shown in Table 1.
Treatment
All but one patient received neoadjuvant radiotherapy with a median dose of 50 (range 
25–50·4) Gy. A mid sacral resection was performed in 12 patients (level S3) and a low 
sacral resection in 13 (level S4/S5). Total exenteration was necessary in five patients who 
underwent a mid-sacral excision because of combined posterior and anterior tumour 
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growth into the bladder. Urinary reconstruction was performed in all patients using a 
Bricker deviation. Seven patients who underwent a mid sacral resection had bladder-sparing 
surgery. Two of these patients developed urinary retention leading to recurrent urinary 
tract infections. Five patients had posterior exenteration because of invasion of the uterus 
or vagina. A permanent colostomy was fashioned in all patients. A gracilis muscle flap 
was constructed in three patients. IORT was given to 14 patients: eight with a complete 
resection (R0) but circumferential margins smaller than 2 mm and six with a microscopically 
(R1) or macroscopically (R2) incomplete resection. The median duration of operation 
was 480 (range 320–620) min. Median blood loss was 6500 (range 800–18 000) ml. The 
resection was complete (R0) in 19 patients; four had residual microscopic disease (R1) and 
two had macroscopic disease (R2). Incomplete resection was due to involvement of the 
presacral fascia in one patient and involvement of the lateral pelvic sidewall in the others. 
The pathological stage is summarised in Table 2. Two patients with liver metastases at the 
time of operation underwent partial liver resection, with curative intent, during a second 
operation. Five patients had pathologically proven cortical invasion of tumour into the 
sacral bone, which was demonstrated before operation in four patients (Figure 1a). All had 
recurrent tumours, underwent incomplete resection and died from ongoing disease within a 
year of the operation. In all other patients a close relationship between the tumour and sacral 
bone was demonstrated at pathological examination, but no tumour invasion into the bone. 
Preoperative imaging such as CT or MRI did not demonstrate suspicion of invasion into 
the cortical bone in any of these patients (Figure 1b). After surgery four patients received 
adjuvant radiotherapy and three had adjuvant 5-fluorouracil-based chemotherapy.
Follow-up
Median follow-up was 32 (range 2–63) months. Postoperative complications and 
reinterventions are shown in Table 3. Postoperative morbidity occurred in 17 patients 
(68 per cent). Eleven reinterventions were necessary in eight patients. Four patients with 
postoperative perineal wound dehiscence were treated with a muscle flap reconstruction. 
Three patients had a gracilis muscle flap reconstruction and one a vertical rectus abdominus 
musculocutaneous flap reconstruction. No patient died within30 days of operation.
Local recurrence
The median time to local recurrence was 36 (range 6–120) months. The overall 3- and 
5-year local control rates were 49 and 34 per cent respectively. The 5-year local control rate 
was 10 per cent for patients with recurrent tumour compared with 88 per cent for those 
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with a primary locally advanced tumour (P = 0·011). Positive lymph nodes and incomplete 
resections had a negative influence on local recurrence; the 5-year local control rate was 43 
versus 0 per cent in those with and without positive lymph nodes, and 42 versus 0 per cent 
in those with complete and incomplete resections (P < 0·001). Preoperative pain, previous 
surgical procedure (low anterior resection versus abdominoperineal resection), IORT and 
the level of sacral resection had no impact on the local control rate.
Table 1. Patient Characteristics
N (%)
Total 25 100
Presenting symptoms
 − Pain
 − Rectal bleeding
 − Diarrhea
 − Combination
9
7
2
7
36
28
8
28
Tumour height (distance to anal verge or perineum)
 − < 5 cm
 − 6-10 cm
19
6
76
24
Fixation tumour
 − Posterior
 − Lateral 
 − Multiple sites (lateral and posterior or completely fixed)
10
2
13
40
8
52
Overall recurrence
The median time to the development of local and/or distant recurrence was 33 (range 12–
120) months. Overall 3- and 5-year overall recurrence-free survival rates were 48 and 41 per 
cent respectively. The 5-year overall recurrencefree survival rate was 0 per cent in patients 
with positive lymph nodes compared with 77 per cent in node-negative patients (P<0·001). 
Preoperative pain, IORT, operating time, blood loss and the level of sacral resection had no 
influence on overall recurrence.
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Table 2. pTNM / Wanebo Classification
Primary % Recurrence %
pTNM stage
Tumour stage
 − T3
 − T4
Nodal stage
 − N0
 − N1, 2
 − Not found
Metastases stage
 − M0
 − M1
n=8
6
2
1
7
-
7
1
75
25
12,5
87,5
-
87,5
12,5
Wanebo classification
Tr stage
 − Tr3
 − Tr4
 − Tr5
Nodal stage
 − N0
 − N1, 2
 − Not found
Metastases stage
 − M0
 − M1
n=17
3
9
5
2
2
13
16
1
18
53
29
12
12
76
94
6
Overall survival
Median survival of the whole group was 32 (range 7–120) months. The overall 3- and 5-year 
survival rates were 46 and 30 per cent respectively. Five-year survival differed significantly 
in patients who had complete versus incomplete resection (38 vs. 0 per cent; P=0·011) and 
locally advanced versus recurrent rectal cancer (56 vs. 19 per cent; P=0·036). Lymph node 
stage and other studied factors such as preoperative pain, IORT, operating time, blood loss 
and the level of sacral resection had no effect on overall survival. Multivariable analysis 
revealed that only incomplete resection was an independent predictor of overall survival 
(P= 0·053). Patients with an incomplete resection or pathological invasion into the sacral 
bone had a median survival of 9 months and none survived for 5 years.
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Table 3. Post-operative morbidity and reinterventions
Total number of patients
Major complications
 − Perineal wound dehiscence
 − Abscess
 − Anastomotic leakage (Bricker)
25
10
4
5
2
100%
40%
16%
20%
8%
Minor complications
 − Wound dehiscence (superficial)
 − Urinary Tract Infection
 − Pneumonia
 − Fistula
 − Neuropathy
 − XXXXXXXX
23
10
6
3
2
2
92%
40%
24%
12%
8%
8%
Reinterventions
 − Percutaneous abscess drainage
 − Percutaneous nephrostomy 
 − Muscle flap reconstruction 
 − Revision stoma (Bricker)
11
5
2
4
1
44%
20%
8%
16%
4%
P<0.0010.00
0.25
0.50
0.75
1.00
0 12 24 36 48 60
n=15
n=9
Local control by nodal status
analysis time months
N=neg N=pos
Figure 1. Local control by nodal status
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P<0.0010.00
0.25
0.50
0.75
1.00
0 12 24 36 48 60
n=19
n=6
Local control by R0-R1
analysis time months
RO R1
Figure 2. Local control by resection status (R0 versus R1)
P=0.030.00
0.25
0.50
0.75
1.00
0 12 24 36 48 60
n=8
n=17
Overall survival by tumor status
analysis time months
locally advanced recurrent
Figure 3. Overall survival by tumour status
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Figure 4a MRI: recurrent rectal cancer with close relation of the tumour with the sacrum
Figure 4b MRI: recurrent rectal cancer with cortical invasion in sacrum
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DISCUSSION
Primary locally advanced or recurrent rectal tumours that involve or are close to the 
sacral bone are often considered unresectable and incurable, and are therefore treated 
with palliative intent. Complete resection of such tumours requires extended surgical 
techniques, with removal of part of the sacrum en bloc with the tumour. In this series, APSR 
with curative intent in 25 patients resulted in a 5-year overall survival rate of 30 per cent. 
This is comparable to published rates of 18–37 per cent.[11-13,19-22] In line with previous 
findings,[1,12] in the present study patients with primary locally advanced tumours had 
significantly better survival than those with recurrent rectal tumours (56 and 19 per cent 
respectively at 5 years). The results in patients with primary rectal cancer seem comparable 
to those for patients who underwent a rectal amputation without sacral resection.[23] 
Although promising results after treatment of local recurrence have been described in recent 
studies,[10,13] those with recurrent rectal tumours did exceptionally poorly in the present 
series, especially the five patients with pathological invasion of the sacral bone who did not 
survive more than 1 year. In another study cortical bone invasion was present in 38 per cent 
of patients and was associated with worse disease-specific survival.[12] Invasion into the 
sacral bone probably reflects aggressive tumour behaviour and such tumour is difficult if not 
impossible to remove completely.[24] High-resolution MRI is highly accurate and superior 
to CT in predicting infiltration of locally advanced primary or recurrent rectal tumours 
into surrounding structures, and is recommended in the preoperative investigation of such 
lesions. MRI can correctly predict sacral bone invasion, which may be missed by CT.[25] 
It is therefore important to perform meticulous preoperative evaluation using positron 
emission tomography-CT and pelvic MRI to judge whether bone invasion is present. If so, 
palliative treatment can be considered because surgery might not improve survival compared 
with current (radio)chemotherapy protocols.[26] This study has confirmed the importance 
of complete resection of rectal tumours, as reported by others,[1,4,5,10–13,15,20,27] because 
local control and overall survival were significantly better for patients who had an R0 
resection. Although it has been shown previously that IORT improves local control 
of locally advanced and recurrent rectal cancers,[4,5,16,28-30] this was not the case in the 
present series. Mannaerts and colleagues [1] also failed to show an increase in local control or 
survival when IORT was used patients who underwent sacral en bloc resection, although the 
number of patients was small. Other prognostic factors such as preoperative pain or raised 
carcinoembryonic antigen levels, as mentioned in other studies,[9,20] were not independent 
prognostic factors for overall survival in the present study. The abdominosacral approach 
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permits a wide resection in the pelvis, as it allows resection of the large part of the bony 
pelvis posteriorly. The major problems of such extensive resection are the risk of neurological 
defects involving bladder, anorectal and sexual functions, and the potential musculoskeletal 
defects relating to wound dehiscence. In the present study the morbidity rate was 68 per 
cent and there were no deaths within 30 days. As reported by Wanebo and co-workers[11] 
serious neurological defects depend on the level of resection. Among twelve patients who 
had resection of S3 in the present study, seven underwent total exenteration with a Bricker 
reconstruction and four had bladder-sparing surgery. Two of the latter patients developed 
urinary retention, but there was no bladder dysfunction in the other two patients or in any 
of those who had lower dissections. Most major complications in the present study were 
musculoskeletal defects or perineal wound dehiscence, as reported in other series.[10,31,32] 
A secondary muscle flap reconstruction was needed to close the perineal wound in four 
patients. Nowadays, the present authors[17] and others[33] always perform a vertical rectus 
abdominal muscle flap as the preferred reconstruction in major pelvic surgical procedures. 
Other techniques, such as gluteus maximus muscle transfer, might be useful for closing the 
perineal defect and decreasing pelvic infections.[34] 
CONCLUSION
APSR can be performed as a potentially curative resection in selected patients without 
mortality but with substantial morbidity. Meticulous preoperative evaluation is essential for 
judging whether complete resection is feasible. If the tumour lies close to the bony structures, 
resection with sacrectomy seems justified. Surgery might not be the best option when there 
is clear evidence of sacral cortical invasion by recurrent rectal tumour as outcome in such 
patients is poor.
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AbSTRACT
background
The primary treatment for anal cancer is chemoradiation (CRT). Failures after CRT are 
potentially curable with an abdominoperineal resection (APR). A major problem of surgery 
in the anal area is poor healing of the perineal wound. 
Study design
Between 1985 and 2000, 129 patients treated for anal cancer were retrospectively reviewed. 
Of the 24 patients with local failure, 18 patients were treated with an APR. The aim of 
this study was to review the results and long-term outcome after salvage APR with special 
emphasis on perineal wound healing.
Results
Mean age at diagnosis was 59 (range 41–83) years. After a median follow up of 16 months, 
only 2 patients developed a local recurrence. The 5-year overall survival was 30%. In 11 
patients the perineal wound was closed primary, in 3 patients the perineal wound was left 
open and in 4 patients a vertical rectus abdominus musculocutaneous (VRAM) flap was 
used. Perineal wound breakdown occurred in 5 of the 14 patients not treated with primary 
muscle reconstruction (36%). In all patients treated with a VRAM flap the perineal wound 
healed primarily.
Conclusions
Salvage APR in recurrent or persistent anal cancer results in good local control and 5-year 
overall survival in the present study of 30%. When performing an APR a VRAM flap 
reconstruction should be considered to prevent disabling perineal wound complications.
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INTRODUCTION
Cancers of the anus originate either in the perianal skin, between the anal verge and the dentate 
line or proximal to the dentate line. In comparison with adenocarcinoma of the rectum, anal 
cancer is relatively uncommon.[1] Cancer of the anal canal constitutes 1.5% of gastrointestinal 
neoplasm’s.[2] Different series report similar frequencies of the different histology subtypes: 
squamous cell 60%–65%; cloacogenic 20%–25%, adenocarcinoma 5%–10% and others 
(e.g. melanoma or basal cell carcinoma) are sporadic.[2-5] The treatment of anal cancer has 
changed radically during the past few decades, from predominantly surgery to radiotherapy 
or radiotherapy combined with chemotherapy. An abdominoperineal resection (APR) was 
found to be curative in 45 to 60% of patients,[6-8] whereas chemoradiation therapy (CRT), 
introduced by Nigro et al.[9] in 1974 reported to eradicate tumours in 75% to 95%.[10-13] 
Despite the overall excellent results of CRT in the primary treatment of anal carcinoma, a 
proportion of patients fails treatment. Initial treatment failure occurs in 10%–15% and an 
additional 10%–15% of patients develop a local recurrence after an initial complete response 
to CRT.[9,14,15] The majority of these failures is isolated to the primary tumour site[14,16,17] 
and would therefore seem to be curable by an abdominoperineal resection (APR). A major 
problem of surgery in the previously irradiated anal area is poor healing of the often large 
perineal wound.[18] The aim of this retrospective study was to review the results of salvage 
abdominoperineal resection in patients with local recurrent or persistent anal cancer and to 
evaluate healing of the perineal wound in these patients.
PATIENTS AND METHODS
Between 1985 and 2000 the hospital charts of 129 patients treated at our tertial referral 
centre for anal cancer were retrospectively reviewed. All patients had biopsy proven 
anal carcinoma and were treated with curative intent by radiotherapy with or without 
concomitant chemotherapy. Twenty-four (19%) patients subsequently presented with 
a local failure, in 2 cases with combined regional metastases. Failure of chemoradiation 
therapy (CRT) was defined as the presence of histologically proven persistent disease within 
6 months or recurrent disease after an initial complete response to CRT. Of the 24 patients 
with local failure, 18 patients were treated with salvage abdominoperineal resection. The 
other 6 patients received different treatment for their failure of CRT (e.g. local excision, 
chemotherapy or radiotherapy) and were excluded from further analysis.
152 | Chapter X
Prior treatment
All 18 patients were initially treated with chemoradiation therapy delivered in a split course. 
The median delivered total radiation dose was 60 Gy (range 40-80Gy). The pelvis was treated 
with 40 Gy (2Gy/fraction) during 4 weeks, with concomittant chemotherapy administered 
on day 1 to day 4. Thereafter, a break of 2 weeks was scheduled. In the last 2 weeks a boost was 
given to the tumour bed with a dose of 20 Gy (2Gy/fraction). During the boost concomittant 
chemotherapy was given on day 43 to 47. Chemotherapy consisted of 5-Fu (1000mg/m2) 
and Mitomycine C (10mg/m2).
Surgery
Because the tumour was isolated in the anal canal or in the pelvis and therefore potentially 
curable, APR was the treatment of choice. None of the patients had distant metastases at the 
time of surgery. In a majority of cases the perineal wound was closed primarily. If available, 
the omentum was used to create an omentoplasty to fill the perineum. In a few patients the 
wound was left open and in four patients a vertical rectus abdominus musculocutaneous 
(VRAM) flap was used to fill the perineal and pelvic defect. Technique of distal placement 
of VRAM flaps has been described previously.[19-21] In summary the flap is freed entirely 
from the posterior sheath of the rectus muscle. The anterior sheet of fascia is incised from the 
umbilicus to the pubic bone and the flap is isolated. The flap is then tunnelled retroperitoneally 
to the pelvis and positioned paravesically (in women posterior to the uterus) to facilitate the 
reconstruction of the perineum. 
Statistical methods
Local control and overall survival curves were calculated from the time of APR and were 
based on the method of Kaplan and Meier.[22]
RESULTS
Of the 18 surgically treated patients, 9 (50%) were men and 9 (50%) were women. Mean age 
at diagnosis was 59 (range 41–83) years. Seven (39%) patients presented with persistent local 
disease and 11 (61%) with local recurrence. The median interval, between the end of CRT 
and the diagnosis of failure, was 12 (range 0–98) months. Two (11%) patients presented 
with concurrent regional lymph nodal disease. The initial (before CRT) tumour stage was 
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T2 (n=13), T3 (n= 4) and T4 (n=1). The initial lymph node status was N0 (n=16) and N1 
(n=2) (table 1).
Table 1. Patient characteristics
Patients (n=18)
Type of disease
 − Persistent
 − Recurrence
7
11
39%
61%
Initial stage
 − T2
 − T3
 − T4
 − N0
 − N1
Pathology stage
 − T0 
 − T1
 − T2
 − T3
 − T4
 − N0
 − N1
 − Nx
Histology
 − Squamous
 − Cloacogenic
 − Adenocarcinoma
13
4
1
16
2
2
2
6
6
1
8
3
6
11
3
2
72%
22%
6%
89%
11%
11%
11%
33%
33%
6%
44%
17%
33%
72%
17%
11%
Surgical results
The median duration of surgery was 210 (range 150–456) min and the median operative 
blood loss was 1250 (range 500–7500) ml. In eleven patients the perineal wound was closed 
primary, in 3 (17%) patients the perineal wound was left open and in 4 (22%) patients a 
VRAM flap was used. An omentoplasty to fill the pelvic defect after APR was used in 10 
(56%) patients.
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Fourteen (78%) patients underwent a complete excision of the tumour (R0) and 4 (22%) 
patients had a microscopic irradical resection (R1). The postoperative tumour stage 
is demonstrated in table 1. In one patient with a T0 tumour stage, preoperative biopsies 
demonstrated malignant cells, but in the final pathology report after the resection no tumour 
was found. In another patient, with a T0 tumour stage, an APR was performed because of 
multiple abscesses in the anal area thought to be a recurrence. According to the lymph node 
status, three patients were diagnosed with positive lymph nodes in the mesorectum. In 6 
patients there were no lymph nodes retrieved. Pathology reports showed squamous carcinoma 
in 11 (61%) patients, cloacogenic carcinoma in 3 (17%) patients and adenocarcinoma in 
2 (11%) patients. Two patients did not show malignancy as mentioned above and will be 
excluded of local control and survival analysis.
Follow-up
The median follow up of 18 patients was 16.3 months (range 1–170 months). Complications 
and re-interventions are shown in table 2. Twelve patients (67%) developed a post-operative 
complication. Perineal wound breakdown occurred in 5 patients (45%) with median duration 
of 278 (range 126–427) days. In 4 patients treated with a VRAM flap the perineal wound 
healed primarily and no herniation was observed. Figure 1 depicts a VRAM flap 3 months 
after surgery. One patient developed an umbilical necrosis, due to the incision left from the 
umbilicus, which compromised blood flow after preparation. This patient also developed a 
CVC infection. A surgical re-intervention was needed in 8 (47%) patients. In two patients 
with perineal dehiscence a gracilis flap from both sides was used to cover the perineal defect. 
In two patients with a perineal hernia a mesh repair was needed to close the hernia. There was 
no peri-operative or post-operative mortality.
Recurrence
In the present study only two of 16 patients (13%) developed a local recurrence during 
follow up. Local control was achieved in all 12 patients who underwent a complete (R0) 
resection, but 2 out of 4 patients with an incomplete (R1) resection failed. Seven patients 
developed loco-regional metastases in the groin, which were treated with regional excision 
in one patient, chemotherapy in 3 patients and radiotherapy combined with hyperthermia in 
3 cases. Seven patients developed distant metastases during follow-up.
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Table 2. Complications and reinterventions after salvage APR 
Patients
No VRAM (n = 14) VRAM (n = 4)
Complication
 − Total
 − Perineal dehiscence
 − Perineal hernia
 − Abdominal dehiscence
 − Stenosis stoma
 − Necrosis umbilicus
 − Pulmonary embolism
 − UTI
 − Urine retention
 − CVC infection
15
5
4
1
2
0
1
1
1
0
3
0
0
1
0
1
0
0
0
1
Reintervention
 − Total
 −
 − Mesh repair perineal
 − Gracilis muscle repair
 − Correction stoma
 − Abdominal hernia
 − Nettoyage umbilicus
7
2
2
2
1
0
1
0
0
0
0
1
VRAM = Vertical Rectus Abdominis Muscle; UTI = Urine Tract Infection; CVC = Central Venous Catheter
Overall survival
The median survival was 27 months. The actuarial overall 3- and 5-year survival rates were 50 
and 30% respectively (Figure 1). Five-year overall survival of persistent disease was 63% in 
contrast to 13% in recurrent disease. Because patient numbers are small, a statistical analysis 
was not performed on these results.
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Figure 1. Overall survival after salvage APR for anal carcinoma. APR = abdominoperineal 
resection
DISCUSSION
Since the publication of Nigro et al.[9] chemo-radiation therapy (CRT) has become the 
treatment of choice for primary anal cancer.[16,23,24] Locoregional failures after primary 
treatment with CRT are reported to occur in 17–45% 23,24 and was 19% in the present 
study (24 of 129 patients). Although APR as a therapeutic option in patients with primary 
anal cancer is obsolete, it is often the only possible treatment option in patients who fail 
CRT.[5,15] Flam et al.[25] demonstrated that an additional boost of radiation therapy and 
concurrent cisplatin based chemotherapy could also be used in treating recurrences, but only 
in 4 out of 24 patients an APR could eventually be avoided with this modality. Salvage APR 
offers good local control, demonstrated by only two patients with a local recurrence in the 
present study. Five year overall survival rate after salvage APR was 30% in the present study, 
which is comparable to previous reports in the literature (see Table 3).[23,24,26-29] Salvage 
APR seems therefore the treatment of choice for patients with persistent or recurrent disease 
after CRT.
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Table 3. Overall survival after salvage APR
Reference No. Median survival (mo) 5-year survival (%)
Nilsson et al. (2002) 35 33 52
Van der Wal et al. (2001) 13 33 47
Allal et al. (1999) 23 22 45
Pocard et al. (1998) 21 35 33
Ellenhorn et al. (1994) 38 41 44
Zelnick et al. (1992) 9 20 24
Current study 18 27 30
APR = abdomino perineal resection
Although there are only few reports in the literature after salvage APR for recurrent or 
persistent anal cancer, there is discussion regarding prognostic factors that might influence 
outcome. In our study, involved lymph nodes in the mesorectal excision specimen was 
the only important prognostic factor and resulted in a statistically significantly impaired 
prognosis compared to patients with uninvolved lymph nodes (p=0.01). Previous reports 
have suggested that patients with regional (inguinal) lymph node metastases at initial 
presentation have a very poor prognosis and the biology of this disease differs greatly 
from patients who did not have lymph node metastases.[30] This could not be confirmed 
in the present study, but only two patients presented with positive lymph nodes at initial 
presentation, which makes statistical analysis difficult. Regarding the difference in survival 
between persistent and recurrent anal cancer, Allal et al.[27] found an improved overall 
survival of recurrent disease compared patients presenting with persistent disease. A more 
aggressive biologic phenotype of tumours was suggested to reflect this outcome since many 
patients with persistent disease after CRT presented with advanced initial disease stage. In 
contrast with this other authors[23] demonstrated no difference in survival and this was also 
demonstrated in the present study. Other risk factors for survival were studied but not found 
to be significant such as resection margin, age and sex. 
The incidence of perineal wound complications is rather high after salvage treatment with 
APR and complications in up to 30% of patients[23,24,27] have been reported previously. 
In the present series perineal breakdown occurred in 5 of 14 patients (36%) who were not 
treated with direct VRAM transposition. When perineal breakdown occurred, median 
duration was long (278 days) and needed secondary reconstruction using gracilis muscle 
transposition in two patients. Four patients treated with a VRAM flap reconstruction 
did not show a perineal wound breakdown or perineal hernia. Similar to Tei et al.,[18] the 
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VRAM flap reconstructive procedure resulted in primary healing with acceptable donor-site 
morbidity and low complication rates. Especially in anal cancer resection margins of the 
perianal skin can easily be compromised when primary closure is performed. The use of a 
VRAM flap also enables the surgeon to remove the recurrent or persistent tumour mass with 
wide resection margins, since large skin defect can easily be managed.
CONCLUSION
This retrospective study demonstrated that salvage abdominoperineal resection in anal 
cancer is feasible offering good local control and a 5-year overall survival of 30%. A VRAM 
flap reconstruction should be considered when performing salvage APR in persistent 
or recurrent anal cancer. In contrast to primary closure or no closure, this reconstructive 
procedure results in primary healing without perineal complications and a good functional 
and aesthetic outcome.
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INTRODUCTION
The majority of patients with primary rectal cancer present with a tumour located within 
the mesorectal fascia. The treatment of these tumours has evolved from simple tumour 
resection into a multidisciplinary treatment with standardized surgical, pathological and 
radiotherapeutical procedures.[1-7] Since the introduction of TME-surgery by Dr Heald 
significant lower rates of local recurrences have been reported varying between 3 and 15 
percent.[8-10] The addition of preoperative short-term radiotherapy (5x5Gy) delivered one 
week prior to surgery has been shown to further improve local control, without an effect 
on survival.[1, 11] Introduction of preoperative radiotherapy in the treatment protocol 
of the Rotterdam Comprehensive Cancer Registry Region in 2001showed an increase of 
preoperative radiotherapy from 21 to 69%.[12] Results from a community hospital in this 
region showed that TME with short-term preoperative radiotherapy was feasible with an 
acceptable rate of postoperative morbidity and low mortality .[7] In this and other studies 
risk factors of poor prognosis after rectal surgery have been identified, such as positive lymph 
nodes, an incomplete resection, aged above 80 and/or a high level of CEA.[1, 11, 13-21 22-24]
In an attempt to avoid the morbidity and mortality of TME, local excision has been 
developed as a therapeutic option in the treatment of well-selected patients with early rectal 
cancer (T1).[25-29] The introduction of transanal endoscopic microsurgery (TEM) by Buess 
et al.[30] proved to be a feasible technique for removal of rectal tumours, although local 
recurrences are reported to be high.[31-34] Other techniques of rectal saving surgery such as 
chemoradiation treatment followed by TEM surgery are currently being explored.
Most rectal cancers are located within the mesorectal fascia, but in approximately 10% of all 
rectal cancer patients the tumour extends into or beyond the enveloping fascia propria of the 
mesorectal compartment.[35] Often these tumours infiltrate adjacent structures and therefore 
have a higher risk to develop a local recurrence.[36] Patients with these primary locally 
advanced rectal cancers are historically difficult to treat with surgery alone, but outcome 
has significantly improved using multimodality treatment options. Although preoperative, 
intraoperative and adjuvant (chemo) radiation therapy is important in these patients, the 
mainstay of treatment in rectal cancer is complete surgical removal if the tumour. In both 
locally advanced and recurrent rectal cancers this involves not only the removal of the total 
mesorectum, but en bloc resection of involved structures is often needed. This involves 
extended resections such as posterior or total exenterations and abdominoperineal sacral 
resections. Especially after these extended resections reconstruction of the perineal defect is 
of great concern and warrants careful selection of patients and surgical strategies.
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IMAGING AND STAGING
At present, MR imaging is considered ‘gold standard’ for rectal cancer imaging because it has 
been demonstrated to be superior to CT for prediction of tumour invasion in surrounding 
pelvic structures.[37-42] This is important to identify locally advanced rectal cancers that not 
only need other preoperative treatment strategies, but also other surgical procedures. Based 
on clinical information it is difficult to distinguish patients with locally advanced tumours 
although certain patient complaints such as pneumaturia, haematuria and vaginal bleeding 
suggest involvement of other organs. Also digital rectal examination can provide useful 
information such as large bulky lesions or lesions that are tethered or fixed to the pelvic wall.
[43] However, accurate and detailed anatomic information of the tumour extent is essential 
to select locally advanced rectal tumours for neoadjuvant treatment modalities and planning 
of the optimal surgical procedure. Few studies have addressed the problems of predicting 
rectal tumour infiltration into adjacent organs.[44] CT scan has long been used to evaluate 
the local tumour extent because of initial optimistic results and the advantage of a single 
investigation to combine local, regional and systemic staging.[45] The large difference in 
outcome between MR and CT in the comparative studies could be partially attributed to the 
fact that a state-of-the-art MR technique was compared with conventional CT techniques. 
In theory new generation multi-detector row spiral CT scanners, with superior contrast 
and spatial resolution and capability for reconstructions in multiple planes, are expected 
to provide better performances. Results of further studies are awaited to determine if new-
generation CT can compete with MR imaging.
Neither clinical assessment nor imaging tools, including MRI, CT, PET an ERUS have 
the ability to accurately identify or exclude lymph node involvement. It might clinically be 
important to identify lymph node negative patients for instance to perform rectal saving 
procedures or treat them with surgery only (without preoperative radiotherapy). On the 
other hand in case of true positive mesorectal or extra-mesorectal nodes more extensive 
preoperative and operative procedures might be indicated. Recent studies demonstrated 
that the accuracy of preoperative imaging (including ERUS/MRI) for staging T3N0 rectal 
cancer was limited because 22% of patients will have undetected mesorectal lymph node 
involvement.[46, 47] According to Lahaye et al,[48, 49] the white region within the node seen 
by USPIO-enhanced MR images is the most accurate and practical predictive criterion for 
malignant lymph nodes. Their results suggest that USPIO-enhanced MR imaging could 
become a promising tool for nodal malignancy prediction not only for experienced but also 
for less experienced readers. However, the use of USPIO is not (yet) commercially available 
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for MR imaging and until that time further studies are needed to improve the accuracy of 
imaging modalities to establish treatment options that will provide the best outcome for this 
group of patients.
Probably the most important factor is using the most optimal imaging techniques in 
combination with preoperative multidisciplinary team discussions. This enables a tailor-
made treatment for each rectal cancer patient and has demonstrated to decrease the number 
of positive resection margins.[48-50]
PREOPERATIVE TREATMENT
After the Dutch TME trial in 20011 most patients with rectal cancer in the Netherlands are 
treated preoperatively with short-term radiotherapy. With additional data from randomized 
trials and increasing follow-up, a highly significant effect of short-term preoperative 
radiotherapy remained on local recurrence rate without an effect on overall survival.[6, 11] 
The value of preoperative radiotherapy on local recurrence rates in small- and lymph node 
negative tumours is under debate.[17, 51] Because of the excellent results in these patients 
treated without radiotherapy, it would be helpful to identify these patients before treatment 
is started. Meticulous pre-operative work-up is of major importance helping to identify 
patients with small tumours and without positive lymph node involvement to save them 
from the early and late complications of radiotherapy.
Patients with evidence of lymph node involvement or tumour growth close to or into the 
mesorectal fascia are supposed to be treated with a more aggressive approach. In many 
European centers radiotherapy was used as neo-adjuvant treatment for locally advanced rectal 
cancer[35] but addition of chemotherapy has recently demonstrated to improve local control 
in two large randomized trials.[52, 53] Addition of 5–FU and leucovorin to preoperative 
radiation increased the amount of acute toxicity in T3–T4 resectable rectal cancer patients, 
but it increased the number of complete responses and decreased the local recurrence rate 
after 5 years.[54] Important is to notice that overall survival did not differ in these studies 
and that sphincter preservation was not increased. Postoperative chemo-radiotherapy has 
long been recommended for locally advanced and node positive rectal cancer patients, 
but preoperative treatment has demonstrated improved compliance, reduced toxicity and 
increased local control[55] New chemoradiation strategies are now published in numerous 
phase II trials including the use of oral 5–FU[56-58] and the addition of irinotecan[59, 60] 
and oxaliplatin[61] to 5–FU-based regimens. A recent British trial has demonstrated high 
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response rates in non-resectable rectal cancer patients after induction systemic chemotherapy 
followed by chemoradiation.[62] Although this was accompanied with considerable toxicity 
the number of patients with a (near) complete response was promising. Not only new 
chemotherapeutic drugs, but also a VEGF specific monoclonal antibody in combination 
with chemoradiation was recently reported by Willet et al. to increase downstaging of the 
tumour.[63] Other modalities such as the use of intensity-modulated radiotherapy (IMRT) 
which has the potential of more accurate delivery of higher radiotherapy dosages, avoiding 
the damage of critical structures surrounding the tumour are currently tested in rectal cancer. 
Higher radiation dosages could result in more radiation-induced necrosis and eventually in 
the possibility of further tumour downstaging.[64] These and other phase II and III trials are 
ongoing, but until randomised phase III trials demonstrate improved results, 5–FU based 
chemoradiation therapy is the golden standard for locally advanced and recurrent rectal 
cancer patients.[65]
SURGERY
Primary rectal cancer
Since the introduction of TME by Heald et al. this technique became the gold standard for 
surgery in rectal cancer.[66] TME provides sharp meticulous dissection to keep the visceral 
layer of the pelvic fascia intact and this is important to avoid breach in the mesorectum, 
which is an important risk factor for a local recurrence.[9 67, 68] With the introduction 
of TME the recurrence rate dropped to approximately 10%. Even in low volume centers, 
TME is a feasible technique with an acceptable rate of postoperative morbidity and low 
mortality.[7] It was recognised that involvement of the circumferential margin by tumour 
cells is predictive for local recurrences.[69] Other important factors for both survival and 
local recurrence rate are lymph node involvement, elevated CEA and age.[7, 24, 70] 
Although short course radiotherapy followed by TME surgery is considered gold standard, 
complications are not uncommon. Serious clinical problems such as anastomotic leakage and 
fecal incontinence are described after this treatment and should be carefully discussed with 
the patient prior to treatment.[71, 72] New rectumsaving techniques are currently explored 
to improve short- and longterm quality of life while oncological outcome is uneffected. 
Examples of such strategies are TEM surgery for small T1 tumours[34, 51, 73, 74] and 
chemoradiation followed by TEM surgery for larger distal rectal cancers.[75, 76] Long-term 
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follow-up and well designed phase II and III trials are necessary to evaluate the benefits and 
risks of such strategies.
Primary locally advanced rectal cancer 
Primary locally advanced rectal cancer is sometimes defined as stage III rectal cancer, which 
also represents resectable tumours with clinically suspicious lymph nodal involvement. 
Although these patients are treated in many centers with aggressive chemoradiation 
protocols, surgery can be performed with standard TME surgery[66] and after short course 
radiotherapy (5x5Gy) local recurrence rates and survival were demonstrated to be excellent.
[1, 6] Locally advanced rectal cancer is here characterized as tumours invading or extending 
close to the mesorectal fascia. A complete excision of the tumour is of significant beneficial 
influence on local control and survival, especially in patients with locally advanced tumours.
[2, 35, 77] During surgery distinction between benign adherence and malignant invasion is 
difficult to make, especially after neo-adjuvant therapy. Because of this difficulty the surgeon 
must resect en bloc the adjacent structures depending on the location and depth of invasion. 
[43] In case of clear lateral lymph node involvement, dissection of these nodes or parts of the 
pelvic wall sometimes including autonomic nerves is inevitable, but in these cases prognosis 
is generally poor.[78] Direct invasion in iliac vessels and obturator space is even more 
uncommon and only in selected cases resection of these structures might be indicated.[79]
In case of dorsal invasion abdominosacral resections can be performed,[80, 81] but this is 
a demanding procedure not often necessary in primary rectal cancer. Ventral invasion in a 
female patient usually requires resection of the uterus and/or part of the vaginal wall. In 
men partial removal of the prostate is possible in case of ventral invasion but a total pelvic 
exenteration is more commonly performed in patients with involvement of the prostate or 
bladder, which is discussed later in this review.
In the literature, completeness of resection, negative lymph node status, extent of resection, 
fixation of the tumour and presentation of pain are reported as prognostic factors for survival 
and local control.[35, 82-86]
Distant metastases were traditionally contraindications for surgical treatment of patients 
with locally advanced rectal cancer. Recent improvements in systemic chemotherapy and 
a more aggressive surgical approach have made patients with resectable distant metastatic 
disease candidates for curative surgery.[87] Especially in patients with oligometastatic liver 
metastases complete resection of the metastases can lead to long-term survival and cure.
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Recurrent rectal cancer
Despite improvements in the treatment of primary rectal cancer, recurrences occur in 
approximately 5–15% of the patients. The development of a local recurrence depends on 
various factors such as surgical technique88, lymph node involvement1, resection margins2 
and location of the tumour.[1, 89] Locally recurrent rectal cancer is often associated with 
severe symptomatic disease, especially pain.[85] Due to neoadjuvant treatment modalities 
a selective group of patients with recurrent disease can be operated on with curative intent.
[81, 85] Curative treatment seems best possible in selected patients with true anastomotic 
recurrence or those without pelvic sidewall involvement and early detection of the tumour.90 
Recent studies show that the current multimodality treatment provides possibility for 
curative resection in 40–80%.[85, 91-97] This lower rate of complete resections is reflected in 
a lower local control and overall survival of patients with recurrent rectal cancer compared 
to primary rectal cancer. [36, 85 86, 91, 98-102] Symptomatic disease indicates a more advanced 
character of tumour growth, which will result in a higher rate of incomplete resections 
and an associated lower local control and survival.[85, 92, 103] Symptoms such as pain or 
hydronephrosis104 are therefore considered to be a relative contraindication for resection of 
recurrent rectal cancer due to poor outcome.
Since most patients are nowadays treated with radiotherapy for their primary rectal cancer, 
most recurrences occur in a previously irradiated pelvis. This changes the clinical nature 
and prognosis of patients who develop locally recurrent rectal cancer. Overall prognosis is 
poor in these patients, but some patients can be reirradiated. An Italian multi-center study 
reported promising results after hyperfractionated chemoradiation in previously irradiated 
patients with an overall survival of 39% in all patients. Survival was exceptionally good in 21 
patients were a R0 resection was performed with a 67% 5 years survival.[105] Further studies 
are needed to identify those patients with recurrent rectal cancer that are candidates for 
multimodality treatment protocols and extensive surgery.[85]
Recurrences after local excision for T1 rectal cancer
In an attempt to avoid the morbidity and mortality of TME, local excision has been developed 
as a therapeutic option in the treatment of well-selected patients with early rectal cancer.
[73, 106] The introduction of transanal endoscopic microsurgery (TEM) enables excellent 
access and visualization of the surgical field and allows precise and full-thickness excision 
of the tumour.[30] The rate of tumour resection with clear margins, even with standardised 
pathology, for T1 tumours has increased to more than 90%.[107, 108] Considering the very 
low mortality and morbidity rates, local excision by TEM is now considered a potential 
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alternative for the surgical treatment of T1 tumours by many surgeons.[25, 109, 110]However, 
the wide range of local recurrence rates from 0 to 24%,[111, 112] and the results of salvage 
surgery in recurrent tumours are matters of concern. In the literature only few series report 
on surgical procedures following recurrent disease after transanal surgery.[31-33] Conclusion 
as written in abstract chapter VII.
Pelvic exenteration
Total pelvic exenteration (TPE) is a widely used technique for resection of locally advanced 
pelvic tumours, invading the bladder and/or prostate.[113] Long term survival with excellent 
local control is possible after TPE for primary locally advanced rectal cancer.[98, 100, 114-121] 
In recurrent rectal cancer the visceral fascia surrounding the rectum has been resected in 
previous surgery, which makes a complete resection of all recurrent disease more difficult.
[115 100, 122 123 99, 116, 121, 124]
Morbidity is generally high after TPE with morbidity rates between 37-78%. The 
complications related to the urinary conduit are frequent causes for reintervention, which 
was demonstrated to occur especially in patients who previously received radiotherapy.[115, 
121, 125] Although the refinements in the radiation therapy (3D-planning and exclusion of 
small-bowel from the irradiated field) may have resulted in a decreased toxicity, radiotherapy 
is still considered as one of the reasons for a high complications rate.[93, 126] In recent years, 
mortality after TPE has decreased from rates up to 33% down to rates varying from 0–10%.
[98, 100, 125, 127] Although, current guidelines for colorectal cancer surgery advocate TPE, 
only one-third of the patients in a study based on SEER data underwent the appropriate 
surgical resection. These patients had a clinically significant overall survival benefit with no 
increase in short-term mortality compared with similar patients who did not receive a multi-
visceral resection.[114]
Abdominoperineal Sacral Resection
In selected cases patients have large tumours attached or infiltrating the bony structures of 
the dorsal pelvis. Some of these patients are candidates to undergo a sacro-pelvic resection 
or composite resection as developed and described by Wanebo et al. and others.[81, 128-131] 
This procedure is even more demanding than a total pelvic exenteration and is accompanied 
with a high morbidity rate and mortality rate of approximately 10%.[131, 132] Some authors 
have reported long term survivors after sacrectomy or composite resections and for highly 
motivated and carefully selected patients even in patients with tumour infiltration in bony 
structures.[133] We and others (ref ) have demonstrated that patients with pathological 
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tumour ingrowth in the bony sacrum do not survive more than 3 years and APSR seems 
only indicated for patients with a close relation to the sacrum. Since most of these patients 
develop secondary recurrences and die of distant metastases, future studies have to focus on 
more adequate treatment of systemic disease in this group of patients. Each patient should 
carefully be judged preoperatively by a multidisciplinary team including a surgeon, urologist, 
gynaecologist, radiotherapist, medical oncologist, radiologist and an anaesthetist before 
these extended surgical procedures are commenced.
Reconstructions
After extensive pelvic surgery, wounds too large for primary closure will require complex 
closure. These wounds can take several months to heal and bring with them a high chance 
of infection. In combination with preoperative or intraoperative radiotherapy and/or 
chemotherapy, chances for infection are even higher.[134, 135] Reported minor complication 
rates after treatment of primary or recurrent rectal cancer range from 25 to 60 percent, 
with major complication rates around 12 percent.[136-138] After extended pelvic surgery a 
large pelvic dead space can exist andfilling of this space has a favourable influence on the 
postoperative morbidity. In these circumstances the transfer of a myocutaneous flap has 
successfully been used for the management in primary reconstruction, preventing wound 
infections by directly filling up the pelvic space after surgery.[139] Bartholdson and Hulten in 
1975 were the first to report the use of the gracilis myocutaneous flap, and since their report 
others have used this technique with excellent results.[140-142] A vertical rectus abdominus 
muscle (VRAM) transpostion can fill up larger defects and should be considered in case of 
a large dead perineal space after wide perineal AP(S)R for rectal cancer and salvage APR 
for other pelvic cancers. In contrast to primary closure or no closure, this reconstructive 
procedure results in primary healing without perineal complications and a good functional 
and aesthetic outcome.[139, 143, 144]
INTRAOPERATIVE RADIOTHERAPY
Local control in rectal cancer patients is related to the dose of irradiation, but because of 
toxicity to radiosensitive organs such as small bowels, the external radiation dose should 
not exceed 60 Gy. A combination of external radiation and intraoperative radiation therapy 
(IORT) allows the safe delivery of higher effective doses of irradiation than can be delivered 
with external beam only techniques. IORT is used when resection margins are narrow or 
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involved with tumour cells and can be applied very specifically to an area at risk, under direct 
visual control and with the possibility to shield the surrounding structures from radiation. 
The biological effectiveness of single-dose IORT is considered to be as effective as two to 
three times the equivalent dose of fractionated radiotherapy.[124, 145] IORT can be delivered 
using intraoperative electron beam radiotherapy (IOERT) or high-dose-rate brachytherapy 
(HDR-IORT). The advantages of IOERT are the treatment depth of >1 cm with a choice 
of electron energies and quick delivery of the radiation. The flexible template in HDR-
IORT can treat all surfaces with the highest dose at the area at risk, however, treatment 
time is longer.[146] Different centers worldwide use one of these techniques. Although no 
randomised trials concerning IORT have been performed, several studies have reported that 
IORT was feasible, safe and improved both local control and overall survival, but patient 
numbers are often small in these series.[77, 82-84, 102, 146-152] In the analysis of our complete 
database of patients with both recurrent and locally advanced rectal cancer, patients who 
received IORT for narrow or microscopically incompletely resected tumours had a local 
control rate comparable to patients with wide R0 resection margins.[35, 36] Since there is a 
good rationale for dose escalation in locally advanced and recurrent rectal cancer, IORT is 
one of those promising techniques for further improving local control and overall survival.
CONCLUSIONS
A multidisciplinary approach in patients with rectal cancer or other pelvic tumours is of major 
importance. A meticulous work-up, tailor-made preoperative and postoperative treatment 
and highly specialised surgery will potentially lead to better results. Multidisciplinary 
treatment has shown to reduce morbidity and mortality, but also improved long-term 
survival rates.[153-155] To futher improving results in rectal cancer patients specialists should 
work and generate trials together.
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INTRODUCTION
Patients with rectal cancer mostly present with tumours located within the mesorectal 
fascia and are generally treated with total mesorectal excision (TME). Results of TME are 
good with a significant improvement of the local control when preoperative short-term 
radiotherapy (5x5Gy) is delivered one week prior to surgery. In approximately 10% of all 
rectal cancer patients the tumour extends into or beyond the enveloping fascia propria 
of the mesorectal compartment. These tumours often infiltrate adjacent structures and 
therefore have a higher risk to develop a local recurrence. Patients with these primary locally 
advanced or recurrent rectal cancer were historically difficult to treat with surgery alone, 
but results have significantly improved using multimodality treatment. A multidisciplinary 
approach for patients with rectal cancer or other pelvic tumours reduces morbidity and 
mortality, but also improves long-term survival rate. A meticulous work-up, tailor made 
preoperative treatment and highly specialised surgery will lead to better results. In this thesis 
the multimodality treatment for rectal cancer and other pelvic tumours is discussed with 
a focus on preoperative (chemo) radiation therapy for primary and locally advanced rectal 
cancer, multimodality treatment including IORT for recurrent rectal cancer and extended 
resections and reconstructions after pelvic surgery.
PART I | PRIMARY RECTAL CANCER
Based on the results of the Dutch TME trial the treatment in The Netherlands of patients 
with a tumour in the lower two-third of the rectum has changed to preoperative radiotherapy 
(5*5Gy) followed by TME-surgery. In chapter 2 the results preoperative radiotherapy and 
surgery in the treatment of 210 patients with primary rectal cancer in a low volume centre 
were analysed. A total of 145 patients were treated with an anterior rectal resection and 
65 patients underwent an abdomino perineal resection (APR). Anastomotic leakage rate 
was 5% and postoperative mortality was 3%. The 5-year the local recurrence-free rate in 
patients with microscopically complete resections was 91% and the overall survival rate was 
58%. An increased serum carcinoembryonic antigen (CEA), an APR, positive lymph nodes, 
and an incomplete resection all significantly influenced the 5-year overall survival and local 
recurrence rate negatively. In a multivariate analysis, age was the most important prognostic 
factor for overall survival. It was concluded patients with rectal cancer can safely be treated 
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with TME in a community teaching hospital and leads to a good overall survival and an 
excellent local control. 
In patients with T2–3, N0 rectal cancer, the role of preoperative radiotherapy remains 
controversial. In chapter 3 a review of the benefit of radiotherapy in T2 and T3, N0 rectal 
cancer patients was studied. Between 1996 and 2003, 103 patients with T2–3, N0 rectal 
cancer were identified in a prospective database. The 5-year local control rate was 94% and the 
overall survival was 65%. Preoperative radiotherapy did not show any statistical differences. 
Abdomino perineal resection, T3 tumours and advanced age negatively influenced overall 
survival. Preoperative radiotherapy does not seem to be of significant importance in patients 
with T2–3, N0 rectal cancer regarding local recurrence and survival. Since preoperative 
radiotherapy is associated with short- and long-term morbidity, identification of patients 
with T2–3, N0 tumours should be improved and preferably treated with surgery alone.
PART II | LOCALLY ADVANCED RECTAL CANCER
Primary locally advanced rectal cancer is characterised as a tumour invading or extending 
close to the mesorectal fascia. In chapter 4 the results of a multimodality treatment of 
123 patients with primary locally advanced rectal cancer, using preoperative radiotherapy 
(median dose of 50 Gy), followed by surgery and on indication intraoperative radiotherapy 
(IORT) were described. The 5-year local control was 65% and the 5-year overall survival 
was 50%. Positive lymph nodes and incomplete resections negatively influenced both local 
control and overall survival. Preoperative pain also proved to be a significantly important 
factor for local control. IORT significantly improved 5-year local control (P=0.016) and 
overall survival (P=0.026) for patients with R1/2 resections. Addition of IORT for patients 
with a narrow or microscopic incomplete resection seems to overrule the unfavourable 
prognostic histological findings. The presented multimodality treatment for primary locally 
advanced rectal cancer was feasible with an acceptable mortality and 5-year overall survival.
Recent studies have demonstrated that preoperative radiation therapy in combination with 
5-fluoracil (5–FU) improves local tumour control in locally advanced rectal cancer. The aim 
of chapter 5 was to evaluate the toxicity and efficacy of preoperative chemoradiation using 
the oral 5–FU prodrug capecitabine in locally advanced rectal cancer. Sixty patients with 
locally advanced rectal cancer were treated with preoperative chemoradiation. Radiotherapy 
consisted of a total dose of 50 Gy delivered in 25 fractions to the pelvis. Chemotherapy 
was concurrently administered and consisted of oral capecitabine only on radiotherapy 
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days. Surgery was performed six to ten weeks after completion of chemoradiation. All but 
two patients received the full dose of chemoradiation. No grade III or IV haematological 
toxicities developed. Two patients (3%) developed grade III radiation dermatitis and one 
a grade III diarrhoea. All patients underwent definitive surgery and one patient with a low 
anterior resection developed an anastomotic leakage (4%). Final pathology demonstrated 
eight patients (13%) with a complete pathological response. Primary tumour and nodal 
downstaging occurred in 67 and 84% of the patients, respectively. It was concluded 
preoperative chemoradiation with oral capecitabine is safe and well tolerated in locally 
advanced rectal cancer patients. This preoperative treatment has a considerable downstaging 
effect on the tumour and lymph nodes.
PART III | RECURRENT RECTAL CANCER
The main goals in the treatment of recurrent rectal cancer are palliation of symptoms, 
good quality of life and, if possible, curative surgery. When local recurrent rectal cancer is 
diagnosed without signs of metastases, a potentially curative resection can be performed. In 
chapter 6 the results of 92 patients with recurrent rectal cancer treated with preoperative 
hyperfractioned radiotherapy followed by surgery (n=59) or with surgery only (n=33) 
were described. There were no differences in morbidity and reintervention rate between the 
two groups. Complete resections (R0) were achieved in 64% of the patients who received 
preoperative radiation and 45% of the non-irradiated patients. A complete response after 
radiotherapy was found in 10% of the patients and improved local control and survival. 
Local control after preoperative radiotherapy was statistically significantly higher after 3 and 
5 years compared to the non-irradiated patient (P=0,036). Overall survival and metastasis 
free survival were not different in both groups. In concurrence with beneficial results of 
preoperative radiotherapy on local control in the treatment of primary rectal cancer, it 
was concluded that preoperative radiotherapy for recurrent rectal cancer resulted in more 
complete resections and improved local control. Preoperative radiotherapy should therefore 
be standard treatment in recurrent rectal cancer.
Recurrent disease after transanal excision for T1 rectal cancers is not uncommon, but its 
impact on survival is not clear. The aim of chapter 7 was to evaluate the management and 
outcome of local recurrences after transanal endoscopic microsurgery (TEM) for pT1 rectal 
cancer. From 1996, 88 consecutive patients who underwent TEM for pT1 were registered 
in a prospective database. Eighteen patients developed a local recurrence during follow-up. 
Summary | 187
Median time to local recurrence was 16 months (range, 4–50 months). Two patients were 
not operated because of concomitant metastatic disease. abstract chapter VII result section:
All remaining 14 patients adhered to the intensive follow-up protocol. In two patients 
(patient number 3 and 6) synchronous liver metastases, initially deemed resectable, were 
found. Despite obtaining a microscopic radical resection in both, rapidly progressive 
metastatic disease developed and patients were treated with palliative chemotherapy. They 
died eight and respectively 22 months following the salvage procedure. In 15 out of 16 salvage 
procedures, a microscopic radical resection was possible without the need for extensive 
surgical procedures. In one patient a microscopic irradical resection (R1) was performed, 
and patient received adjuvant chemotherapy. There was no post-operative mortality. Median 
follow up after salvage treatment of all patients with a recurrence was 20 months (range, 2 – 
112). One of the operated patients developed a local re-recurrence and 7 patients developed 
distant metastases and died because of progressive disease. 
The actuarial 3-year overall survival was 29% (figure 1). Patients in which a microscopic 
radical resection could be obtained without the presence of metastatic disease, 3-year 
survival was better compared to non-operated patients, stage IV disease at presentation or 
microscopic irradical resections (40 versus 0%; p=0.001).
The 3-year disease-free survival was 57%. Although survival in T1 rectal cancer patients 
is generally good, recurrence after TEM for T1 rectal cancer leads to a limited survival. A 
microscopic radical resection can almost always be obtained, without the need for extensive 
surgical procedures. In the near future we need to focus on improving selection in T1 rectal 
cancers suitable for TEM. Also possible adjuvant treatment strategies following salvage 
procedures need to be explored, in order to safe as many patients the adverse effects of TME. 
PART IV | EXTENDED RESECTIONS AND RECONSTRUCTIONS
Despite efforts in the early detection and the intense follow-up of rectal cancer, primary 
locally advanced and recurrent rectal cancer with involvement into adjacent organs or 
structures is not uncommon. Radical margins are sometimes difficult to obtain because of 
close relation to or growth in adjacent organs/structures. Total pelvic exenteration (TPE) is 
an exenterative operation for these advanced tumours and involves en bloc resection of the 
rectum, bladder, and internal genital organs (prostate/ seminal vesicles or uterus, ovaries and/
or vagina). Chapter 8 describes the results of TPE in our tertiary referral centre. Between 
1994 and 2008, a TPE was performed in 69 patients with pelvic cancer; 48 with rectal 
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cancer (32 primary and 16 recurrent), 14 with cervical cancer (1 primary and 13 recurrent), 
5 with sarcoma (3 primary and 2 recurrent), 1 with primary vaginal, and 1 with recurrent 
endometrial carcinoma. Overall major and minor complication rates were 34% and 57%, 
respectively. The in-hospital mortality rate was 1%. A complete resection was possible in 75% 
of all patients. Five-year local control for primary locally advanced rectal cancer, recurrent 
rectal cancer, and cervical cancer was 89%, 38%, and 64%, respectively. Overall survival 
after 5 years for primary locally advanced rectal cancer, recurrent rectal cancer, and cervical 
cancer was 66%, 8%, and 45%, respectively. Total pelvic exenteration is accompanied with 
considerable morbidity, but good local control and acceptable overall survival justifies the 
use of this extensive surgical technique in most patients, especially patients with primary 
locally advanced rectal cancer or recurrent cervical cancer.
In chapter 9 a critical analysis of the results of resection of locally advanced and recurrent 
rectal cancers including the sacrum was evaluated. Between 1987 and 2007, 25 of 353 patients 
with locally advanced or recurrent rectal cancer underwent an en-bloc sacral resection in our 
tertiary referral centre. A mid sacrum resection was performed in 12 patients (level S3) and 
a low sacrum resection in 13 patients (level S4/5). A R0 resection was performed in 19/25 
patients; R1 in 4/25 patients; R2 in 2/25 patients. There was no postoperative mortality. 
Positive lymph nodes and incomplete resections independently negatively influenced local 
control (P<0.001). The 5-year overall survival was 30%. Five patients with a recurrent tumour 
had pathological invasion in the sacral bone and no survival beyond 1 year. In conclusion 
abdomino sacral resections can be performed in patients with locally advanced and recurrent 
rectal cancer. Patients who cannot undergo a complete resection or have clear evidence of 
cortical invasion should not be scheduled for these extensive procedures.
After APR or extended pelvic resections large perineal defects can occur which are difficult 
to manage. Filling of the perineal space can be favourable using an omentoplasty or muscle- 
and myocutaneous transpositioning, providing well-vascularised and nonirradiated tissue. 
Results in chapter 10 show that direct transposition of the vertical rectus abdominus muscle 
(VRAM) resulted in closure of the perineal wound in all patients treated with salvage APR 
for anal cancer. The morbidity-rate after VRAM transfer in combination with resection 
of the malignancy was not higher than morbidity after abdominoperineal resection alone. 
Perineal wound breakdown occurred in 5 of the 14 patients (36%) not treated with primary 
muscle reconstruction. In all patients treated with a VRAM flap the perineal wound healed 
primarily. In the present study salvage APR in recurrent or persistent anal cancer results in 
good local control and 5-year overall survival of 30%. When performing an APR a VRAM 
flap reconstruction should be considered to prevent disabling perineal wound complications.
Chapter XIII
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INTRODUCTIE
In de meerderheid van de patiënten die zich presenteert met een rectumcarcinoom is 
er sprake van een tumor beperkt tot de mesorectale fascie en bestaat de behandeling uit 
totale mesorectale excisie (TME). De resultaten van deze chirurgische behandeling zijn 
goed met een significante daling van het recidiefpercentage als kortdurende preoperatieve 
radiotherapie wordt toegepast. Tien procent van de rectumtumoren reikt tot in of buiten 
de fascia propria van het perirectale vet. Deze tumoren groeien vaak in omliggende 
structuren en hebben een grotere kans op het ontwikkelen van een lokaal recidief. Curatieve 
behandeling van primair lokaal uitgebreide tumoren en lokale recidieven was voorheen niet 
mogelijk met een behandeling die alleen uit chirurgie bestond. De resultaten verbeteren 
echter sinds de introductie van de multidisciplinaire aanpak. Een multidisciplinaire 
behandeling van deze patiënten leidt tot verminderde morbiditeit en mortaliteit en verbetert 
de lange termijn overleving. In dit proefschrift wordt de multidisciplinaire behandeling 
van het rectumcarcinoom en andere kleine bekken tumoren bediscussieerd, met hierbij 
speciale aandacht voor de effecten van preoperatieve (chemo)radiotherapie, intraoperatieve 
radiotherapie (IORT), lokale excisie van beperkte rectum tumoren, reconstructie van het 
bekken na uitgebreide chirurgie en sacrale resecties bij uitgebreide rectum tumoren.
DEEL I | PRIMAIR RECTUM CARCINOOM
Naar aanleiding van de Nederlandse TME trial, worden patiënten met een rectum tumor 
van 0 – 10cm vanaf de anus kortdurend voorbestraald waarna een resectie volgens het TME 
principe plaatsvindt. In hoofdstuk 2 worden de resultaten van deze behandeling bij 210 
patiënten geanalyseerd. Honderdvijfenveertig patiënten werden behandeld met een lage 
anterieure resectie (LAR) en 65 patiënten ondergingen een abdomino perineale resectie 
(APR). Klinische relevante naadlekkage kwam voor in 5% en de postoperatieve mortaliteit 
was 3%. De 5-jaars kans op een lokaal recidief bij patiënten met een microscopisch radicaal 
verwijderde tumor was 9% en de 5-jaars overleving was 58%. Een gestegen CEA, een APR, 
positieve lymfeklieren en een incomplete resectie hadden een significante negatieve invloed 
op de overleving en op het krijgen van een recidief. In een multivariate analyse was leeftijd 
de meest prognostische factor voor overleving. Concluderend kan men zeggen dat deze 
categorie patiënten veilig kan worden behandeld in een gespecialiseerd ziekenhuis en er een 
goede overleving en zeer goede lokale controle is.
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Bij patiënten met een T2-3, N0 rectum carcinoom is de rol van preoperatieve radiotherapie 
controversieel. In hoofdstuk 3 wordt de waarde van preoperatieve radiotherapie bij deze 
patiënten geëvalueerd. Vanaf 1996 tot en met 2003 werden 103 patiënten met een T2-3, 
N0 rectum carcinoom geïdentificeerd in een prospectieve databank. De 5-jaars lokale 
controle was 94% en de totale overleving 65%. Het geven van preoperatieve radiotherapie 
liet geen statistisch voor- of nadeel zien. Een APR, T3 tumoren en oudere leeftijd hadden 
een significante negatieve invloed op de overleving. Preoperatieve radiotherapie lijkt geen 
significante positieve invloed te hebben op patiënten met een T2-3, N0 rectum carcinoom 
met betrekking tot overleving en lokale controle. Vanwege het feit dat preoperatieve 
radiotherapie wel is geassocieerd met verhoogde morbiditeit is het van groot belang om deze 
patiënten preoperatief te identificeren en bij voorkeur alleen chirurgisch te behandelen.
DEEL II | PRIMAIR LOKAAL UITGEbREID RECTUM CARCINOOM
Een primair lokaal uitgebreid rectum carcinoom wordt gekenmerkt door een tumor die tegen 
of door de mesorectale fascie heen groeit. In hoofdstuk 4 worden de resultaten beschreven van 
123 patiënten met een lokaal uitgebreid rectum carcinoom, voorbehandeld met radiotherapie 
(mediane dosis 50 Gy), gevolgd door chirurgie en op indicatie intraoperatieve radiotherapie 
(IORT). Het percentage lokale controle na 5 jaar was 65% en de 5-jaars overleving 50%. Er 
was een negatieve invloed van positieve lymfeklieren en een incomplete resectie op de lokale 
controle en overleving. Preoperatieve pijn had een significante negatief voorspellende waarde 
t.a.v. lokale controle. IORT had een positieve invloed op de lokale controle (P = 0.016) en 
de overleving (P = 0.026) bij patiënten met een R1-2 resectie. Het toevoegen van IORT 
bij patiënten met een incomplete resectie lijkt de prognostisch ongunstige histologie teniet 
te doen. De in deze studie gepresenteerde multidisciplinaire behandeling van het primair 
uitgebreide rectum carcinoom is uitvoerbaar met een acceptabele mortaliteit en 5-jaars 
overleving.
Recente studies laten zien dat preoperatieve radiotherapie in combinatie met 5-FU een 
positief effect heeft op de lokale controle bij uitgebreide primaire rectumcarcinomen. In 
hoofdstuk 5 wordt de toxiciteit en effectiviteit van preoperatieve chemoradiotherapie m.b.v. 
orale 5-FU (capecitabine) onderzocht. Zestig patiënten met een lokaal uitgebreid rectum 
carcinoom werden behandeld met preoperatieve chemo- en radiotherapie. Radiotherapie 
bestond uit een totale dosis van 50 Gy over 25 fracties verdeeld. Chemotherapie werd alleen 
gegeven op de dag van de radiotherapie. Patiënten werden 6-10 weken na de laatste gift 
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geopereerd. Op 2 patiënten na kreeg iedereen de volledige dosis chemo- en radiotherapie. Er 
trad geen graad III of IV haematologische toxiciteit op. Twee patiënten ontwikkelde graad III 
radiatie dermatitis en 1 graad drie diarree. Alle patiënten werden uiteindelijk geopereerd en 1 
patiënt had een naadlekkage (4%). Uiteindelijke pathologie liet bij 8 patiënten een complete 
pathologische respons zien. Downstaging van zowel de primaire tumor als de lymfeklieren 
trad respectievelijk op in 67% en 84% van de patiënten. Preoperatieve chemoradiatie met 
orale capecitabine is veilig en wordt goed verdragen door patiënten met een lokaal uitgebreid 
primair rectum carcinoom. Deze preoperatieve heeft een aanzienlijk downstaging effect op 
de tumor en de lymfeklieren.
DEEL III | RECIDIEF RECTUM CARCINOOM
De belangrijkste doelstellingen bij de behandeling van het recidief rectum carcinoom zijn 
palliatie van de symptomen, kwaliteit van leven en indien mogelijk curatieve chirurgie. 
Als een lokaal recidief wordt aangetoond zonder tekenen van afstandsmetastasering. In 
hoofdstuk 6 worden de resultaten besproken van 92 patiënten met een recidief rectum 
carcinoom uitgesplitst naar wel (n=59) of geen preoperatieve radiotherapie (n=33). Er was 
geen verschil in morbiditeit en het percentage reinterventie tussen de 2 groepen. Complete 
resecties werden uitgevoerd in 64% van de patiënten die preoperatieve radiotherpie kregen 
en in 45% van de patiënten zonder preoperatieve radiotherapie. Een complete respons werd 
gevonden in 10% en zorgde voor een verbeterde lokale controle en overleving. Het percentage 
lokale controle was significant hoger bij bestraalde patiënten zowel na 3 als na 5 jaar (P = 
0.036). Overleving en metastase vrije overleving lieten geen verschil zien in beide groepen. In 
overeenstemming met eerder beschreven resultaten heeft preoperatieve radiotherapie voor 
recidief rectum carcinomen een positief effect op zowel lokale controle als op het aantal 
complete resecties. Preoperatieve radiotherapie moet derhalve standaard gegeven worden bij 
de behandeling van het recidief rectum carcinoom.
Recidieven na transanale excisie bij T1 rectum carcinomen is vaker beschreven, maar de 
invloed op de overleving is niet bekend. De doelstelling van hoofdstuk 7 was evaluatie van de 
behandeling en uitkomst van recidief rectum tumoren na initiële transanale endoscopische 
microchrirugie (TEM) voor T1 rectum carcinomen. Vanaf 1996 werden er 88 patiënten 
met een pT1 rectum tumor geregistreerd in een prospectieve databank. Achttien patiënten 
ontwikkelde een recidief tijdens de follow-up. De mediane tijd voor het ontwikkelen van 
een recidief was 16 maanden. Twee patiënten werden niet geopereerd i.v.m. metastase 
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op afstand. Alle overige 16 patienten ondergingen "salvage" chirurgie zonder dat er een 
uitgebreide resectie nodig was. In 44% van de patienten werd er een definitief eindstandig 
stoma aangelegd. Er was geen post-operatieve mortaliteit. Vijftien patienten werden radicaal 
geopereerd en 1 patient onderging een microscopisch irradicale resectie. De mediane follow-
up na "salvage" chirurgie was 20 maanden (2–112 maanden). Een patient ontwikkelde 
opnieuw een recidief en 7 patienten ontwikkelde afstandsmetastasen. De 3-jaars overleving 
was 29% en de 3-jaars ziekte vrije overleving 57%. Alhoewel de overleving na TEM voor T1 
rectum carcinomen goed is leidt het optreden van een recidief tot een beperkte overleving. 
Echter, recidief chirurgie is uitvoerbaar en als men in staat is een complete resectie uit te 
voeren is er een substantiële overlevingswinst.
DEEL IV | UITGEbREIDE RESECTIES EN RECONSTRUCTIES
Ondanks het streven om rectum kanker vroeg op te sporen en intensief te vervolgen is ingroei 
in de omgevende organen of structuren bij zowel het primair uitgebreide- als recidief rectum 
carcinoom niet zeldzaam. Radicale resectie randen zijn soms moeilijk te verkrijgen vanwege 
deze ingroei in de omgeving. Een totale bekken exenteratie (TPE) is een uitgebreide operatie 
voor deze type tumoren en bestaat uit een en bloc resectie van het rectum, blaas en genitaliën. 
Hoofdstuk 8 beschrijft de resultaten van TPE in het Erasmus Medisch Centrum, lokatie 
Daniel. Tussen 1994 en 2008 werden er 69 TPE’s verricht bij kleine bekken tumoren. Het 
totale percentage grote- en kleine complicaties was respectievelijk 34% en 57%. De mortaliteit 
was 1%. Een complete resectie was mogelijk in 75% van de patiënten. Het percentage lokale 
controle na 5 jaar voor respectievelijk primair lokaal uitgebreid rectum carcinoom, recidief 
rectum carcinoom en het cervix carcinoom was 89%, 38% en 64%. De 5-jaars overleving was 
respectievelijk 66%, 8% en 45%. Een TPE gaat gepaard met een aanzienlijke morbiditeit, 
echter een goede lokale controle en een acceptabele overleving rechtvaardigt deze extensieve 
chirurgische techniek bij de meeste patiënten, zeker als er sprake is van het primair lokaal 
uitgebreid rectum carcinoom of het cervix carcinoom.
In hoofdstuk 9 worden de resultaten van sacrale resecties in verband met een primair of 
recidief rectum carcinoom kritisch geëvalueerd. Tussen 1987 en 2007 ondergingen in het 
Erasmus Medisch Centrum, lokatie Daniel, 25 patiënten op een totaal van 353 patiënten een 
sacrale resectie bij een primair- of recidief rectum carcinoom. Een mid-sacrum resectie werd 
verricht bij 12 patiënten (niveau S3) en een laag-sacrum resectie bij 13 patiënten (niveau 
S4/5). Een complete resectie werd verricht bij 19/25 patiënten; R1 in 4/25 patiënten; R2 in 
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2/25 patiënten. Er was geen postoperatieve mortaliteit. Positieve lymfeklieren en incomplete 
resectie randen beïnvloedde onafhankelijk van elkaar de lokale controle in negatieve zin 
(P < 0.001). de 5-jaars overleving was 30%. Vijf patiënten met een recidief tumor hadden 
daadwerkelijk ingroei in het sacrum bij pathologisch onderzoek. Al deze patiënten overleden 
binnen 1 jaar. Concluderend zijn abdomino sacrale resecties uitvoerbaar bij patiënten met 
een rectum carcinoom. Indien er een incomplete resectie wordt verricht of als er sprake is 
van evidente corticale ingroei dient afgezien te worden van deze uitgebreide chirurgische 
procedure.
Na een APR of uitgebreide kleine bekken chirurgie kunnen er grote perineale ontstaan die 
moeilijk te behandelen zijn. Het opvullen van deze peritoneale ruimte kan een oplossing 
bieden door gebruik te maken van een omentum plastiek of een spier- of huidspier 
transpositie. Deze transpositie heeft als voordeel dat hij goed gevasculariseerd is en niet 
in bestraald gebied heeft gelegen. De resultaten van hoofdstuk 10 laten zien dat de directe 
transpositie van een vertical rectus abdominus muscle (VRAM) leidt tot primair sluiten van 
de perineale wond in alle patiënten die een APR ondergingen vanwege een anus carcinoom. 
De morbiditeits percentage na een VRAM in combinatie met een resectie van de maligniteit 
was niet hoger dan de morbiditeit na een APR zonder VRAM. Bij 5 van 14 patiënten waarbij 
primair geen VRAM werd gebruikt ontstond er een groot perineaal defect. In al de patiënten 
die primair werden behandeld met een VRAM herstelde de perineale wond primair. In deze 
studie was er sprake van een goede lokale controle en een 5-jaars overleving van 30%. Indien 
men een APR uitvoert dient men een VRAM reconstructie te overwegen.
Dankwoord | 195
Dankwoord
Hooggeleerde heer Alexander M.M. Eggermont. Als mijn promotor wil ik u danken omdat u 
degene was die het aandurfde “Die jongen met de zachte ‘g’ en gitaar” als anios aan te nemen 
in Rotterdam. Woorden die in mij opkomen als ik aan u denk zijn: turbulent, charisma, 
inspirator, Babylonische spraakwaterval, aanwezig (als aanwezig?), helder, duidelijk etc. 
De enorme kracht waarmee u de chirurgische oncologie internationaal voortstuwt is soms 
onnavolgbaar maar bovenal bewonderenswaardig. Dank voor de mogelijkheden die u mij 
heeft geboden om mijzelf te ontplooien tot wie ik nu ben.
Hooggeleerde heer de Wilt, Hans. Opleiding heelkunde, promotie, KWF-fellowship; zonder 
jou was deze trilogie nooit tot stand gekomen. De volharding waarmee jij mij hebt geholpen, 
jouw snelheid, je chirurgische vaardigheden, je gedrevenheid zullen mij altijd bijblijven. Het 
is voor mij een grote eer dat jij, sinds je benoeming tot hoogleraar chirurgische oncologie, 
niet mijn co-promotor maar mijn promotor bent. 
Hooggeleerde leden van de grote & kleine commissie, professor Kuipers, professor Levendag, 
professor Wiggers, professor van Lanschot, professor Lange en dr. Cats en dr. Kirkels. Allen 
dank voor het doornemen van dit proefschrift, uw aanwezigheid en uw inbreng op deze voor 
mij grootse dag.
Maarten Vermaas, paranimf, wetenschapsbroeder! Erop en erover en daar stond jij als 
promovendus reeds in 2008. Gelukkig heb ik nu ook de eindstreep gehaald. Maarten, dank 
voor je grote bijdrage in dit proefschrift, maar met name voor jouw betrokkenheid. Ik ken 
weinig mensen die zo uitgebalanceerd door het leven gaan en dan ook nog dat leven met 
humor, vrolijkheid en warmte vullen. Binnenkort maar weer op de fiets, rondje Rotte!?
Rob Zuidwijk, paranimf ! De allereerste promotie die ik in mijn leven meemaakte was die van 
jou aan de Erasmus Universiteit Rotterdam. Na 5 minuten moest ik inhoudelijk al afhaken 
maar was desalniettemin diep onder de indruk van deze promotie en de ceremonie. Nu 15 
jaar later in precies hetzelfde gebouw, dezelfde zaal sta ik voor dezelfde taak. Dank voor de 
ondersteuning en wetenschappelijke wind die jij met je meevoert.
Dr. I Dawson, beste Imro; mijn opleider in de periferie. Het duurde even maar dan heb je 
ook wat… Dank voor de immer stimulerende, ietwat repeterende evaluatiegesprekken: “Het 
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gaat goed Floris, alleen wetenschappelijk vaart gaan maken, jongen.” Een opleider zoals een 
opleider moet zijn: betrokken, stimulerend, kritisch.
Hooggeleerde heer J.N.M. IJzermans, Jan. Dank voor de tijd die jij mij gunde om een en 
ander af te ronden.
Dr. G.W.M. Tetteroo en dr. E.J.R. de Graaf, Geert en Eelco. Colorectale chirurgische 
ingrepen leerde ik van jullie. Mijn eerste LAR, eerste APR, eerste TEM-procedure, allemaal 
onder jullie bezielende begeleiding. Ik zal jullie ‘aan tafel’ nog vaak citeren! Natuurlijk wil 
ik ook de rest van de maatschap bedanken: Milko, Richard, Steven en Piet die mij het vak 
hebben geleerd. Pascal voor de laatste "spannende" wetenschappelijke ondersteuning en last 
but not least, Cees, net gepensioneerd, maar tot het einde  een gepassioneerd chirurg.
Zeergeleerde heer C. Verhoef, Kees en natuurlijk de dames van het “Daniel” secretariaat, 
dank voor vele jaren krachtige ondersteuning. 
Dr. A.W.K.S. Marinelli, Andreas, jij hebt het initiatief genomen om de rectumdatabase op te 
starten en mij hier vanaf het eerste uur in te betrekken waarvoor dank.
Wilfried Graveland, statisticus. Een echte Graveland; het uiterlijk van een beer, innerlijk 
intelligent, zachtmoedig en behulpzaam. Zeer veel dank voor jouw hulp zelfs nadat je al weg 
was uit de Daniel. Ze hadden je nooit moeten laten gaan!
Mijn zus Wendel, voor 8 bijzondere jaren samen in de stad van onze grootvader; Rotterdam. 
Fijn dat je erbij kunt zijn vanuit Los Angeles.
Annalies, mamma, nu ik samen met Ruth twee kinderen poog op te voeden groeit steeds meer 
het besef wat voor uitzonderlijke taak jij hebt volbracht. Dank voor de nimmer aflatende 
steun en liefde die ik van jou krijg. Ik verheug me op je bezoek in Australië.
Roos en Jonas, de schoonheid en troost die jullie mij schenken is onvoorstelbaar. Door jullie 
bruist het leven. Ik hou van jullie.
Ruth, zonder jou was ik allang verdronken in een zee van activiteiten. Dank voor een stukje 
grensbewaking maar bovenal voor het feit dat jij er bent.
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FLORIS FERENSCHILD
Floris Ferenschild werd geboren op 19 juli 1973 te Herkenbosch. Na het eindexamen HAVO 
begon hij in 1990 met de studie fysiotherapie te Heerlen die hij in 1994 afrondde. Na een jaar 
vervangende dienstplicht te hebben vervuld startte hij in 1995 met de studie geneeskunde 
aan de universiteit van Maastricht. In 5 jaar tijd behaalde hij zijn arts diploma. Hierna was hij 
kort werkzaam als anios chirurgie in Ede waarna hij als anios in de Daniel den Hoed kliniek 
ging werken. Hier werd het huidige promotieonderzoek gestart onder de bezielende leiding 
van prof.dr. A.M.M. Eggermont en prof.dr. J.H.W. de Wilt.
Sinds 1 januari 2004 is hij in opleiding tot algemeen chirurg. De eerste 4 jaar werd hij 
opgeleid in het IJsselland Ziekenhuis (opleider dr. I. Dawson). De laatste 2 jaar doorloopt 
hij in het Erasmus MC te Rotterdam (opleider prof.dr. J.N.M. IJzermans). Het laatste 
jaar differentieert hij in de oncologische chirurgie. Begin 2010 zal hij in het kader van een 
klinisch KWF-fellowship een jaar naar het Royal Prince Alfred Hospital te Sydney gaan om 
zich verder te verdiepen in de colorectale- en kleine bekkenchirurgie.
Floris is in juni 2006 getrouwd met Ruth en heeft een dochter Roos en een zoon Jonas.
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